Ignite Creation Date:
2025-12-24 @ 3:20 PM
Ignite Modification Date:
2025-12-25 @ 8:46 PM
Study NCT ID:
NCT04857892
Status:
COMPLETED
Last Update Posted:
2024-03-12
First Post:
2021-04-20
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D015658', 'term': 'HIV Infections'}], 'ancestors': [{'id': 'D000086982', 'term': 'Blood-Borne Infections'}, {'id': 'D003141', 'term': 'Communicable Diseases'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D015229', 'term': 'Sexually Transmitted Diseases, Viral'}, {'id': 'D012749', 'term': 'Sexually Transmitted Diseases'}, {'id': 'D016180', 'term': 'Lentivirus Infections'}, {'id': 'D012192', 'term': 'Retroviridae Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D007153', 'term': 'Immunologic Deficiency Syndromes'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000723722', 'term': 'GSK3640254'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'GSKClinicalSupportHD@gsk.com', 'phone': '866-435-7343', 'title': 'GSK Response Center', 'organization': 'ViiV Healthcare'}, 'certainAgreement': {'otherDetails': 'GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2', 'description': 'Safety Population consisted of all participants who received at least one dose of study intervention.', 'eventGroups': [{'id': 'EG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.', 'otherNumAtRisk': 22, 'deathsNumAtRisk': 22, 'otherNumAffected': 0, 'seriousNumAtRisk': 22, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.', 'otherNumAtRisk': 21, 'deathsNumAtRisk': 21, 'otherNumAffected': 0, 'seriousNumAtRisk': 21, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.', 'otherNumAtRisk': 20, 'deathsNumAtRisk': 20, 'otherNumAffected': 1, 'seriousNumAtRisk': 20, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.', 'otherNumAtRisk': 17, 'deathsNumAtRisk': 17, 'otherNumAffected': 1, 'seriousNumAtRisk': 17, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG004', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.', 'otherNumAtRisk': 18, 'deathsNumAtRisk': 18, 'otherNumAffected': 2, 'seriousNumAtRisk': 18, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Anxiety', 'stats': [{'groupId': 'EG000', 'numAtRisk': 22, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 17, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.1'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 22, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 17, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.1'}, {'term': 'SARS-CoV-2 test positive', 'stats': [{'groupId': 'EG000', 'numAtRisk': 22, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 17, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.1'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 22, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 17, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.1'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 22, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 17, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.1'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Part 1: Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf]) of GSK3640254', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}, {'value': '16', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'categories': [{'measurements': [{'value': '22.13', 'spread': '46.8', 'groupId': 'OG000'}, {'value': '21.93', 'spread': '36.6', 'groupId': 'OG001'}, {'value': '22.63', 'spread': '38.0', 'groupId': 'OG002'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric Least Square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.025', 'ciLowerLimit': '0.9335', 'ciUpperLimit': '1.126', 'estimateComment': 'An analysis of variance with treatment, period, and sequence as fixed effects and participant nested within a sequence as a random effect was performed on the natural ln-transformed parameter AUC(0-inf).', 'nonInferiorityType': 'OTHER'}, {'groupIds': ['OG000', 'OG002'], 'paramType': 'Ratio of geometric Least Square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.072', 'ciLowerLimit': '0.9693', 'ciUpperLimit': '1.185', 'estimateComment': 'An analysis of variance with treatment, period, and sequence as fixed effects and participant nested within a sequence as a random effect was performed on the natural ln-transformed parameter AUC(0-inf).', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK3640254.', 'unitOfMeasure': 'Hours*microgram per milliliter', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population consisted of all participants who underwent plasma PK sampling and had evaluable PK parameters estimated. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'Part 1: Area Under the Plasma Concentration-time Curve From Time 0 to Time t (AUC[0-t]) of GSK3640254', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'categories': [{'measurements': [{'value': '17.62', 'spread': '55.4', 'groupId': 'OG000'}, {'value': '19.14', 'spread': '42.9', 'groupId': 'OG001'}, {'value': '18.69', 'spread': '42.4', 'groupId': 'OG002'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric Least Square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.126', 'ciLowerLimit': '0.9918', 'ciUpperLimit': '1.278', 'estimateComment': 'An analysis of variance with treatment, period, and sequence as fixed effects and participant nested within a sequence as a random effect was performed on the natural ln-transformed parameter AUC(0-t).', 'nonInferiorityType': 'OTHER'}, {'groupIds': ['OG000', 'OG002'], 'paramType': 'Ratio of geometric Least Square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.055', 'ciLowerLimit': '0.9278', 'ciUpperLimit': '1.201', 'estimateComment': 'An analysis of variance with treatment, period, and sequence as fixed effects and participant nested within a sequence as a random effect was performed on the natural ln-transformed parameter AUC(0-t).', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period', 'description': 'Blood samples were collected at indicated time points for PK analysis of GSK3640254.', 'unitOfMeasure': 'Hours*microgram per milliliter', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population'}, {'type': 'PRIMARY', 'title': 'Part 1: Maximum Observed Concentration (Cmax) of GSK3640254', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.7382', 'spread': '40.3', 'groupId': 'OG000'}, {'value': '0.7610', 'spread': '33.5', 'groupId': 'OG001'}, {'value': '0.7579', 'spread': '40.1', 'groupId': 'OG002'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric Least Square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.036', 'ciLowerLimit': '0.9209', 'ciUpperLimit': '1.166', 'estimateComment': 'An analysis of variance with treatment, period, and sequence as fixed effects and participant nested within a sequence as a random effect was performed on the natural ln-transformed parameter Cmax.', 'nonInferiorityType': 'OTHER'}, {'groupIds': ['OG000', 'OG002'], 'paramType': 'Ratio of geometric Least Square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.020', 'ciLowerLimit': '0.9049', 'ciUpperLimit': '1.151', 'estimateComment': 'An analysis of variance with treatment, period, and sequence as fixed effects and participant nested within a sequence as a random effect was performed on the natural ln-transformed parameter Cmax.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period', 'description': 'Blood samples were collected at indicated time points for PK analysis of GSK3640254.', 'unitOfMeasure': 'Microgram per milliliter', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population'}, {'type': 'PRIMARY', 'title': 'Part 1: AUC(0-inf) of DTG', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'categories': [{'measurements': [{'value': '74.18', 'spread': '30.7', 'groupId': 'OG000'}, {'value': '82.13', 'spread': '26.1', 'groupId': 'OG001'}, {'value': '80.53', 'spread': '34.7', 'groupId': 'OG002'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric Least Square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.129', 'ciLowerLimit': '1.067', 'ciUpperLimit': '1.195', 'estimateComment': 'An analysis of variance with treatment, period, and sequence as fixed effects and participant nested within a sequence as a random effect was performed on the natural ln-transformed parameter AUC(0-inf).', 'nonInferiorityType': 'OTHER'}, {'groupIds': ['OG000', 'OG002'], 'paramType': 'Ratio of geometric Least Square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.112', 'ciLowerLimit': '1.050', 'ciUpperLimit': '1.178', 'estimateComment': 'An analysis of variance with treatment, period, and sequence as fixed effects and participant nested within a sequence as a random effect was performed on the natural ln-transformed parameter AUC(0-inf).', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period', 'description': 'Blood samples were collected at indicated time points for PK analysis of DTG.', 'unitOfMeasure': 'Hours*microgram per milliliter', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population'}, {'type': 'PRIMARY', 'title': 'Part 1: AUC(0-t) of DTG', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'categories': [{'measurements': [{'value': '68.91', 'spread': '32.5', 'groupId': 'OG000'}, {'value': '77.89', 'spread': '29.0', 'groupId': 'OG001'}, {'value': '73.44', 'spread': '37.0', 'groupId': 'OG002'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric Least Square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.164', 'ciLowerLimit': '1.070', 'ciUpperLimit': '1.267', 'estimateComment': 'An analysis of variance with treatment, period, and sequence as fixed effects and participant nested within a sequence as a random effect was performed on the natural ln-transformed parameter AUC(0-t).', 'nonInferiorityType': 'OTHER'}, {'groupIds': ['OG000', 'OG002'], 'paramType': 'Ratio of geometric Least Square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.087', 'ciLowerLimit': '0.9975', 'ciUpperLimit': '1.184', 'estimateComment': 'An analysis of variance with treatment, period, and sequence as fixed effects and participant nested within a sequence as a random effect was performed on the natural ln-transformed parameter AUC(0-t).', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period', 'description': 'Blood samples were collected at indicated time points for PK analysis of DTG.', 'unitOfMeasure': 'Hours*microgram per milliliter', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population'}, {'type': 'PRIMARY', 'title': 'Part 1: Cmax of DTG', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'categories': [{'measurements': [{'value': '4.182', 'spread': '18.5', 'groupId': 'OG000'}, {'value': '4.432', 'spread': '17.8', 'groupId': 'OG001'}, {'value': '4.264', 'spread': '23.2', 'groupId': 'OG002'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric Least Square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.078', 'ciLowerLimit': '1.036', 'ciUpperLimit': '1.122', 'estimateComment': 'An analysis of variance with treatment, period, and sequence as fixed effects and participant nested within a sequence as a random effect was performed on the natural ln-transformed parameter Cmax', 'nonInferiorityType': 'OTHER'}, {'groupIds': ['OG000', 'OG002'], 'paramType': 'Ratio of geometric Least Square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.032', 'ciLowerLimit': '0.9914', 'ciUpperLimit': '1.075', 'estimateComment': 'An analysis of variance with treatment, period, and sequence as fixed effects and participant nested within a sequence as a random effect was performed on the natural ln-transformed parameter Cmax', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period', 'description': 'Blood samples were collected at indicated time points for PK analysis of DTG.', 'unitOfMeasure': 'Microgram per milliliter', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population'}, {'type': 'PRIMARY', 'title': 'Part 2: AUC(0-inf) of GSK3640254', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '21.39', 'spread': '38.0', 'groupId': 'OG000'}, {'value': '6.622', 'spread': '77.4', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric Least Square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '2.705', 'ciLowerLimit': '2.135', 'ciUpperLimit': '3.427', 'estimateComment': 'An analysis of variance with treatment, period, and sequence as fixed effects and participant nested within a sequence as a random effect was performed on the natural ln-transformed parameter AUC(0-inf)', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period', 'description': 'Blood samples were collected at indicated time points for PK analysis of GSK3640254.', 'unitOfMeasure': 'Hours*microgram per milliliter', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'Part 2: AUC(0-t) of GSK3640254', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '19.33', 'spread': '36.6', 'groupId': 'OG000'}, {'value': '6.027', 'spread': '78.8', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric Least Square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '2.761', 'ciLowerLimit': '2.160', 'ciUpperLimit': '3.527', 'estimateComment': 'An analysis of variance with treatment, period, and sequence as fixed effects and participant nested within a sequence as a random effect was performed on the natural ln-transformed parameter AUC(0-t)', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period.', 'description': 'Blood samples were collected at indicated time points for PK analysis of GSK3640254.', 'unitOfMeasure': 'Hours*microgram per milliliter', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'Part 2: Cmax of GSK3640254', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.6093', 'spread': '41.3', 'groupId': 'OG000'}, {'value': '0.2193', 'spread': '92.1', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric Least Square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '2.498', 'ciLowerLimit': '1.821', 'ciUpperLimit': '3.425', 'estimateComment': 'An analysis of variance with treatment, period, and sequence as fixed effects and participant nested within a sequence as a random effect was performed on the natural ln-transformed parameter Cmax', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period', 'description': 'Blood samples were collected at indicated time points for PK analysis of GSK3640254.', 'unitOfMeasure': 'Microgram per milliliter', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'Part 2: AUC(0-inf) of DTG', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '85.07', 'spread': '29.0', 'groupId': 'OG000'}, {'value': '64.61', 'spread': '31.5', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric Least Square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.316', 'ciLowerLimit': '1.193', 'ciUpperLimit': '1.451', 'estimateComment': 'An analysis of variance with treatment, period, and sequence as fixed effects and participant nested within a sequence as a random effect was performed on the natural ln-transformed parameter AUC(0-inf)', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period', 'description': 'Blood samples were collected at indicated time points for PK analysis of DTG.', 'unitOfMeasure': 'Hours*microgram per milliliter', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population'}, {'type': 'PRIMARY', 'title': 'Part 2: AUC(0-t) of DTG', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '83.18', 'spread': '28.2', 'groupId': 'OG000'}, {'value': '63.17', 'spread': '31.0', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric Least Square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.316', 'ciLowerLimit': '1.193', 'ciUpperLimit': '1.452', 'estimateComment': 'An analysis of variance with treatment, period, and sequence as fixed effects and participant nested within a sequence as a random effect was performed on the natural ln-transformed parameter AUC(0-t)', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period', 'description': 'Blood samples were collected at indicated time points for PK analysis of DTG.', 'unitOfMeasure': 'Hours*microgram per milliliter', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population'}, {'type': 'PRIMARY', 'title': 'Part 2: Cmax of DTG', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '4.000', 'spread': '21.1', 'groupId': 'OG000'}, {'value': '3.273', 'spread': '28.4', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric Least Square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.232', 'ciLowerLimit': '1.138', 'ciUpperLimit': '1.333', 'estimateComment': 'An analysis of variance with treatment, period, and sequence as fixed effects and participant nested within a sequence as a random effect was performed on the natural ln-transformed parameter Cmax', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period', 'description': 'Blood samples were collected at indicated time points for PK analysis of DTG.', 'unitOfMeasure': 'Microgram per milliliter', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population'}, {'type': 'SECONDARY', 'title': 'Part 1: Number of Participants With Non-Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Non-SAEs', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'SAEs', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to 17 days', 'description': 'An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any serious adverse event that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or other situations as per medical or scientific judgment. Adverse events which were not Serious Adverse Events were considered as Non-Serious adverse events.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population consisted of all participants who received at least one dose of study intervention.'}, {'type': 'SECONDARY', 'title': 'Part 2: Number of Participants With Non-SAEs and SAEs', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Non-SAEs', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}]}]}, {'title': 'SAEs', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to 9 days', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any serious adverse event that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or other situations as per medical or scientific judgment. Adverse events which were not Serious Adverse Events were considered as Non-Serious adverse events.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population'}, {'type': 'SECONDARY', 'title': 'Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Basophils, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.035', 'spread': '0.0144', 'groupId': 'OG000'}, {'value': '0.036', 'spread': '0.0140', 'groupId': 'OG001'}, {'value': '0.036', 'spread': '0.0132', 'groupId': 'OG002'}]}]}, {'title': 'Basophils, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.036', 'spread': '0.0133', 'groupId': 'OG000'}, {'value': '0.036', 'spread': '0.0120', 'groupId': 'OG001'}, {'value': '0.037', 'spread': '0.0184', 'groupId': 'OG002'}]}]}, {'title': 'Basophils, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.045', 'spread': '0.0138', 'groupId': 'OG000'}, {'value': '0.035', 'spread': '0.0187', 'groupId': 'OG001'}, {'value': '0.028', 'spread': '0.0117', 'groupId': 'OG002'}]}]}, {'title': 'Basophils, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.033', 'spread': '0.0142', 'groupId': 'OG000'}, {'value': '0.040', 'spread': '0.0108', 'groupId': 'OG001'}, {'value': '0.038', 'spread': '0.0169', 'groupId': 'OG002'}]}]}, {'title': 'Eosinophils, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.157', 'spread': '0.1455', 'groupId': 'OG000'}, {'value': '0.150', 'spread': '0.1300', 'groupId': 'OG001'}, {'value': '0.171', 'spread': '0.1559', 'groupId': 'OG002'}]}]}, {'title': 'Eosinophils, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.157', 'spread': '0.1382', 'groupId': 'OG000'}, {'value': '0.146', 'spread': '0.1229', 'groupId': 'OG001'}, {'value': '0.170', 'spread': '0.1482', 'groupId': 'OG002'}]}]}, {'title': 'Eosinophils, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.197', 'spread': '0.1481', 'groupId': 'OG000'}, {'value': '0.182', 'spread': '0.1512', 'groupId': 'OG001'}, {'value': '0.120', 'spread': '0.1210', 'groupId': 'OG002'}]}]}, {'title': 'Eosinophils, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.141', 'spread': '0.1272', 'groupId': 'OG000'}, {'value': '0.152', 'spread': '0.1194', 'groupId': 'OG001'}, {'value': '0.189', 'spread': '0.1613', 'groupId': 'OG002'}]}]}, {'title': 'Lymphocytes, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.683', 'spread': '0.3691', 'groupId': 'OG000'}, {'value': '1.674', 'spread': '0.2885', 'groupId': 'OG001'}, {'value': '1.646', 'spread': '0.3375', 'groupId': 'OG002'}]}]}, {'title': 'Lymphocytes, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.647', 'spread': '0.3715', 'groupId': 'OG000'}, {'value': '1.735', 'spread': '0.3019', 'groupId': 'OG001'}, {'value': '1.711', 'spread': '0.3950', 'groupId': 'OG002'}]}]}, {'title': 'Lymphocytes, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.835', 'spread': '0.4113', 'groupId': 'OG000'}, {'value': '1.663', 'spread': '0.4034', 'groupId': 'OG001'}, {'value': '1.705', 'spread': '0.4574', 'groupId': 'OG002'}]}]}, {'title': 'Lymphocytes, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.630', 'spread': '0.3049', 'groupId': 'OG000'}, {'value': '1.675', 'spread': '0.3398', 'groupId': 'OG001'}, {'value': '1.592', 'spread': '0.3674', 'groupId': 'OG002'}]}]}, {'title': 'Monocytes, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.396', 'spread': '0.0834', 'groupId': 'OG000'}, {'value': '0.396', 'spread': '0.0878', 'groupId': 'OG001'}, {'value': '0.419', 'spread': '0.1464', 'groupId': 'OG002'}]}]}, {'title': 'Monocytes, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.395', 'spread': '0.0803', 'groupId': 'OG000'}, {'value': '0.389', 'spread': '0.0861', 'groupId': 'OG001'}, {'value': '0.410', 'spread': '0.0932', 'groupId': 'OG002'}]}]}, {'title': 'Monocytes, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.422', 'spread': '0.0987', 'groupId': 'OG000'}, {'value': '0.387', 'spread': '0.0497', 'groupId': 'OG001'}, {'value': '0.380', 'spread': '0.1243', 'groupId': 'OG002'}]}]}, {'title': 'Monocytes, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.380', 'spread': '0.0587', 'groupId': 'OG000'}, {'value': '0.398', 'spread': '0.1162', 'groupId': 'OG001'}, {'value': '0.410', 'spread': '0.0903', 'groupId': 'OG002'}]}]}, {'title': 'Neutrophils, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2.729', 'spread': '0.8510', 'groupId': 'OG000'}, {'value': '2.691', 'spread': '1.0455', 'groupId': 'OG001'}, {'value': '2.906', 'spread': '1.3028', 'groupId': 'OG002'}]}]}, {'title': 'Neutrophils, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2.756', 'spread': '0.8228', 'groupId': 'OG000'}, {'value': '2.589', 'spread': '0.9598', 'groupId': 'OG001'}, {'value': '2.573', 'spread': '0.9203', 'groupId': 'OG002'}]}]}, {'title': 'Neutrophils, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2.967', 'spread': '0.8932', 'groupId': 'OG000'}, {'value': '2.648', 'spread': '0.8738', 'groupId': 'OG001'}, {'value': '2.703', 'spread': '2.0389', 'groupId': 'OG002'}]}]}, {'title': 'Neutrophils, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2.462', 'spread': '0.9607', 'groupId': 'OG000'}, {'value': '2.594', 'spread': '1.1921', 'groupId': 'OG001'}, {'value': '2.812', 'spread': '0.9202', 'groupId': 'OG002'}]}]}, {'title': 'Platelets, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '247.8', 'spread': '45.94', 'groupId': 'OG000'}, {'value': '252.5', 'spread': '52.73', 'groupId': 'OG001'}, {'value': '256.5', 'spread': '50.02', 'groupId': 'OG002'}]}]}, {'title': 'Platelets, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '254.6', 'spread': '46.26', 'groupId': 'OG000'}, {'value': '257.0', 'spread': '54.66', 'groupId': 'OG001'}, {'value': '260.4', 'spread': '52.24', 'groupId': 'OG002'}]}]}, {'title': 'Platelets, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '277.8', 'spread': '35.13', 'groupId': 'OG000'}, {'value': '268.7', 'spread': '52.38', 'groupId': 'OG001'}, {'value': '212.2', 'spread': '44.62', 'groupId': 'OG002'}]}]}, {'title': 'Platelets, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '237.9', 'spread': '40.40', 'groupId': 'OG000'}, {'value': '257.1', 'spread': '55.49', 'groupId': 'OG001'}, {'value': '271.4', 'spread': '44.96', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, and platelets. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': '10^9 cells per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Basophils, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.046', 'spread': '0.0289', 'groupId': 'OG000'}, {'value': '0.041', 'spread': '0.0242', 'groupId': 'OG001'}]}]}, {'title': 'Basophils, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.038', 'spread': '0.0183', 'groupId': 'OG000'}, {'value': '0.041', 'spread': '0.0192', 'groupId': 'OG001'}]}]}, {'title': 'Basophils, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.051', 'spread': '0.0253', 'groupId': 'OG000'}, {'value': '0.037', 'spread': '0.0141', 'groupId': 'OG001'}]}]}, {'title': 'Basophils, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.033', 'spread': '0.0141', 'groupId': 'OG000'}, {'value': '0.057', 'spread': '0.0354', 'groupId': 'OG001'}]}]}, {'title': 'Eosinophils, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.128', 'spread': '0.0688', 'groupId': 'OG000'}, {'value': '0.138', 'spread': '0.0880', 'groupId': 'OG001'}]}]}, {'title': 'Eosinophils, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.125', 'spread': '0.0700', 'groupId': 'OG000'}, {'value': '0.136', 'spread': '0.0786', 'groupId': 'OG001'}]}]}, {'title': 'Eosinophils, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.131', 'spread': '0.0869', 'groupId': 'OG000'}, {'value': '0.111', 'spread': '0.0601', 'groupId': 'OG001'}]}]}, {'title': 'Eosinophils, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.123', 'spread': '0.0726', 'groupId': 'OG000'}, {'value': '0.133', 'spread': '0.0652', 'groupId': 'OG001'}]}]}, {'title': 'Lymphocytes, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.786', 'spread': '0.4445', 'groupId': 'OG000'}, {'value': '1.771', 'spread': '0.4902', 'groupId': 'OG001'}]}]}, {'title': 'Lymphocytes, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.884', 'spread': '0.4805', 'groupId': 'OG000'}, {'value': '1.838', 'spread': '0.4761', 'groupId': 'OG001'}]}]}, {'title': 'Lymphocytes, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.663', 'spread': '0.5135', 'groupId': 'OG000'}, {'value': '1.750', 'spread': '0.3384', 'groupId': 'OG001'}]}]}, {'title': 'Lymphocytes, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.827', 'spread': '0.3937', 'groupId': 'OG000'}, {'value': '1.730', 'spread': '0.5080', 'groupId': 'OG001'}]}]}, {'title': 'Monocytes, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.466', 'spread': '0.1086', 'groupId': 'OG000'}, {'value': '0.443', 'spread': '0.1100', 'groupId': 'OG001'}]}]}, {'title': 'Monocytes, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.452', 'spread': '0.1114', 'groupId': 'OG000'}, {'value': '0.458', 'spread': '0.1070', 'groupId': 'OG001'}]}]}, {'title': 'Monocytes, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.479', 'spread': '0.1512', 'groupId': 'OG000'}, {'value': '0.430', 'spread': '0.1021', 'groupId': 'OG001'}]}]}, {'title': 'Monocytes, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.452', 'spread': '0.0987', 'groupId': 'OG000'}, {'value': '0.469', 'spread': '0.1102', 'groupId': 'OG001'}]}]}, {'title': 'Neutrophils, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.094', 'spread': '1.1911', 'groupId': 'OG000'}, {'value': '3.138', 'spread': '1.1817', 'groupId': 'OG001'}]}]}, {'title': 'Neutrophils, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.999', 'spread': '1.1184', 'groupId': 'OG000'}, {'value': '3.122', 'spread': '1.1220', 'groupId': 'OG001'}]}]}, {'title': 'Neutrophils, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.891', 'spread': '2.1672', 'groupId': 'OG000'}, {'value': '3.234', 'spread': '1.3698', 'groupId': 'OG001'}]}]}, {'title': 'Neutrophils, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.967', 'spread': '1.0973', 'groupId': 'OG000'}, {'value': '3.083', 'spread': '1.1599', 'groupId': 'OG001'}]}]}, {'title': 'Platelets, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '291.6', 'spread': '53.57', 'groupId': 'OG000'}, {'value': '292.7', 'spread': '59.84', 'groupId': 'OG001'}]}]}, {'title': 'Platelets, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '302.0', 'spread': '56.30', 'groupId': 'OG000'}, {'value': '299.7', 'spread': '62.53', 'groupId': 'OG001'}]}]}, {'title': 'Platelets, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '278.6', 'spread': '61.63', 'groupId': 'OG000'}, {'value': '314.1', 'spread': '53.97', 'groupId': 'OG001'}]}]}, {'title': 'Platelets, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '307.4', 'spread': '55.38', 'groupId': 'OG000'}, {'value': '274.4', 'spread': '61.27', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, leukocytes and platelets. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': '10^9 cells per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Absolute Values for Hematology Parameter: Hemoglobin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '139.8', 'spread': '16.04', 'groupId': 'OG000'}, {'value': '142.7', 'spread': '16.64', 'groupId': 'OG001'}, {'value': '138.8', 'spread': '16.55', 'groupId': 'OG002'}]}]}, {'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '141.1', 'spread': '15.57', 'groupId': 'OG000'}, {'value': '143.1', 'spread': '15.14', 'groupId': 'OG001'}, {'value': '139.2', 'spread': '16.11', 'groupId': 'OG002'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '134.8', 'spread': '14.74', 'groupId': 'OG000'}, {'value': '135.0', 'spread': '15.19', 'groupId': 'OG001'}, {'value': '141.8', 'spread': '14.89', 'groupId': 'OG002'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '145.8', 'spread': '14.97', 'groupId': 'OG000'}, {'value': '140.6', 'spread': '18.11', 'groupId': 'OG001'}, {'value': '138.1', 'spread': '16.11', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Grams per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Absolute Values for Hematology Parameter: Hemoglobin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '139.8', 'spread': '15.66', 'groupId': 'OG000'}, {'value': '138.4', 'spread': '14.09', 'groupId': 'OG001'}]}]}, {'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '141.0', 'spread': '15.86', 'groupId': 'OG000'}, {'value': '140.7', 'spread': '16.62', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '143.1', 'spread': '11.22', 'groupId': 'OG000'}, {'value': '135.6', 'spread': '18.04', 'groupId': 'OG001'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '134.3', 'spread': '15.82', 'groupId': 'OG000'}, {'value': '144.2', 'spread': '11.11', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Grams per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '86.45', 'spread': '4.446', 'groupId': 'OG000'}, {'value': '86.33', 'spread': '4.376', 'groupId': 'OG001'}, {'value': '86.94', 'spread': '4.244', 'groupId': 'OG002'}]}]}, {'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '86.26', 'spread': '4.324', 'groupId': 'OG000'}, {'value': '86.51', 'spread': '4.392', 'groupId': 'OG001'}, {'value': '86.99', 'spread': '4.171', 'groupId': 'OG002'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '86.48', 'spread': '4.642', 'groupId': 'OG000'}, {'value': '86.08', 'spread': '4.923', 'groupId': 'OG001'}, {'value': '87.58', 'spread': '4.668', 'groupId': 'OG002'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '86.12', 'spread': '4.256', 'groupId': 'OG000'}, {'value': '87.28', 'spread': '4.120', 'groupId': 'OG001'}, {'value': '86.09', 'spread': '4.703', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Femtoliter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '84.55', 'spread': '5.141', 'groupId': 'OG000'}, {'value': '84.89', 'spread': '4.925', 'groupId': 'OG001'}]}]}, {'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '84.30', 'spread': '4.926', 'groupId': 'OG000'}, {'value': '84.74', 'spread': '5.146', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '84.33', 'spread': '3.593', 'groupId': 'OG000'}, {'value': '84.50', 'spread': '6.116', 'groupId': 'OG001'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '84.37', 'spread': '5.841', 'groupId': 'OG000'}, {'value': '85.29', 'spread': '4.042', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Femtoliter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Absolute Values for Hematology Parameter: Erythrocytes', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.757', 'spread': '0.4773', 'groupId': 'OG000'}, {'value': '4.850', 'spread': '0.5190', 'groupId': 'OG001'}, {'value': '4.686', 'spread': '0.4967', 'groupId': 'OG002'}]}]}, {'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.822', 'spread': '0.4863', 'groupId': 'OG000'}, {'value': '4.855', 'spread': '0.4740', 'groupId': 'OG001'}, {'value': '4.700', 'spread': '0.4353', 'groupId': 'OG002'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.658', 'spread': '0.4331', 'groupId': 'OG000'}, {'value': '4.558', 'spread': '0.3547', 'groupId': 'OG001'}, {'value': '4.710', 'spread': '0.5284', 'groupId': 'OG002'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.939', 'spread': '0.5032', 'groupId': 'OG000'}, {'value': '4.752', 'spread': '0.5521', 'groupId': 'OG001'}, {'value': '4.700', 'spread': '0.4412', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': '10^12 cells per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Absolute Values for Hematology Parameter: Erythrocytes', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.914', 'spread': '0.5070', 'groupId': 'OG000'}, {'value': '4.853', 'spread': '0.5060', 'groupId': 'OG001'}]}]}, {'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.958', 'spread': '0.4930', 'groupId': 'OG000'}, {'value': '4.913', 'spread': '0.5727', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.976', 'spread': '0.4861', 'groupId': 'OG000'}, {'value': '4.787', 'spread': '0.4171', 'groupId': 'OG001'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.760', 'spread': '0.5021', 'groupId': 'OG000'}, {'value': '4.942', 'spread': '0.5117', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': '10^12 cells per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Absolute Values for Hematology Parameters: Hematocrit', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.4110', 'spread': '0.04343', 'groupId': 'OG000'}, {'value': '0.4181', 'spread': '0.04561', 'groupId': 'OG001'}, {'value': '0.4070', 'spread': '0.04490', 'groupId': 'OG002'}]}]}, {'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.4156', 'spread': '0.04297', 'groupId': 'OG000'}, {'value': '0.4195', 'spread': '0.04087', 'groupId': 'OG001'}, {'value': '0.4087', 'spread': '0.04260', 'groupId': 'OG002'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.4025', 'spread': '0.03930', 'groupId': 'OG000'}, {'value': '0.3922', 'spread': '0.03854', 'groupId': 'OG001'}, {'value': '0.4117', 'spread': '0.04206', 'groupId': 'OG002'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.4246', 'spread': '0.04202', 'groupId': 'OG000'}, {'value': '0.4144', 'spread': '0.04936', 'groupId': 'OG001'}, {'value': '0.4047', 'spread': '0.04553', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Proportion of red blood cells in blood', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Absolute Values for Hematology Parameters: Hematocrit', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.4145', 'spread': '0.04184', 'groupId': 'OG000'}, {'value': '0.4106', 'spread': '0.03687', 'groupId': 'OG001'}]}]}, {'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.4173', 'spread': '0.04269', 'groupId': 'OG000'}, {'value': '0.4153', 'spread': '0.04510', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.4183', 'spread': '0.03167', 'groupId': 'OG000'}, {'value': '0.4044', 'spread': '0.04641', 'groupId': 'OG001'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.4004', 'spread': '0.04078', 'groupId': 'OG000'}, {'value': '0.4201', 'spread': '0.03113', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Proportion of red blood cells in blood', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Absolute Values for Hematology Parameters: Erythrocytes Mean Corpuscular Hemoglobin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '29.37', 'spread': '1.743', 'groupId': 'OG000'}, {'value': '29.47', 'spread': '1.859', 'groupId': 'OG001'}, {'value': '29.65', 'spread': '1.819', 'groupId': 'OG002'}]}]}, {'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '29.28', 'spread': '1.811', 'groupId': 'OG000'}, {'value': '29.51', 'spread': '1.834', 'groupId': 'OG001'}, {'value': '29.63', 'spread': '1.823', 'groupId': 'OG002'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '28.95', 'spread': '2.117', 'groupId': 'OG000'}, {'value': '29.63', 'spread': '2.113', 'groupId': 'OG001'}, {'value': '30.23', 'spread': '2.111', 'groupId': 'OG002'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '29.61', 'spread': '1.924', 'groupId': 'OG000'}, {'value': '29.61', 'spread': '1.853', 'groupId': 'OG001'}, {'value': '29.34', 'spread': '1.735', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Picograms', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Absolute Values for Hematology Parameters: Erythrocytes Mean Corpuscular Hemoglobin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '28.51', 'spread': '2.271', 'groupId': 'OG000'}, {'value': '28.62', 'spread': '2.379', 'groupId': 'OG001'}]}]}, {'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '28.49', 'spread': '2.208', 'groupId': 'OG000'}, {'value': '28.68', 'spread': '2.266', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '28.84', 'spread': '1.508', 'groupId': 'OG000'}, {'value': '28.32', 'spread': '2.810', 'groupId': 'OG001'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '28.32', 'spread': '2.878', 'groupId': 'OG000'}, {'value': '29.27', 'spread': '1.665', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Picograms', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Basophils, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.000', 'spread': '0.0112', 'groupId': 'OG000'}, {'value': '0.000', 'spread': '0.0128', 'groupId': 'OG001'}, {'value': '0.002', 'spread': '0.0114', 'groupId': 'OG002'}]}]}, {'title': 'Basophils, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.003', 'spread': '0.0137', 'groupId': 'OG000'}, {'value': '0.002', 'spread': '0.0117', 'groupId': 'OG001'}, {'value': '-0.007', 'spread': '0.0121', 'groupId': 'OG002'}]}]}, {'title': 'Basophils, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.002', 'spread': '0.0075', 'groupId': 'OG000'}, {'value': '0.002', 'spread': '0.0109', 'groupId': 'OG001'}, {'value': '0.006', 'spread': '0.0117', 'groupId': 'OG002'}]}]}, {'title': 'Eosinophils, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.005', 'spread': '0.0340', 'groupId': 'OG000'}, {'value': '-0.004', 'spread': '0.0393', 'groupId': 'OG001'}, {'value': '-0.001', 'spread': '0.0253', 'groupId': 'OG002'}]}]}, {'title': 'Eosinophils, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.012', 'spread': '0.0722', 'groupId': 'OG000'}, {'value': '-0.020', 'spread': '0.0379', 'groupId': 'OG001'}, {'value': '-0.022', 'spread': '0.0739', 'groupId': 'OG002'}]}]}, {'title': 'Eosinophils, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.006', 'spread': '0.0437', 'groupId': 'OG000'}, {'value': '0.013', 'spread': '0.0632', 'groupId': 'OG001'}, {'value': '-0.015', 'spread': '0.0450', 'groupId': 'OG002'}]}]}, {'title': 'Lymphocytes, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.006', 'spread': '0.2568', 'groupId': 'OG000'}, {'value': '0.061', 'spread': '0.1626', 'groupId': 'OG001'}, {'value': '0.065', 'spread': '0.1831', 'groupId': 'OG002'}]}]}, {'title': 'Lymphocytes, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.012', 'spread': '0.2670', 'groupId': 'OG000'}, {'value': '-0.103', 'spread': '0.2293', 'groupId': 'OG001'}, {'value': '0.053', 'spread': '0.5253', 'groupId': 'OG002'}]}]}, {'title': 'Lymphocytes, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.023', 'spread': '0.1443', 'groupId': 'OG000'}, {'value': '0.069', 'spread': '0.2843', 'groupId': 'OG001'}, {'value': '0.031', 'spread': '0.2409', 'groupId': 'OG002'}]}]}, {'title': 'Monocytes, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.000', 'spread': '0.0662', 'groupId': 'OG000'}, {'value': '-0.008', 'spread': '0.0650', 'groupId': 'OG001'}, {'value': '-0.009', 'spread': '0.1268', 'groupId': 'OG002'}]}]}, {'title': 'Monocytes, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.022', 'spread': '0.0679', 'groupId': 'OG000'}, {'value': '0.000', 'spread': '0.0672', 'groupId': 'OG001'}, {'value': '0.012', 'spread': '0.0286', 'groupId': 'OG002'}]}]}, {'title': 'Monocytes, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.006', 'spread': '0.0585', 'groupId': 'OG000'}, {'value': '-0.005', 'spread': '0.0901', 'groupId': 'OG001'}, {'value': '-0.044', 'spread': '0.1607', 'groupId': 'OG002'}]}]}, {'title': 'Neutrophils, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.000', 'spread': '0.6401', 'groupId': 'OG000'}, {'value': '-0.103', 'spread': '0.6015', 'groupId': 'OG001'}, {'value': '-0.334', 'spread': '0.9923', 'groupId': 'OG002'}]}]}, {'title': 'Neutrophils, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.092', 'spread': '0.4511', 'groupId': 'OG000'}, {'value': '0.007', 'spread': '0.1939', 'groupId': 'OG001'}, {'value': '0.222', 'spread': '1.1719', 'groupId': 'OG002'}]}]}, {'title': 'Neutrophils, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.269', 'spread': '0.6770', 'groupId': 'OG000'}, {'value': '-0.066', 'spread': '0.6836', 'groupId': 'OG001'}, {'value': '-0.642', 'spread': '1.3252', 'groupId': 'OG002'}]}]}, {'title': 'Platelets, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.4', 'spread': '9.28', 'groupId': 'OG000'}, {'value': '4.5', 'spread': '15.78', 'groupId': 'OG001'}, {'value': '4.0', 'spread': '14.96', 'groupId': 'OG002'}]}]}, {'title': 'Platelets, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '5.2', 'spread': '13.27', 'groupId': 'OG000'}, {'value': '-1.5', 'spread': '15.06', 'groupId': 'OG001'}, {'value': '-7.5', 'spread': '16.21', 'groupId': 'OG002'}]}]}, {'title': 'Platelets, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.2', 'spread': '20.03', 'groupId': 'OG000'}, {'value': '7.9', 'spread': '26.01', 'groupId': 'OG001'}, {'value': '3.1', 'spread': '32.56', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, and platelets. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': '10^9 cells per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Basophils, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.004', 'spread': '0.0121', 'groupId': 'OG000'}, {'value': '-0.001', 'spread': '0.0111', 'groupId': 'OG001'}]}]}, {'title': 'Basophils, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.010', 'spread': '0.0200', 'groupId': 'OG000'}, {'value': '0.003', 'spread': '0.0071', 'groupId': 'OG001'}]}]}, {'title': 'Basophils, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.000', 'spread': '0.0100', 'groupId': 'OG000'}, {'value': '0.008', 'spread': '0.0273', 'groupId': 'OG001'}]}]}, {'title': 'Eosinophils, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.006', 'spread': '0.0234', 'groupId': 'OG000'}, {'value': '-0.002', 'spread': '0.0342', 'groupId': 'OG001'}]}]}, {'title': 'Eosinophils, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.001', 'spread': '0.0236', 'groupId': 'OG000'}, {'value': '-0.012', 'spread': '0.0205', 'groupId': 'OG001'}]}]}, {'title': 'Eosinophils, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.000', 'spread': '0.0260', 'groupId': 'OG000'}, {'value': '-0.020', 'spread': '0.0400', 'groupId': 'OG001'}]}]}, {'title': 'Lymphocytes, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.068', 'spread': '0.2198', 'groupId': 'OG000'}, {'value': '0.067', 'spread': '0.1895', 'groupId': 'OG001'}]}]}, {'title': 'Lymphocytes, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.075', 'spread': '0.1507', 'groupId': 'OG000'}, {'value': '-0.077', 'spread': '0.1678', 'groupId': 'OG001'}]}]}, {'title': 'Lymphocytes, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.003', 'spread': '0.2733', 'groupId': 'OG000'}, {'value': '0.016', 'spread': '0.1068', 'groupId': 'OG001'}]}]}, {'title': 'Monocytes, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.023', 'spread': '0.0422', 'groupId': 'OG000'}, {'value': '0.014', 'spread': '0.0497', 'groupId': 'OG001'}]}]}, {'title': 'Monocytes, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.009', 'spread': '0.1040', 'groupId': 'OG000'}, {'value': '-0.022', 'spread': '0.0851', 'groupId': 'OG001'}]}]}, {'title': 'Monocytes, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.006', 'spread': '0.0923', 'groupId': 'OG000'}, {'value': '0.034', 'spread': '0.0706', 'groupId': 'OG001'}]}]}, {'title': 'Neutrophils, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.077', 'spread': '0.4373', 'groupId': 'OG000'}, {'value': '-0.016', 'spread': '0.4117', 'groupId': 'OG001'}]}]}, {'title': 'Neutrophils, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.719', 'spread': '1.2615', 'groupId': 'OG000'}, {'value': '0.268', 'spread': '0.8053', 'groupId': 'OG001'}]}]}, {'title': 'Neutrophils, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.058', 'spread': '0.6203', 'groupId': 'OG000'}, {'value': '-0.226', 'spread': '0.4835', 'groupId': 'OG001'}]}]}, {'title': 'Platelets, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.1', 'spread': '16.69', 'groupId': 'OG000'}, {'value': '7.1', 'spread': '12.62', 'groupId': 'OG001'}]}]}, {'title': 'Platelets, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '7.19', 'groupId': 'OG000'}, {'value': '6.7', 'spread': '11.32', 'groupId': 'OG001'}]}]}, {'title': 'Platelets, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.2', 'spread': '29.94', 'groupId': 'OG000'}, {'value': '-3.4', 'spread': '30.53', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, and platelets. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': '10^9 cells per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Change From Baseline in Hematology Parameter: Hemoglobin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.2', 'spread': '5.98', 'groupId': 'OG000'}, {'value': '0.4', 'spread': '5.44', 'groupId': 'OG001'}, {'value': '0.4', 'spread': '5.09', 'groupId': 'OG002'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.5', 'spread': '4.46', 'groupId': 'OG000'}, {'value': '-2.7', 'spread': '4.59', 'groupId': 'OG001'}, {'value': '-1.3', 'spread': '5.01', 'groupId': 'OG002'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.8', 'spread': '3.16', 'groupId': 'OG000'}, {'value': '-3.2', 'spread': '7.57', 'groupId': 'OG001'}, {'value': '0.0', 'spread': '5.10', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Grams per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Change From Baseline in Hematology Parameter: Hemoglobin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.4', 'spread': '4.86', 'groupId': 'OG000'}, {'value': '2.2', 'spread': '4.66', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.4', 'spread': '4.00', 'groupId': 'OG000'}, {'value': '1.2', 'spread': '5.52', 'groupId': 'OG001'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.2', 'spread': '4.35', 'groupId': 'OG000'}, {'value': '1.7', 'spread': '3.84', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Grams per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed'}, {'type': 'SECONDARY', 'title': 'Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.06', 'spread': '0.576', 'groupId': 'OG000'}, {'value': '0.18', 'spread': '0.658', 'groupId': 'OG001'}, {'value': '0.05', 'spread': '0.664', 'groupId': 'OG002'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.32', 'spread': '0.615', 'groupId': 'OG000'}, {'value': '0.42', 'spread': '0.611', 'groupId': 'OG001'}, {'value': '0.13', 'spread': '0.423', 'groupId': 'OG002'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.58', 'spread': '0.456', 'groupId': 'OG000'}, {'value': '0.10', 'spread': '0.663', 'groupId': 'OG001'}, {'value': '-0.09', 'spread': '0.780', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Femtoliter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.05', 'spread': '0.629', 'groupId': 'OG000'}, {'value': '-0.16', 'spread': '0.444', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.31', 'spread': '0.479', 'groupId': 'OG000'}, {'value': '0.13', 'spread': '0.552', 'groupId': 'OG001'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.11', 'spread': '0.992', 'groupId': 'OG000'}, {'value': '-0.13', 'spread': '0.418', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Femtoliter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Change From Baseline in Hematology Parameter: Erythrocytes', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.052', 'spread': '0.1937', 'groupId': 'OG000'}, {'value': '0.005', 'spread': '0.1651', 'groupId': 'OG001'}, {'value': '0.014', 'spread': '0.1672', 'groupId': 'OG002'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.020', 'spread': '0.1642', 'groupId': 'OG000'}, {'value': '-0.097', 'spread': '0.1592', 'groupId': 'OG001'}, {'value': '-0.062', 'spread': '0.1297', 'groupId': 'OG002'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.043', 'spread': '0.1286', 'groupId': 'OG000'}, {'value': '-0.115', 'spread': '0.2308', 'groupId': 'OG001'}, {'value': '0.010', 'spread': '0.2011', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': '10^12 cells per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Change From Baseline in Hematology Parameter: Erythrocytes', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.034', 'spread': '0.1628', 'groupId': 'OG000'}, {'value': '0.061', 'spread': '0.1886', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.024', 'spread': '0.1464', 'groupId': 'OG000'}, {'value': '0.027', 'spread': '0.2285', 'groupId': 'OG001'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.077', 'spread': '0.1875', 'groupId': 'OG000'}, {'value': '-0.003', 'spread': '0.1151', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': '10^12 cells per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Change From Baseline in Hematology Parameter: Hematocrit', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.0042', 'spread': '0.01656', 'groupId': 'OG000'}, {'value': '0.0013', 'spread': '0.01405', 'groupId': 'OG001'}, {'value': '0.0017', 'spread': '0.01477', 'groupId': 'OG002'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.0027', 'spread': '0.01253', 'groupId': 'OG000'}, {'value': '-0.0067', 'spread': '0.01369', 'groupId': 'OG001'}, {'value': '-0.0048', 'spread': '0.01148', 'groupId': 'OG002'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.0066', 'spread': '0.01184', 'groupId': 'OG000'}, {'value': '-0.0092', 'spread': '0.01971', 'groupId': 'OG001'}, {'value': '0.0011', 'spread': '0.01930', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: hemotocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Proportion of red blood cells in blood', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Change From Baseline in Hematology Parameter: Hematocrit', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.0029', 'spread': '0.01474', 'groupId': 'OG000'}, {'value': '0.0047', 'spread': '0.01576', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.0038', 'spread': '0.01403', 'groupId': 'OG000'}, {'value': '0.0040', 'spread': '0.02060', 'groupId': 'OG001'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.0074', 'spread': '0.01795', 'groupId': 'OG000'}, {'value': '-0.0007', 'spread': '0.01093', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameters: hemotocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Proportion of red blood cells in blood', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.02', 'spread': '0.319', 'groupId': 'OG000'}, {'value': '0.04', 'spread': '0.368', 'groupId': 'OG001'}, {'value': '-0.02', 'spread': '0.233', 'groupId': 'OG002'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.05', 'spread': '0.138', 'groupId': 'OG000'}, {'value': '0.07', 'spread': '0.280', 'groupId': 'OG001'}, {'value': '0.17', 'spread': '0.301', 'groupId': 'OG002'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.05', 'spread': '0.372', 'groupId': 'OG000'}, {'value': '0.01', 'spread': '0.423', 'groupId': 'OG001'}, {'value': '-0.16', 'spread': '0.320', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Picograms', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.07', 'spread': '0.451', 'groupId': 'OG000'}, {'value': '0.06', 'spread': '0.463', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.13', 'spread': '0.255', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.387', 'groupId': 'OG001'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.21', 'spread': '0.483', 'groupId': 'OG000'}, {'value': '0.34', 'spread': '0.445', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Picograms', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'ALT, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '16.4', 'spread': '9.44', 'groupId': 'OG000'}, {'value': '19.1', 'spread': '13.65', 'groupId': 'OG001'}, {'value': '18.9', 'spread': '15.33', 'groupId': 'OG002'}]}]}, {'title': 'ALT, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '16.3', 'spread': '9.32', 'groupId': 'OG000'}, {'value': '17.4', 'spread': '9.99', 'groupId': 'OG001'}, {'value': '18.4', 'spread': '12.29', 'groupId': 'OG002'}]}]}, {'title': 'ALT, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '14.0', 'spread': '4.56', 'groupId': 'OG000'}, {'value': '16.7', 'spread': '8.64', 'groupId': 'OG001'}, {'value': '19.5', 'spread': '16.67', 'groupId': 'OG002'}]}]}, {'title': 'ALT, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '20.5', 'spread': '14.81', 'groupId': 'OG000'}, {'value': '20.8', 'spread': '18.34', 'groupId': 'OG001'}, {'value': '17.2', 'spread': '9.60', 'groupId': 'OG002'}]}]}, {'title': 'ALP, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '54.6', 'spread': '14.90', 'groupId': 'OG000'}, {'value': '55.6', 'spread': '15.14', 'groupId': 'OG001'}, {'value': '53.4', 'spread': '15.34', 'groupId': 'OG002'}]}]}, {'title': 'ALP, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '56.5', 'spread': '14.72', 'groupId': 'OG000'}, {'value': '57.6', 'spread': '14.03', 'groupId': 'OG001'}, {'value': '55.2', 'spread': '15.58', 'groupId': 'OG002'}]}]}, {'title': 'ALP, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '49.8', 'spread': '13.69', 'groupId': 'OG000'}, {'value': '60.8', 'spread': '12.62', 'groupId': 'OG001'}, {'value': '53.8', 'spread': '17.62', 'groupId': 'OG002'}]}]}, {'title': 'ALP, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '55.1', 'spread': '14.74', 'groupId': 'OG000'}, {'value': '52.8', 'spread': '16.34', 'groupId': 'OG001'}, {'value': '59.3', 'spread': '16.35', 'groupId': 'OG002'}]}]}, {'title': 'AST, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '16.3', 'spread': '4.84', 'groupId': 'OG000'}, {'value': '17.0', 'spread': '5.63', 'groupId': 'OG001'}, {'value': '17.1', 'spread': '6.23', 'groupId': 'OG002'}]}]}, {'title': 'AST, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '15.8', 'spread': '4.02', 'groupId': 'OG000'}, {'value': '16.1', 'spread': '4.57', 'groupId': 'OG001'}, {'value': '17.1', 'spread': '5.92', 'groupId': 'OG002'}]}]}, {'title': 'AST, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '14.8', 'spread': '4.26', 'groupId': 'OG000'}, {'value': '16.2', 'spread': '4.92', 'groupId': 'OG001'}, {'value': '16.3', 'spread': '2.07', 'groupId': 'OG002'}]}]}, {'title': 'AST, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '16.5', 'spread': '5.13', 'groupId': 'OG000'}, {'value': '17.5', 'spread': '7.31', 'groupId': 'OG001'}, {'value': '17.5', 'spread': '6.19', 'groupId': 'OG002'}]}]}, {'title': 'GGT, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '22.1', 'spread': '15.68', 'groupId': 'OG000'}, {'value': '22.9', 'spread': '16.21', 'groupId': 'OG001'}, {'value': '22.2', 'spread': '15.53', 'groupId': 'OG002'}]}]}, {'title': 'GGT, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '22.0', 'spread': '14.57', 'groupId': 'OG000'}, {'value': '22.8', 'spread': '15.45', 'groupId': 'OG001'}, {'value': '22.7', 'spread': '13.77', 'groupId': 'OG002'}]}]}, {'title': 'GGT, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '22.3', 'spread': '19.38', 'groupId': 'OG000'}, {'value': '21.8', 'spread': '6.11', 'groupId': 'OG001'}, {'value': '20.5', 'spread': '12.36', 'groupId': 'OG002'}]}]}, {'title': 'GGT, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '21.4', 'spread': '10.08', 'groupId': 'OG000'}, {'value': '22.9', 'spread': '18.60', 'groupId': 'OG001'}, {'value': '26.8', 'spread': '20.97', 'groupId': 'OG002'}]}]}, {'title': 'LDH, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '121.7', 'spread': '19.59', 'groupId': 'OG000'}, {'value': '121.0', 'spread': '24.41', 'groupId': 'OG001'}, {'value': '119.5', 'spread': '22.30', 'groupId': 'OG002'}]}]}, {'title': 'LDH, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '119.1', 'spread': '16.92', 'groupId': 'OG000'}, {'value': '120.1', 'spread': '23.02', 'groupId': 'OG001'}, {'value': '123.5', 'spread': '25.15', 'groupId': 'OG002'}]}]}, {'title': 'LDH, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '119.5', 'spread': '15.54', 'groupId': 'OG000'}, {'value': '114.0', 'spread': '21.22', 'groupId': 'OG001'}, {'value': '107.5', 'spread': '16.08', 'groupId': 'OG002'}]}]}, {'title': 'LDH, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '105.3', 'spread': '12.41', 'groupId': 'OG000'}, {'value': '118.1', 'spread': '22.72', 'groupId': 'OG001'}, {'value': '116.0', 'spread': '20.23', 'groupId': 'OG002'}]}]}, {'title': 'CK, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '101.0', 'spread': '49.01', 'groupId': 'OG000'}, {'value': '115.1', 'spread': '114.93', 'groupId': 'OG001'}, {'value': '106.8', 'spread': '93.82', 'groupId': 'OG002'}]}]}, {'title': 'CK, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '89.7', 'spread': '51.73', 'groupId': 'OG000'}, {'value': '104.8', 'spread': '109.70', 'groupId': 'OG001'}, {'value': '107.0', 'spread': '114.66', 'groupId': 'OG002'}]}]}, {'title': 'CK, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '69.0', 'spread': '33.00', 'groupId': 'OG000'}, {'value': '96.5', 'spread': '63.32', 'groupId': 'OG001'}, {'value': '85.8', 'spread': '40.74', 'groupId': 'OG002'}]}]}, {'title': 'CK, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '90.8', 'spread': '51.77', 'groupId': 'OG000'}, {'value': '104.6', 'spread': '109.85', 'groupId': 'OG001'}, {'value': '88.2', 'spread': '46.19', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1), and Days 2, 5, and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: ALT, ALP, AST, GGT, LDH, CK. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'International units per Liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'ALT, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '18.9', 'spread': '12.42', 'groupId': 'OG000'}, {'value': '18.8', 'spread': '13.37', 'groupId': 'OG001'}]}]}, {'title': 'ALT, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '18.6', 'spread': '11.57', 'groupId': 'OG000'}, {'value': '18.9', 'spread': '12.65', 'groupId': 'OG001'}]}]}, {'title': 'ALT, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '18.5', 'spread': '11.82', 'groupId': 'OG000'}, {'value': '25.2', 'spread': '20.47', 'groupId': 'OG001'}]}]}, {'title': 'ALT, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '21.8', 'spread': '16.34', 'groupId': 'OG000'}, {'value': '18.1', 'spread': '9.97', 'groupId': 'OG001'}]}]}, {'title': 'ALP Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '63.2', 'spread': '18.86', 'groupId': 'OG000'}, {'value': '61.6', 'spread': '18.57', 'groupId': 'OG001'}]}]}, {'title': 'ALP, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '62.1', 'spread': '18.43', 'groupId': 'OG000'}, {'value': '62.1', 'spread': '18.75', 'groupId': 'OG001'}]}]}, {'title': 'ALP, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '61.6', 'spread': '18.18', 'groupId': 'OG000'}, {'value': '70.4', 'spread': '21.18', 'groupId': 'OG001'}]}]}, {'title': 'ALP, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '66.6', 'spread': '17.59', 'groupId': 'OG000'}, {'value': '58.8', 'spread': '19.73', 'groupId': 'OG001'}]}]}, {'title': 'AST, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '16.4', 'spread': '4.15', 'groupId': 'OG000'}, {'value': '16.7', 'spread': '4.92', 'groupId': 'OG001'}]}]}, {'title': 'AST, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '15.6', 'spread': '3.36', 'groupId': 'OG000'}, {'value': '16.1', 'spread': '4.30', 'groupId': 'OG001'}]}]}, {'title': 'AST, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '17.0', 'spread': '2.88', 'groupId': 'OG000'}, {'value': '20.1', 'spread': '7.79', 'groupId': 'OG001'}]}]}, {'title': 'AST, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '17.7', 'spread': '6.56', 'groupId': 'OG000'}, {'value': '15.9', 'spread': '2.71', 'groupId': 'OG001'}]}]}, {'title': 'GGT, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '21.6', 'spread': '8.81', 'groupId': 'OG000'}, {'value': '21.7', 'spread': '9.34', 'groupId': 'OG001'}]}]}, {'title': 'GGT, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '20.9', 'spread': '8.62', 'groupId': 'OG000'}, {'value': '22.2', 'spread': '9.67', 'groupId': 'OG001'}]}]}, {'title': 'GGT, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '21.6', 'spread': '8.33', 'groupId': 'OG000'}, {'value': '22.8', 'spread': '11.91', 'groupId': 'OG001'}]}]}, {'title': 'GGT, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '20.8', 'spread': '9.65', 'groupId': 'OG000'}, {'value': '21.8', 'spread': '8.30', 'groupId': 'OG001'}]}]}, {'title': 'LDH, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '125.5', 'spread': '14.23', 'groupId': 'OG000'}, {'value': '123.4', 'spread': '14.62', 'groupId': 'OG001'}]}]}, {'title': 'LDH, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '117.8', 'spread': '13.32', 'groupId': 'OG000'}, {'value': '118.4', 'spread': '11.64', 'groupId': 'OG001'}]}]}, {'title': 'LDH, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '122.6', 'spread': '16.59', 'groupId': 'OG000'}, {'value': '122.6', 'spread': '14.56', 'groupId': 'OG001'}]}]}, {'title': 'LDH, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '119.2', 'spread': '14.92', 'groupId': 'OG000'}, {'value': '124.9', 'spread': '17.95', 'groupId': 'OG001'}]}]}, {'title': 'CK, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '101.8', 'spread': '52.32', 'groupId': 'OG000'}, {'value': '103.3', 'spread': '56.84', 'groupId': 'OG001'}]}]}, {'title': 'CK, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '89.5', 'spread': '45.43', 'groupId': 'OG000'}, {'value': '89.9', 'spread': '41.11', 'groupId': 'OG001'}]}]}, {'title': 'CK, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '95.8', 'spread': '38.31', 'groupId': 'OG000'}, {'value': '99.8', 'spread': '65.97', 'groupId': 'OG001'}]}]}, {'title': 'CK, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '97.7', 'spread': '65.84', 'groupId': 'OG000'}, {'value': '85.9', 'spread': '31.47', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: ALT, ALP, AST, GGT, LDH, CK. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'International units per Liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Calcium, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2.357', 'spread': '0.0999', 'groupId': 'OG000'}, {'value': '2.366', 'spread': '0.1034', 'groupId': 'OG001'}, {'value': '2.347', 'spread': '0.0839', 'groupId': 'OG002'}]}]}, {'title': 'Calcium, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2.371', 'spread': '0.0986', 'groupId': 'OG000'}, {'value': '2.377', 'spread': '0.0868', 'groupId': 'OG001'}, {'value': '2.379', 'spread': '0.1009', 'groupId': 'OG002'}]}]}, {'title': 'Calcium, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2.345', 'spread': '0.0948', 'groupId': 'OG000'}, {'value': '2.407', 'spread': '0.0509', 'groupId': 'OG001'}, {'value': '2.393', 'spread': '0.1171', 'groupId': 'OG002'}]}]}, {'title': 'Calcium, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2.380', 'spread': '0.0949', 'groupId': 'OG000'}, {'value': '2.348', 'spread': '0.1014', 'groupId': 'OG001'}, {'value': '2.371', 'spread': '0.1201', 'groupId': 'OG002'}]}]}, {'title': 'CO2, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '30.5', 'spread': '1.90', 'groupId': 'OG000'}, {'value': '30.2', 'spread': '2.14', 'groupId': 'OG001'}, {'value': '30.3', 'spread': '1.83', 'groupId': 'OG002'}]}]}, {'title': 'CO2, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '29.4', 'spread': '2.24', 'groupId': 'OG000'}, {'value': '29.8', 'spread': '2.12', 'groupId': 'OG001'}, {'value': '29.8', 'spread': '2.36', 'groupId': 'OG002'}]}]}, {'title': 'CO2, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '28.2', 'spread': '1.94', 'groupId': 'OG000'}, {'value': '29.3', 'spread': '2.34', 'groupId': 'OG001'}, {'value': '29.7', 'spread': '2.50', 'groupId': 'OG002'}]}]}, {'title': 'CO2, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '30.5', 'spread': '2.50', 'groupId': 'OG000'}, {'value': '30.5', 'spread': '1.98', 'groupId': 'OG001'}, {'value': '30.0', 'spread': '2.05', 'groupId': 'OG002'}]}]}, {'title': 'Chloride, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '101.7', 'spread': '1.49', 'groupId': 'OG000'}, {'value': '101.8', 'spread': '2.07', 'groupId': 'OG001'}, {'value': '102.1', 'spread': '2.21', 'groupId': 'OG002'}]}]}, {'title': 'Chloride, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '102.0', 'spread': '2.53', 'groupId': 'OG000'}, {'value': '101.6', 'spread': '2.11', 'groupId': 'OG001'}, {'value': '102.0', 'spread': '2.32', 'groupId': 'OG002'}]}]}, {'title': 'Chloride, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '102.8', 'spread': '1.47', 'groupId': 'OG000'}, {'value': '101.3', 'spread': '2.16', 'groupId': 'OG001'}, {'value': '101.7', 'spread': '1.86', 'groupId': 'OG002'}]}]}, {'title': 'Chloride, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '101.9', 'spread': '1.92', 'groupId': 'OG000'}, {'value': '102.4', 'spread': '2.02', 'groupId': 'OG001'}, {'value': '101.8', 'spread': '1.03', 'groupId': 'OG002'}]}]}, {'title': 'Glucose, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '5.125', 'spread': '0.4472', 'groupId': 'OG000'}, {'value': '5.114', 'spread': '0.3745', 'groupId': 'OG001'}, {'value': '5.074', 'spread': '0.3816', 'groupId': 'OG002'}]}]}, {'title': 'Glucose, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.927', 'spread': '0.4659', 'groupId': 'OG000'}, {'value': '4.979', 'spread': '0.4960', 'groupId': 'OG001'}, {'value': '4.813', 'spread': '0.4044', 'groupId': 'OG002'}]}]}, {'title': 'Glucose, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.643', 'spread': '0.3725', 'groupId': 'OG000'}, {'value': '5.153', 'spread': '0.3527', 'groupId': 'OG001'}, {'value': '5.123', 'spread': '0.4912', 'groupId': 'OG002'}]}]}, {'title': 'Glucose, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '5.207', 'spread': '0.3982', 'groupId': 'OG000'}, {'value': '4.980', 'spread': '0.4112', 'groupId': 'OG001'}, {'value': '4.946', 'spread': '0.3303', 'groupId': 'OG002'}]}]}, {'title': 'Potassium, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.20', 'spread': '0.233', 'groupId': 'OG000'}, {'value': '4.30', 'spread': '4.24', 'groupId': 'OG001'}, {'value': '4.24', 'spread': '0.315', 'groupId': 'OG002'}]}]}, {'title': 'Potassium, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.22', 'spread': '0.246', 'groupId': 'OG000'}, {'value': '4.12', 'spread': '0.266', 'groupId': 'OG001'}, {'value': '4.27', 'spread': '0.334', 'groupId': 'OG002'}]}]}, {'title': 'Potassium, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.18', 'spread': '0.147', 'groupId': 'OG000'}, {'value': '4.08', 'spread': '0.271', 'groupId': 'OG001'}, {'value': '4.15', 'spread': '0.513', 'groupId': 'OG002'}]}]}, {'title': 'Potassium, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.35', 'spread': '0.383', 'groupId': 'OG000'}, {'value': '4.24', 'spread': '0.331', 'groupId': 'OG001'}, {'value': '4.16', 'spread': '0.165', 'groupId': 'OG002'}]}]}, {'title': 'Sodium, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '137.5', 'spread': '2.48', 'groupId': 'OG000'}, {'value': '137.9', 'spread': '2.15', 'groupId': 'OG001'}, {'value': '137.6', 'spread': '2.37', 'groupId': 'OG002'}]}]}, {'title': 'Sodium, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '137.5', 'spread': '2.22', 'groupId': 'OG000'}, {'value': '137.8', 'spread': '1.73', 'groupId': 'OG001'}, {'value': '137.9', 'spread': '1.76', 'groupId': 'OG002'}]}]}, {'title': 'Sodium, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '137.8', 'spread': '1.83', 'groupId': 'OG000'}, {'value': '137.2', 'spread': '2.14', 'groupId': 'OG001'}, {'value': '137.8', 'spread': '2.64', 'groupId': 'OG002'}]}]}, {'title': 'Sodium, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '138.2', 'spread': '1.99', 'groupId': 'OG000'}, {'value': '138.2', 'spread': '2.20', 'groupId': 'OG001'}, {'value': '137.2', 'spread': '2.39', 'groupId': 'OG002'}]}]}, {'title': 'Urea nitrogen, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.105', 'spread': '0.9931', 'groupId': 'OG000'}, {'value': '4.398', 'spread': '0.9260', 'groupId': 'OG001'}, {'value': '4.216', 'spread': '0.5976', 'groupId': 'OG002'}]}]}, {'title': 'Urea nitrogen, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.625', 'spread': '0.8713', 'groupId': 'OG000'}, {'value': '4.731', 'spread': '0.8265', 'groupId': 'OG001'}, {'value': '4.491', 'spread': '0.8115', 'groupId': 'OG002'}]}]}, {'title': 'Urea nitrogen, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '3.980', 'spread': '0.4246', 'groupId': 'OG000'}, {'value': '4.378', 'spread': '0.6674', 'groupId': 'OG001'}, {'value': '4.368', 'spread': '0.6707', 'groupId': 'OG002'}]}]}, {'title': 'Urea nitrogen, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.810', 'spread': '1.0170', 'groupId': 'OG000'}, {'value': '4.220', 'spread': '0.5511', 'groupId': 'OG001'}, {'value': '4.439', 'spread': '1.0769', 'groupId': 'OG002'}]}]}, {'title': 'Phosphate, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.126', 'spread': '0.1429', 'groupId': 'OG000'}, {'value': '1.095', 'spread': '0.1602', 'groupId': 'OG001'}, {'value': '1.156', 'spread': '0.1414', 'groupId': 'OG002'}]}]}, {'title': 'Phosphate, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.195', 'spread': '0.1672', 'groupId': 'OG000'}, {'value': '1.173', 'spread': '0.1474', 'groupId': 'OG001'}, {'value': '1.238', 'spread': '0.1306', 'groupId': 'OG002'}]}]}, {'title': 'Phosphate, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.267', 'spread': '0.1007', 'groupId': 'OG000'}, {'value': '1.142', 'spread': '0.2344', 'groupId': 'OG001'}, {'value': '1.178', 'spread': '0.1574', 'groupId': 'OG002'}]}]}, {'title': 'Phosphate, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.114', 'spread': '0.0886', 'groupId': 'OG000'}, {'value': '1.198', 'spread': '0.1058', 'groupId': 'OG001'}, {'value': '1.172', 'spread': '0.1494', 'groupId': 'OG002'}]}]}, {'title': 'Triglycerides, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.161', 'spread': '0.3495', 'groupId': 'OG000'}, {'value': '1.284', 'spread': '0.6031', 'groupId': 'OG001'}, {'value': '1.011', 'spread': '0.3381', 'groupId': 'OG002'}]}]}, {'title': 'Triglycerides, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.255', 'spread': '0.5400', 'groupId': 'OG000'}, {'value': '1.271', 'spread': '0.6676', 'groupId': 'OG001'}, {'value': '1.022', 'spread': '0.3455', 'groupId': 'OG002'}]}]}, {'title': 'Triglycerides, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.907', 'spread': '0.2482', 'groupId': 'OG000'}, {'value': '1.020', 'spread': '0.4494', 'groupId': 'OG001'}, {'value': '0.827', 'spread': '0.2523', 'groupId': 'OG002'}]}]}, {'title': 'Triglycerides Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.316', 'spread': '0.6488', 'groupId': 'OG000'}, {'value': '0.972', 'spread': '0.3031', 'groupId': 'OG001'}, {'value': '1.048', 'spread': '0.3121', 'groupId': 'OG002'}]}]}, {'title': 'Cholesterol, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.666', 'spread': '0.6505', 'groupId': 'OG000'}, {'value': '4.737', 'spread': '0.7591', 'groupId': 'OG001'}, {'value': '4.674', 'spread': '0.6908', 'groupId': 'OG002'}]}]}, {'title': 'Cholesterol, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.783', 'spread': '0.6972', 'groupId': 'OG000'}, {'value': '4.795', 'spread': '0.7617', 'groupId': 'OG001'}, {'value': '4.726', 'spread': '0.7404', 'groupId': 'OG002'}]}]}, {'title': 'Cholesterol, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.863', 'spread': '0.6029', 'groupId': 'OG000'}, {'value': '4.507', 'spread': '1.2255', 'groupId': 'OG001'}, {'value': '4.292', 'spread': '0.4032', 'groupId': 'OG002'}]}]}, {'title': 'Cholesterol, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.415', 'spread': '0.5871', 'groupId': 'OG000'}, {'value': '4.776', 'spread': '0.6017', 'groupId': 'OG001'}, {'value': '4.590', 'spread': '0.7417', 'groupId': 'OG002'}]}]}, {'title': 'Anion gap, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '9.5', 'spread': '1.30', 'groupId': 'OG000'}, {'value': '10.1', 'spread': '1.62', 'groupId': 'OG001'}, {'value': '9.6', 'spread': '1.43', 'groupId': 'OG002'}]}]}, {'title': 'Anion gap, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '10.3', 'spread': '1.94', 'groupId': 'OG000'}, {'value': '10.5', 'spread': '1.29', 'groupId': 'OG001'}, {'value': '10.3', 'spread': '2.23', 'groupId': 'OG002'}]}]}, {'title': 'Anion gap, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '10.8', 'spread': '1.72', 'groupId': 'OG000'}, {'value': '10.7', 'spread': '1.63', 'groupId': 'OG001'}, {'value': '10.8', 'spread': '1.72', 'groupId': 'OG002'}]}]}, {'title': 'Anion gap, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '10.2', 'spread': '1.25', 'groupId': 'OG000'}, {'value': '9.7', 'spread': '1.38', 'groupId': 'OG001'}, {'value': '9.4', 'spread': '1.65', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1), and Days 2, 5, and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: calcium, CO2, chloride, glucose, potassium, sodium, urea nitrogen, phosphorus, triglycerides, cholesterol, and anion gap. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Millimoles per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Calcium, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.356', 'spread': '0.0947', 'groupId': 'OG000'}, {'value': '2.354', 'spread': '0.0833', 'groupId': 'OG001'}]}]}, {'title': 'Calcium, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.343', 'spread': '0.0922', 'groupId': 'OG000'}, {'value': '2.362', 'spread': '0.0854', 'groupId': 'OG001'}]}]}, {'title': 'Calcium, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.315', 'spread': '0.0991', 'groupId': 'OG000'}, {'value': '2.381', 'spread': '0.0764', 'groupId': 'OG001'}]}]}, {'title': 'Calcium, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.362', 'spread': '0.1049', 'groupId': 'OG000'}, {'value': '2.340', 'spread': '0.0616', 'groupId': 'OG001'}]}]}, {'title': 'CO2, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '31.2', 'spread': '1.42', 'groupId': 'OG000'}, {'value': '31.1', 'spread': '1.51', 'groupId': 'OG001'}]}]}, {'title': 'CO2, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '29.8', 'spread': '2.10', 'groupId': 'OG000'}, {'value': '30.1', 'spread': '2.10', 'groupId': 'OG001'}]}]}, {'title': 'CO2, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '30.1', 'spread': '1.64', 'groupId': 'OG000'}, {'value': '30.8', 'spread': '1.86', 'groupId': 'OG001'}]}]}, {'title': 'CO2, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '31.3', 'spread': '1.87', 'groupId': 'OG000'}, {'value': '31.1', 'spread': '1.17', 'groupId': 'OG001'}]}]}, {'title': 'Chloride, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '101.8', 'spread': '2.11', 'groupId': 'OG000'}, {'value': '102.1', 'spread': '1.45', 'groupId': 'OG001'}]}]}, {'title': 'Chloride, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '102.3', 'spread': '1.34', 'groupId': 'OG000'}, {'value': '101.7', 'spread': '1.64', 'groupId': 'OG001'}]}]}, {'title': 'Chloride, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '102.0', 'spread': '1.93', 'groupId': 'OG000'}, {'value': '101.4', 'spread': '1.01', 'groupId': 'OG001'}]}]}, {'title': 'Chloride, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '102.3', 'spread': '1.87', 'groupId': 'OG000'}, {'value': '102.1', 'spread': '2.20', 'groupId': 'OG001'}]}]}, {'title': 'Glucose, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.872', 'spread': '0.3107', 'groupId': 'OG000'}, {'value': '4.913', 'spread': '0.3252', 'groupId': 'OG001'}]}]}, {'title': 'Glucose, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.784', 'spread': '0.3470', 'groupId': 'OG000'}, {'value': '4.989', 'spread': '0.3379', 'groupId': 'OG001'}]}]}, {'title': 'Glucose, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.606', 'spread': '0.3351', 'groupId': 'OG000'}, {'value': '4.729', 'spread': '0.1985', 'groupId': 'OG001'}]}]}, {'title': 'Glucose, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.984', 'spread': '0.3691', 'groupId': 'OG000'}, {'value': '4.754', 'spread': '0.3304', 'groupId': 'OG001'}]}]}, {'title': 'Potassium, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.29', 'spread': '0.183', 'groupId': 'OG000'}, {'value': '4.27', 'spread': '0.225', 'groupId': 'OG001'}]}]}, {'title': 'Potassium, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.30', 'spread': '0.193', 'groupId': 'OG000'}, {'value': '4.36', 'spread': '0.350', 'groupId': 'OG001'}]}]}, {'title': 'Potassium, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.33', 'spread': '0.369', 'groupId': 'OG000'}, {'value': '4.18', 'spread': '0.222', 'groupId': 'OG001'}]}]}, {'title': 'Potassium, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.26', 'spread': '0.133', 'groupId': 'OG000'}, {'value': '4.46', 'spread': '0.364', 'groupId': 'OG001'}]}]}, {'title': 'Sodium, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '138.2', 'spread': '2.02', 'groupId': 'OG000'}, {'value': '138.1', 'spread': '1.55', 'groupId': 'OG001'}]}]}, {'title': 'Sodium, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '137.8', 'spread': '1.83', 'groupId': 'OG000'}, {'value': '137.8', 'spread': '2.39', 'groupId': 'OG001'}]}]}, {'title': 'Sodium, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '137.4', 'spread': '1.69', 'groupId': 'OG000'}, {'value': '138.1', 'spread': '1.90', 'groupId': 'OG001'}]}]}, {'title': 'Sodium, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '138.9', 'spread': '1.17', 'groupId': 'OG000'}, {'value': '138.4', 'spread': '2.40', 'groupId': 'OG001'}]}]}, {'title': 'Urea nitrogen, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.193', 'spread': '0.9707', 'groupId': 'OG000'}, {'value': '4.289', 'spread': '0.8517', 'groupId': 'OG001'}]}]}, {'title': 'Urea nitrogen, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.511', 'spread': '0.8025', 'groupId': 'OG000'}, {'value': '4.917', 'spread': '1.2215', 'groupId': 'OG001'}]}]}, {'title': 'Urea nitrogen, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.488', 'spread': '0.7840', 'groupId': 'OG000'}, {'value': '4.197', 'spread': '0.9577', 'groupId': 'OG001'}]}]}, {'title': 'Urea nitrogen, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.130', 'spread': '0.9850', 'groupId': 'OG000'}, {'value': '4.889', 'spread': '1.2618', 'groupId': 'OG001'}]}]}, {'title': 'Phosphate, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.129', 'spread': '0.1711', 'groupId': 'OG000'}, {'value': '1.137', 'spread': '0.1644', 'groupId': 'OG001'}]}]}, {'title': 'Phosphate, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.163', 'spread': '0.1414', 'groupId': 'OG000'}, {'value': '1.181', 'spread': '0.1402', 'groupId': 'OG001'}]}]}, {'title': 'Phosphate, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.149', 'spread': '0.1183', 'groupId': 'OG000'}, {'value': '1.159', 'spread': '0.1837', 'groupId': 'OG001'}]}]}, {'title': 'Phosphate, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.147', 'spread': '0.1777', 'groupId': 'OG000'}, {'value': '1.146', 'spread': '0.1261', 'groupId': 'OG001'}]}]}, {'title': 'Triglycerides, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.380', 'spread': '0.5675', 'groupId': 'OG000'}, {'value': '1.346', 'spread': '0.6796', 'groupId': 'OG001'}]}]}, {'title': 'Triglycerides, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.255', 'spread': '0.5644', 'groupId': 'OG000'}, {'value': '1.226', 'spread': '0.4816', 'groupId': 'OG001'}]}]}, {'title': 'Triglycerides, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.268', 'spread': '0.6846', 'groupId': 'OG000'}, {'value': '1.044', 'spread': '0.4087', 'groupId': 'OG001'}]}]}, {'title': 'Triglycerides, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.200', 'spread': '0.5402', 'groupId': 'OG000'}, {'value': '1.461', 'spread': '0.7119', 'groupId': 'OG001'}]}]}, {'title': 'Cholesterol, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.477', 'spread': '0.8449', 'groupId': 'OG000'}, {'value': '4.454', 'spread': '0.7606', 'groupId': 'OG001'}]}]}, {'title': 'Cholesterol, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.603', 'spread': '0.7998', 'groupId': 'OG000'}, {'value': '4.531', 'spread': '0.8227', 'groupId': 'OG001'}]}]}, {'title': 'Cholesterol, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.591', 'spread': '0.8199', 'groupId': 'OG000'}, {'value': '4.287', 'spread': '0.9845', 'groupId': 'OG001'}]}]}, {'title': 'Cholesterol, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.173', 'spread': '0.7740', 'groupId': 'OG000'}, {'value': '4.617', 'spread': '0.8221', 'groupId': 'OG001'}]}]}, {'title': 'Anion Gap, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '9.5', 'spread': '0.87', 'groupId': 'OG000'}, {'value': '9.2', 'spread': '0.92', 'groupId': 'OG001'}]}]}, {'title': 'Anion Gap, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '9.9', 'spread': '0.85', 'groupId': 'OG000'}, {'value': '10.4', 'spread': '0.98', 'groupId': 'OG001'}]}]}, {'title': 'Anion Gap, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '9.6', 'spread': '0.92', 'groupId': 'OG000'}, {'value': '9.0', 'spread': '2.83', 'groupId': 'OG001'}]}]}, {'title': 'Anion Gap, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '9.3', 'spread': '0.87', 'groupId': 'OG000'}, {'value': '9.6', 'spread': '0.88', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: calcium, CO2, chloride, glucose, potassium, sodium, urea nitrogen, phosphorus, triglycerides, cholesterol, and anion gap. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Millimoles per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Absolute Values for Chemistry Parameters: Serum Lipase, Serum Amylase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Serum lipase, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '32.5', 'spread': '12.77', 'groupId': 'OG000'}, {'value': '34.6', 'spread': '17.45', 'groupId': 'OG001'}, {'value': '31.1', 'spread': '13.95', 'groupId': 'OG002'}]}]}, {'title': 'Serum lipase, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '32.1', 'spread': '13.07', 'groupId': 'OG000'}, {'value': '40.4', 'spread': '27.76', 'groupId': 'OG001'}, {'value': '34.2', 'spread': '13.50', 'groupId': 'OG002'}]}]}, {'title': 'Serum lipase, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '34.3', 'spread': '15.08', 'groupId': 'OG000'}, {'value': '40.2', 'spread': '19.87', 'groupId': 'OG001'}, {'value': '27.7', 'spread': '5.61', 'groupId': 'OG002'}]}]}, {'title': 'Serum lipase, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '33.1', 'spread': '17.23', 'groupId': 'OG000'}, {'value': '28.8', 'spread': '11.77', 'groupId': 'OG001'}, {'value': '35.0', 'spread': '17.18', 'groupId': 'OG002'}]}]}, {'title': 'Serum amylase, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '54.9', 'spread': '13.67', 'groupId': 'OG000'}, {'value': '58.9', 'spread': '16.72', 'groupId': 'OG001'}, {'value': '58.4', 'spread': '14.51', 'groupId': 'OG002'}]}]}, {'title': 'Serum amylase, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '58.9', 'spread': '15.47', 'groupId': 'OG000'}, {'value': '62.8', 'spread': '18.88', 'groupId': 'OG001'}, {'value': '61.7', 'spread': '16.92', 'groupId': 'OG002'}]}]}, {'title': 'Serum amylase, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '63.3', 'spread': '9.91', 'groupId': 'OG000'}, {'value': '55.2', 'spread': '15.47', 'groupId': 'OG001'}, {'value': '62.2', 'spread': '23.16', 'groupId': 'OG002'}]}]}, {'title': 'Serum amylase, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '62.0', 'spread': '19.18', 'groupId': 'OG000'}, {'value': '62.2', 'spread': '14.71', 'groupId': 'OG001'}, {'value': '56.2', 'spread': '13.57', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1), and Days 2, 5, and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: serum lipase and serum amylase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Units per Liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Absolute Values for Chemistry Parameters: Serum Lipase, Serum Amylase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Serum lipase, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '32.1', 'spread': '11.73', 'groupId': 'OG000'}, {'value': '30.2', 'spread': '10.22', 'groupId': 'OG001'}]}]}, {'title': 'Serum lipase, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '30.5', 'spread': '11.60', 'groupId': 'OG000'}, {'value': '30.4', 'spread': '11.12', 'groupId': 'OG001'}]}]}, {'title': 'Serum lipase, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '28.6', 'spread': '19.28', 'groupId': 'OG000'}, {'value': '40.3', 'spread': '15.17', 'groupId': 'OG001'}]}]}, {'title': 'Serum lipase, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '35.0', 'spread': '6.22', 'groupId': 'OG000'}, {'value': '25.2', 'spread': '12.59', 'groupId': 'OG001'}]}]}, {'title': 'Serum amylase, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '58.7', 'spread': '17.33', 'groupId': 'OG000'}, {'value': '56.7', 'spread': '15.19', 'groupId': 'OG001'}]}]}, {'title': 'Serum amylase, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '58.3', 'spread': '17.08', 'groupId': 'OG000'}, {'value': '58.8', 'spread': '15.21', 'groupId': 'OG001'}]}]}, {'title': 'Serum amylase, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '53.9', 'spread': '16.40', 'groupId': 'OG000'}, {'value': '62.7', 'spread': '14.06', 'groupId': 'OG001'}]}]}, {'title': 'Serum amylase, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '63.3', 'spread': '15.98', 'groupId': 'OG000'}, {'value': '51.7', 'spread': '14.27', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: serum lipase, serum amylase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Units per Liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Albumin, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '43.8', 'spread': '2.91', 'groupId': 'OG000'}, {'value': '43.8', 'spread': '3.12', 'groupId': 'OG001'}, {'value': '43.8', 'spread': '2.38', 'groupId': 'OG002'}]}]}, {'title': 'Albumin, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '44.6', 'spread': '2.61', 'groupId': 'OG000'}, {'value': '44.5', 'spread': '2.29', 'groupId': 'OG001'}, {'value': '44.5', 'spread': '2.46', 'groupId': 'OG002'}]}]}, {'title': 'Albumin, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '43.8', 'spread': '2.23', 'groupId': 'OG000'}, {'value': '43.8', 'spread': '2.32', 'groupId': 'OG001'}, {'value': '43.2', 'spread': '4.12', 'groupId': 'OG002'}]}]}, {'title': 'Albumin, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '43.6', 'spread': '2.66', 'groupId': 'OG000'}, {'value': '43.9', 'spread': '2.22', 'groupId': 'OG001'}, {'value': '45.3', 'spread': '2.16', 'groupId': 'OG002'}]}]}, {'title': 'Globulin, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '26.4', 'spread': '4.04', 'groupId': 'OG000'}, {'value': '27.0', 'spread': '3.25', 'groupId': 'OG001'}, {'value': '26.0', 'spread': '3.63', 'groupId': 'OG002'}]}]}, {'title': 'Globulin, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '27.3', 'spread': '3.85', 'groupId': 'OG000'}, {'value': '27.4', 'spread': '3.72', 'groupId': 'OG001'}, {'value': '27.1', 'spread': '4.51', 'groupId': 'OG002'}]}]}, {'title': 'Globulin, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '26.0', 'spread': '2.61', 'groupId': 'OG000'}, {'value': '28.0', 'spread': '3.52', 'groupId': 'OG001'}, {'value': '26.2', 'spread': '3.37', 'groupId': 'OG002'}]}]}, {'title': 'Globulin, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '27.1', 'spread': '3.78', 'groupId': 'OG000'}, {'value': '25.8', 'spread': '3.60', 'groupId': 'OG001'}, {'value': '25.9', 'spread': '4.31', 'groupId': 'OG002'}]}]}, {'title': 'Protein, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '70.1', 'spread': '5.10', 'groupId': 'OG000'}, {'value': '70.8', 'spread': '4.12', 'groupId': 'OG001'}, {'value': '69.7', 'spread': '4.46', 'groupId': 'OG002'}]}]}, {'title': 'Protein, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '71.9', 'spread': '4.86', 'groupId': 'OG000'}, {'value': '71.9', 'spread': '4.03', 'groupId': 'OG001'}, {'value': '71.6', 'spread': '5.60', 'groupId': 'OG002'}]}]}, {'title': 'Protein, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '69.8', 'spread': '1.94', 'groupId': 'OG000'}, {'value': '71.8', 'spread': '4.71', 'groupId': 'OG001'}, {'value': '69.3', 'spread': '5.28', 'groupId': 'OG002'}]}]}, {'title': 'Protein, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '70.7', 'spread': '4.90', 'groupId': 'OG000'}, {'value': '69.8', 'spread': '4.17', 'groupId': 'OG001'}, {'value': '71.2', 'spread': '4.71', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1), and Days 2, 5, and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Grams per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Albumin, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '42.9', 'spread': '3.72', 'groupId': 'OG000'}, {'value': '43.1', 'spread': '3.40', 'groupId': 'OG001'}]}]}, {'title': 'Albumin, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '43.3', 'spread': '2.91', 'groupId': 'OG000'}, {'value': '43.2', 'spread': '3.26', 'groupId': 'OG001'}]}]}, {'title': 'Albumin, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '44.4', 'spread': '2.56', 'groupId': 'OG000'}, {'value': '44.9', 'spread': '4.04', 'groupId': 'OG001'}]}]}, {'title': 'Albumin, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '43.3', 'spread': '4.33', 'groupId': 'OG000'}, {'value': '43.2', 'spread': '2.39', 'groupId': 'OG001'}]}]}, {'title': 'Globulin, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '28.0', 'spread': '3.39', 'groupId': 'OG000'}, {'value': '27.2', 'spread': '3.64', 'groupId': 'OG001'}]}]}, {'title': 'Globulin, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '28.5', 'spread': '3.27', 'groupId': 'OG000'}, {'value': '28.1', 'spread': '3.47', 'groupId': 'OG001'}]}]}, {'title': 'Globulin, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '27.1', 'spread': '3.94', 'groupId': 'OG000'}, {'value': '30.4', 'spread': '3.78', 'groupId': 'OG001'}]}]}, {'title': 'Globulin, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '28.4', 'spread': '3.64', 'groupId': 'OG000'}, {'value': '25.9', 'spread': '3.48', 'groupId': 'OG001'}]}]}, {'title': 'Protein, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '70.9', 'spread': '4.83', 'groupId': 'OG000'}, {'value': '70.3', 'spread': '4.69', 'groupId': 'OG001'}]}]}, {'title': 'Protein, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '71.8', 'spread': '3.60', 'groupId': 'OG000'}, {'value': '71.3', 'spread': '4.60', 'groupId': 'OG001'}]}]}, {'title': 'Protein, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '71.5', 'spread': '3.96', 'groupId': 'OG000'}, {'value': '75.3', 'spread': '5.00', 'groupId': 'OG001'}]}]}, {'title': 'Protein, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '71.8', 'spread': '6.04', 'groupId': 'OG000'}, {'value': '69.1', 'spread': '4.23', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Grams per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Creatinine, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '74.58', 'spread': '13.770', 'groupId': 'OG000'}, {'value': '77.79', 'spread': '14.328', 'groupId': 'OG001'}, {'value': '75.32', 'spread': '15.250', 'groupId': 'OG002'}]}]}, {'title': 'Creatinine, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '82.89', 'spread': '15.880', 'groupId': 'OG000'}, {'value': '84.90', 'spread': '17.025', 'groupId': 'OG001'}, {'value': '81.47', 'spread': '15.445', 'groupId': 'OG002'}]}]}, {'title': 'Creatinine, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '76.77', 'spread': '9.046', 'groupId': 'OG000'}, {'value': '77.20', 'spread': '17.447', 'groupId': 'OG001'}, {'value': '79.57', 'spread': '18.646', 'groupId': 'OG002'}]}]}, {'title': 'Creatinine, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '82.05', 'spread': '14.136', 'groupId': 'OG000'}, {'value': '78.55', 'spread': '15.613', 'groupId': 'OG001'}, {'value': '74.53', 'spread': '13.793', 'groupId': 'OG002'}]}]}, {'title': 'Direct bilirubin, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.93', 'spread': '0.540', 'groupId': 'OG000'}, {'value': '2.03', 'spread': '0.597', 'groupId': 'OG001'}, {'value': '2.03', 'spread': '0.634', 'groupId': 'OG002'}]}]}, {'title': 'Direct bilirubin, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.80', 'spread': '0.532', 'groupId': 'OG000'}, {'value': '1.97', 'spread': '0.678', 'groupId': 'OG001'}, {'value': '2.03', 'spread': '0.687', 'groupId': 'OG002'}]}]}, {'title': 'Direct bilirubin, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.67', 'spread': '0.437', 'groupId': 'OG000'}, {'value': '2.08', 'spread': '0.694', 'groupId': 'OG001'}, {'value': '2.28', 'spread': '0.778', 'groupId': 'OG002'}]}]}, {'title': 'Direct bilirubin, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2.00', 'spread': '0.548', 'groupId': 'OG000'}, {'value': '1.88', 'spread': '0.577', 'groupId': 'OG001'}, {'value': '2.04', 'spread': '0.648', 'groupId': 'OG002'}]}]}, {'title': 'Bilirubin, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '10.38', 'spread': '3.283', 'groupId': 'OG000'}, {'value': '11.43', 'spread': '3.510', 'groupId': 'OG001'}, {'value': '10.93', 'spread': '3.805', 'groupId': 'OG002'}]}]}, {'title': 'Bilirubin, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '9.70', 'spread': '2.714', 'groupId': 'OG000'}, {'value': '11.04', 'spread': '3.619', 'groupId': 'OG001'}, {'value': '10.72', 'spread': '3.862', 'groupId': 'OG002'}]}]}, {'title': 'Bilirubin, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '8.38', 'spread': '3.021', 'groupId': 'OG000'}, {'value': '9.95', 'spread': '3.605', 'groupId': 'OG001'}, {'value': '11.05', 'spread': '3.553', 'groupId': 'OG002'}]}]}, {'title': 'Bilirubin, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '10.92', 'spread': '2.975', 'groupId': 'OG000'}, {'value': '10.34', 'spread': '3.510', 'groupId': 'OG001'}, {'value': '10.11', 'spread': '3.473', 'groupId': 'OG002'}]}]}, {'title': 'Urate, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '287.0', 'spread': '67.20', 'groupId': 'OG000'}, {'value': '291.8', 'spread': '58.22', 'groupId': 'OG001'}, {'value': '276.0', 'spread': '58.76', 'groupId': 'OG002'}]}]}, {'title': 'Urate, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '280.1', 'spread': '64.07', 'groupId': 'OG000'}, {'value': '283.9', 'spread': '62.39', 'groupId': 'OG001'}, {'value': '271.9', 'spread': '54.52', 'groupId': 'OG002'}]}]}, {'title': 'Urate, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '235.0', 'spread': '40.83', 'groupId': 'OG000'}, {'value': '290.5', 'spread': '53.91', 'groupId': 'OG001'}, {'value': '292.3', 'spread': '53.16', 'groupId': 'OG002'}]}]}, {'title': 'Urate, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '305.1', 'spread': '55.55', 'groupId': 'OG000'}, {'value': '271.8', 'spread': '58.66', 'groupId': 'OG001'}, {'value': '280.0', 'spread': '53.36', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1), and Days 2, 5, and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: creatinine, direct bilirubin, bilirubin, urate. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Micromoles per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Creatinine, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '81.02', 'spread': '17.857', 'groupId': 'OG000'}, {'value': '83.19', 'spread': '19.817', 'groupId': 'OG001'}]}]}, {'title': 'Creatinine, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '88.29', 'spread': '21.603', 'groupId': 'OG000'}, {'value': '90.17', 'spread': '22.148', 'groupId': 'OG001'}]}]}, {'title': 'Creatinine, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '85.31', 'spread': '13.191', 'groupId': 'OG000'}, {'value': '83.79', 'spread': '24.894', 'groupId': 'OG001'}]}]}, {'title': 'Creatinine, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '82.51', 'spread': '25.513', 'groupId': 'OG000'}, {'value': '82.90', 'spread': '12.663', 'groupId': 'OG001'}]}]}, {'title': 'Direct bilirubin, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.71', 'spread': '0.506', 'groupId': 'OG000'}, {'value': '1.73', 'spread': '0.470', 'groupId': 'OG001'}]}]}, {'title': 'Direct bilirubin, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.69', 'spread': '0.431', 'groupId': 'OG000'}, {'value': '1.77', 'spread': '0.621', 'groupId': 'OG001'}]}]}, {'title': 'Direct bilirubin, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.89', 'spread': '0.295', 'groupId': 'OG000'}, {'value': '1.99', 'spread': '0.851', 'groupId': 'OG001'}]}]}, {'title': 'Direct bilirubin, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.62', 'spread': '0.565', 'groupId': 'OG000'}, {'value': '1.72', 'spread': '0.286', 'groupId': 'OG001'}]}]}, {'title': 'Bilirubin, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '9.64', 'spread': '3.401', 'groupId': 'OG000'}, {'value': '9.27', 'spread': '2.548', 'groupId': 'OG001'}]}]}, {'title': 'Bilirubin, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '8.98', 'spread': '1.548', 'groupId': 'OG000'}, {'value': '9.58', 'spread': '3.048', 'groupId': 'OG001'}]}]}, {'title': 'Bilirubin, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '9.55', 'spread': '1.125', 'groupId': 'OG000'}, {'value': '10.50', 'spread': '5.312', 'groupId': 'OG001'}]}]}, {'title': 'Bilirubin, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '8.57', 'spread': '3.324', 'groupId': 'OG000'}, {'value': '9.90', 'spread': '0.758', 'groupId': 'OG001'}]}]}, {'title': 'Urate, Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '324.4', 'spread': '66.68', 'groupId': 'OG000'}, {'value': '329.2', 'spread': '73.48', 'groupId': 'OG001'}]}]}, {'title': 'Urate, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '307.0', 'spread': '64.72', 'groupId': 'OG000'}, {'value': '331.8', 'spread': '81.70', 'groupId': 'OG001'}]}]}, {'title': 'Urate, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '330.1', 'spread': '68.86', 'groupId': 'OG000'}, {'value': '306.0', 'spread': '73.64', 'groupId': 'OG001'}]}]}, {'title': 'Urate, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '308.0', 'spread': '74.35', 'groupId': 'OG000'}, {'value': '332.3', 'spread': '62.07', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: creatinine, direct bilirubin, bilirubin, and urate. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Micromoles per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'ALT, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '2.49', 'groupId': 'OG000'}, {'value': '-1.7', 'spread': '4.74', 'groupId': 'OG001'}, {'value': '-0.5', 'spread': '5.50', 'groupId': 'OG002'}]}]}, {'title': 'ALT, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.7', 'spread': '4.37', 'groupId': 'OG000'}, {'value': '-0.2', 'spread': '2.23', 'groupId': 'OG001'}, {'value': '-3.0', 'spread': '8.39', 'groupId': 'OG002'}]}]}, {'title': 'ALT, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.1', 'spread': '5.97', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '9.32', 'groupId': 'OG001'}, {'value': '0.5', 'spread': '7.93', 'groupId': 'OG002'}]}]}, {'title': 'ALP, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.8', 'spread': '5.14', 'groupId': 'OG000'}, {'value': '2.0', 'spread': '3.76', 'groupId': 'OG001'}, {'value': '1.8', 'spread': '4.66', 'groupId': 'OG002'}]}]}, {'title': 'ALP, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.8', 'spread': '3.25', 'groupId': 'OG000'}, {'value': '-1.0', 'spread': '5.66', 'groupId': 'OG001'}, {'value': '-2.7', 'spread': '6.74', 'groupId': 'OG002'}]}]}, {'title': 'ALP, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.4', 'spread': '3.67', 'groupId': 'OG000'}, {'value': '0.8', 'spread': '3.75', 'groupId': 'OG001'}, {'value': '3.9', 'spread': '5.55', 'groupId': 'OG002'}]}]}, {'title': 'AST, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.5', 'spread': '1.65', 'groupId': 'OG000'}, {'value': '-0.9', 'spread': '2.32', 'groupId': 'OG001'}, {'value': '0.0', 'spread': '3.08', 'groupId': 'OG002'}]}]}, {'title': 'AST, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.0', 'spread': '2.90', 'groupId': 'OG000'}, {'value': '0.3', 'spread': '1.63', 'groupId': 'OG001'}, {'value': '0.0', 'spread': '3.58', 'groupId': 'OG002'}]}]}, {'title': 'AST, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '2.06', 'groupId': 'OG000'}, {'value': '-0.9', 'spread': '3.62', 'groupId': 'OG001'}, {'value': '0.6', 'spread': '2.76', 'groupId': 'OG002'}]}]}, {'title': 'GGT, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '2.24', 'groupId': 'OG000'}, {'value': '0.0', 'spread': '1.43', 'groupId': 'OG001'}, {'value': '0.6', 'spread': '3.76', 'groupId': 'OG002'}]}]}, {'title': 'GGT, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.0', 'spread': '4.20', 'groupId': 'OG000'}, {'value': '-1.3', 'spread': '1.86', 'groupId': 'OG001'}, {'value': '-1.0', 'spread': '2.28', 'groupId': 'OG002'}]}]}, {'title': 'GGT, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '3.11', 'groupId': 'OG000'}, {'value': '-1.2', 'spread': '2.48', 'groupId': 'OG001'}, {'value': '2.4', 'spread': '8.13', 'groupId': 'OG002'}]}]}, {'title': 'LDH, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.6', 'spread': '11.67', 'groupId': 'OG000'}, {'value': '-0.9', 'spread': '10.41', 'groupId': 'OG001'}, {'value': '4.0', 'spread': '9.89', 'groupId': 'OG002'}]}]}, {'title': 'LDH, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-16.5', 'spread': '14.90', 'groupId': 'OG000'}, {'value': '0.3', 'spread': '7.26', 'groupId': 'OG001'}, {'value': '2.2', 'spread': '14.15', 'groupId': 'OG002'}]}]}, {'title': 'LDH, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-8.8', 'spread': '10.09', 'groupId': 'OG000'}, {'value': '-10.2', 'spread': '9.54', 'groupId': 'OG001'}, {'value': '-5.3', 'spread': '15.43', 'groupId': 'OG002'}]}]}, {'title': 'CK, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-11.4', 'spread': '33.22', 'groupId': 'OG000'}, {'value': '-10.3', 'spread': '20.22', 'groupId': 'OG001'}, {'value': '0.2', 'spread': '27.16', 'groupId': 'OG002'}]}]}, {'title': 'CK, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-18.5', 'spread': '20.66', 'groupId': 'OG000'}, {'value': '-1.8', 'spread': '11.58', 'groupId': 'OG001'}, {'value': '8.8', 'spread': '13.75', 'groupId': 'OG002'}]}]}, {'title': 'CK, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-26.2', 'spread': '43.88', 'groupId': 'OG000'}, {'value': '-27.3', 'spread': '43.24', 'groupId': 'OG001'}, {'value': '-9.3', 'spread': '22.62', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: ALT, ALP, AST, GGT, LDH, CK. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'International units per Liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'ALT, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.7', 'spread': '3.48', 'groupId': 'OG000'}, {'value': '0.1', 'spread': '3.30', 'groupId': 'OG001'}]}]}, {'title': 'ALT, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.1', 'spread': '2.64', 'groupId': 'OG000'}, {'value': '3.4', 'spread': '7.21', 'groupId': 'OG001'}]}]}, {'title': 'ALT, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.6', 'spread': '5.77', 'groupId': 'OG000'}, {'value': '2.2', 'spread': '3.67', 'groupId': 'OG001'}]}]}, {'title': 'ALP, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '4.22', 'groupId': 'OG000'}, {'value': '0.4', 'spread': '3.65', 'groupId': 'OG001'}]}]}, {'title': 'ALP, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.1', 'spread': '3.56', 'groupId': 'OG000'}, {'value': '3.9', 'spread': '9.20', 'groupId': 'OG001'}]}]}, {'title': 'ALP, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.0', 'spread': '3.81', 'groupId': 'OG000'}, {'value': '2.1', 'spread': '4.26', 'groupId': 'OG001'}]}]}, {'title': 'AST, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.8', 'spread': '2.32', 'groupId': 'OG000'}, {'value': '-0.7', 'spread': '1.81', 'groupId': 'OG001'}]}]}, {'title': 'AST, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.4', 'spread': '1.06', 'groupId': 'OG000'}, {'value': '2.4', 'spread': '3.32', 'groupId': 'OG001'}]}]}, {'title': 'AST, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.7', 'spread': '2.55', 'groupId': 'OG000'}, {'value': '0.1', 'spread': '1.69', 'groupId': 'OG001'}]}]}, {'title': 'GGT, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.3', 'spread': '1.08', 'groupId': 'OG000'}, {'value': '0.5', 'spread': '1.38', 'groupId': 'OG001'}]}]}, {'title': 'GGT, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.9', 'spread': '0.83', 'groupId': 'OG000'}, {'value': '2.0', 'spread': '3.67', 'groupId': 'OG001'}]}]}, {'title': 'GGT, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.6', 'spread': '3.09', 'groupId': 'OG000'}, {'value': '-0.9', 'spread': '2.71', 'groupId': 'OG001'}]}]}, {'title': 'LDH, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-7.1', 'spread': '11.65', 'groupId': 'OG000'}, {'value': '-4.9', 'spread': '8.68', 'groupId': 'OG001'}]}]}, {'title': 'LDH, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-4.6', 'spread': '10.89', 'groupId': 'OG000'}, {'value': '3.3', 'spread': '16.90', 'groupId': 'OG001'}]}]}, {'title': 'LDH, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-4.8', 'spread': '12.02', 'groupId': 'OG000'}, {'value': '-2.7', 'spread': '11.92', 'groupId': 'OG001'}]}]}, {'title': 'CK, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-6.9', 'spread': '12.25', 'groupId': 'OG000'}, {'value': '-13.4', 'spread': '20.32', 'groupId': 'OG001'}]}]}, {'title': 'CK, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '7.6', 'spread': '11.56', 'groupId': 'OG000'}, {'value': '2.1', 'spread': '13.70', 'groupId': 'OG001'}]}]}, {'title': 'CK, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-16.3', 'spread': '34.30', 'groupId': 'OG000'}, {'value': '-23.1', 'spread': '36.97', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: ALT, ALP, AST, GGT, LDH, CK. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'International units per Liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Calcium, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.014', 'spread': '0.0547', 'groupId': 'OG000'}, {'value': '0.011', 'spread': '0.0599', 'groupId': 'OG001'}, {'value': '0.033', 'spread': '0.0838', 'groupId': 'OG002'}]}]}, {'title': 'Calcium, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.007', 'spread': '0.0333', 'groupId': 'OG000'}, {'value': '0.013', 'spread': '0.0432', 'groupId': 'OG001'}, {'value': '0.007', 'spread': '0.0535', 'groupId': 'OG002'}]}]}, {'title': 'Calcium, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.011', 'spread': '0.0650', 'groupId': 'OG000'}, {'value': '-0.002', 'spread': '0.0867', 'groupId': 'OG001'}, {'value': '0.018', 'spread': '0.0875', 'groupId': 'OG002'}]}]}, {'title': 'CO2, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.1', 'spread': '1.41', 'groupId': 'OG000'}, {'value': '-0.5', 'spread': '1.33', 'groupId': 'OG001'}, {'value': '-0.5', 'spread': '1.57', 'groupId': 'OG002'}]}]}, {'title': 'CO2, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.7', 'spread': '1.37', 'groupId': 'OG000'}, {'value': '-0.8', 'spread': '1.17', 'groupId': 'OG001'}, {'value': '-1.7', 'spread': '1.63', 'groupId': 'OG002'}]}]}, {'title': 'CO2, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.5', 'spread': '1.69', 'groupId': 'OG000'}, {'value': '0.4', 'spread': '2.22', 'groupId': 'OG001'}, {'value': '0.0', 'spread': '1.05', 'groupId': 'OG002'}]}]}, {'title': 'Chloride, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '1.94', 'groupId': 'OG000'}, {'value': '-0.1', 'spread': '1.15', 'groupId': 'OG001'}, {'value': '-0.1', 'spread': '1.47', 'groupId': 'OG002'}]}]}, {'title': 'Chloride, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.7', 'spread': '2.25', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '1.03', 'groupId': 'OG001'}, {'value': '-1.5', 'spread': '2.51', 'groupId': 'OG002'}]}]}, {'title': 'Chloride, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '1.89', 'groupId': 'OG000'}, {'value': '0.8', 'spread': '2.17', 'groupId': 'OG001'}, {'value': '-0.1', 'spread': '2.23', 'groupId': 'OG002'}]}]}, {'title': 'Glucose, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.197', 'spread': '0.2209', 'groupId': 'OG000'}, {'value': '-0.135', 'spread': '0.2856', 'groupId': 'OG001'}, {'value': '-0.262', 'spread': '0.1809', 'groupId': 'OG002'}]}]}, {'title': 'Glucose, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.093', 'spread': '0.2550', 'groupId': 'OG000'}, {'value': '-0.035', 'spread': '0.1792', 'groupId': 'OG001'}, {'value': '-0.105', 'spread': '0.1735', 'groupId': 'OG002'}]}]}, {'title': 'Glucose, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.086', 'spread': '0.3962', 'groupId': 'OG000'}, {'value': '-0.066', 'spread': '0.3024', 'groupId': 'OG001'}, {'value': '-0.171', 'spread': '0.1920', 'groupId': 'OG002'}]}]}, {'title': 'Potassium, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.02', 'spread': '0.234', 'groupId': 'OG000'}, {'value': '-0.18', 'spread': '0.274', 'groupId': 'OG001'}, {'value': '0.03', 'spread': '0.281', 'groupId': 'OG002'}]}]}, {'title': 'Potassium, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.10', 'spread': '0.290', 'groupId': 'OG000'}, {'value': '-0.05', 'spread': '0.226', 'groupId': 'OG001'}, {'value': '-0.20', 'spread': '0.369', 'groupId': 'OG002'}]}]}, {'title': 'Potassium, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.10', 'spread': '0.310', 'groupId': 'OG000'}, {'value': '-0.06', 'spread': '0.198', 'groupId': 'OG001'}, {'value': '-0.08', 'spread': '0.361', 'groupId': 'OG002'}]}]}, {'title': 'Sodium, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '1.95', 'groupId': 'OG000'}, {'value': '1.64', 'spread': '0.3', 'groupId': 'OG001'}, {'value': '0.3', 'spread': '2.24', 'groupId': 'OG002'}]}]}, {'title': 'Sodium, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.0', 'spread': '1.79', 'groupId': 'OG000'}, {'value': '-0.2', 'spread': '1.17', 'groupId': 'OG001'}, {'value': '-1.3', 'spread': '2.66', 'groupId': 'OG002'}]}]}, {'title': 'Sodium, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '2.36', 'groupId': 'OG000'}, {'value': '0.4', 'spread': '2.14', 'groupId': 'OG001'}, {'value': '-0.3', 'spread': '2.31', 'groupId': 'OG002'}]}]}, {'title': 'Urea nitrogen, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.520', 'spread': '0.7073', 'groupId': 'OG000'}, {'value': '0.333', 'spread': '0.4752', 'groupId': 'OG001'}, {'value': '0.4553', 'spread': '0.4553', 'groupId': 'OG002'}]}]}, {'title': 'Urea nitrogen, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.857', 'spread': '0.4584', 'groupId': 'OG000'}, {'value': '0.143', 'spread': '0.5844', 'groupId': 'OG001'}, {'value': '-0.017', 'spread': '0.6301', 'groupId': 'OG002'}]}]}, {'title': 'Urea nitrogen, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.618', 'spread': '0.7434', 'groupId': 'OG000'}, {'value': '-0.035', 'spread': '0.5511', 'groupId': 'OG001'}, {'value': '0.309', 'spread': '0.7935', 'groupId': 'OG002'}]}]}, {'title': 'Phosphate, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.069', 'spread': '0.1242', 'groupId': 'OG000'}, {'value': '0.078', 'spread': '0.0972', 'groupId': 'OG001'}, {'value': '0.082', 'spread': '0.0716', 'groupId': 'OG002'}]}]}, {'title': 'Phosphate, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.082', 'spread': '0.1232', 'groupId': 'OG000'}, {'value': '0.048', 'spread': '0.0952', 'groupId': 'OG001'}, {'value': '-0.002', 'spread': '0.0964', 'groupId': 'OG002'}]}]}, {'title': 'Phosphate, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.036', 'spread': '0.1218', 'groupId': 'OG000'}, {'value': '0.099', 'spread': '0.1245', 'groupId': 'OG001'}, {'value': '0.052', 'spread': '0.0487', 'groupId': 'OG002'}]}]}, {'title': 'Triglycerides, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.095', 'spread': '0.3467', 'groupId': 'OG000'}, {'value': '-0.013', 'spread': '0.2499', 'groupId': 'OG001'}, {'value': '0.011', 'spread': '0.2280', 'groupId': 'OG002'}]}]}, {'title': 'Triglycerides, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.192', 'spread': '0.1338', 'groupId': 'OG000'}, {'value': '-0.223', 'spread': '0.3551', 'groupId': 'OG001'}, {'value': '-0.185', 'spread': '0.1778', 'groupId': 'OG002'}]}]}, {'title': 'Triglycerides, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.160', 'spread': '0.4290', 'groupId': 'OG000'}, {'value': '-0.149', 'spread': '0.2656', 'groupId': 'OG001'}, {'value': '-0.016', 'spread': '0.1888', 'groupId': 'OG002'}]}]}, {'title': 'Cholesterol, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.117', 'spread': '0.3551', 'groupId': 'OG000'}, {'value': '0.058', 'spread': '0.3115', 'groupId': 'OG001'}, {'value': '0.052', 'spread': '0.2865', 'groupId': 'OG002'}]}]}, {'title': 'Cholesterol, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.098', 'spread': '0.5254', 'groupId': 'OG000'}, {'value': '-0.022', 'spread': '0.4323', 'groupId': 'OG001'}, {'value': '-0.252', 'spread': '0.3485', 'groupId': 'OG002'}]}]}, {'title': 'Cholesterol, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.033', 'spread': '0.4137', 'groupId': 'OG000'}, {'value': '-0.137', 'spread': '0.4751', 'groupId': 'OG001'}, {'value': '0.056', 'spread': '0.3841', 'groupId': 'OG002'}]}]}, {'title': 'Anion gap, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.8', 'spread': '2.07', 'groupId': 'OG000'}, {'value': '0.3', 'spread': '1.59', 'groupId': 'OG001'}, {'value': '0.8', 'spread': '2.36', 'groupId': 'OG002'}]}]}, {'title': 'Anion gap, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.0', 'spread': '1.41', 'groupId': 'OG000'}, {'value': '1.2', 'spread': '1.17', 'groupId': 'OG001'}, {'value': '1.7', 'spread': '1.37', 'groupId': 'OG002'}]}]}, {'title': 'Anion gap, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.29', 'groupId': 'OG000'}, {'value': '-0.8', 'spread': '1.88', 'groupId': 'OG001'}, {'value': '-0.4', 'spread': '1.35', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: calcium, CO2, chloride, glucose, potassium, sodium, urea nitrogen, phosphorus, triglycerides, cholesterol, and anion gap. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Millimoles per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Calcium, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.008', 'spread': '0.0764', 'groupId': 'OG000'}, {'value': '0.007', 'spread': '0.0585', 'groupId': 'OG001'}]}]}, {'title': 'Calcium, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.033', 'spread': '0.0812', 'groupId': 'OG000'}, {'value': '0.019', 'spread': '0.0971', 'groupId': 'OG001'}]}]}, {'title': 'Calcium, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.002', 'spread': '0.0814', 'groupId': 'OG000'}, {'value': '-0.007', 'spread': '0.0779', 'groupId': 'OG001'}]}]}, {'title': 'CO2, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.3', 'spread': '1.49', 'groupId': 'OG000'}, {'value': '-1.0', 'spread': '1.37', 'groupId': 'OG001'}]}]}, {'title': 'CO2, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.1', 'spread': '0.99', 'groupId': 'OG000'}, {'value': '-0.6', 'spread': '0.73', 'groupId': 'OG001'}]}]}, {'title': 'CO2, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '1.48', 'groupId': 'OG000'}, {'value': '0.3', 'spread': '1.41', 'groupId': 'OG001'}]}]}, {'title': 'Chloride, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '1.85', 'groupId': 'OG000'}, {'value': '-0.4', 'spread': '1.89', 'groupId': 'OG001'}]}]}, {'title': 'Chloride, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '2.00', 'groupId': 'OG000'}, {'value': '-0.9', 'spread': '1.90', 'groupId': 'OG001'}]}]}, {'title': 'Chloride, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.88', 'groupId': 'OG000'}, {'value': '0.2', 'spread': '2.33', 'groupId': 'OG001'}]}]}, {'title': 'Glucose, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.084', 'spread': '0.1480', 'groupId': 'OG000'}, {'value': '0.077', 'spread': '0.2392', 'groupId': 'OG001'}]}]}, {'title': 'Glucose, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.160', 'spread': '0.2754', 'groupId': 'OG000'}, {'value': '-0.256', 'spread': '0.3867', 'groupId': 'OG001'}]}]}, {'title': 'Glucose, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.019', 'spread': '0.3691', 'groupId': 'OG000'}, {'value': '-0.087', 'spread': '0.2601', 'groupId': 'OG001'}]}]}, {'title': 'Potassium, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.01', 'spread': '0.247', 'groupId': 'OG000'}, {'value': '0.09', 'spread': '0.289', 'groupId': 'OG001'}]}]}, {'title': 'Potassium, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.01', 'spread': '0.476', 'groupId': 'OG000'}, {'value': '-0.08', 'spread': '0.192', 'groupId': 'OG001'}]}]}, {'title': 'Potassium, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.01', 'spread': '0.145', 'groupId': 'OG000'}, {'value': '0.18', 'spread': '0.393', 'groupId': 'OG001'}]}]}, {'title': 'Sodium, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '1.41', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '2.24', 'groupId': 'OG001'}]}]}, {'title': 'Sodium, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.8', 'spread': '1.49', 'groupId': 'OG000'}, {'value': '-0.8', 'spread': '1.86', 'groupId': 'OG001'}]}]}, {'title': 'Sodium, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.6', 'spread': '1.33', 'groupId': 'OG000'}, {'value': '1.2', 'spread': '2.22', 'groupId': 'OG001'}]}]}, {'title': 'Urea nitrogen, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.228', 'spread': '0.4467', 'groupId': 'OG000'}, {'value': '0.628', 'spread': '0.7585', 'groupId': 'OG001'}]}]}, {'title': 'Urea nitrogen, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.138', 'spread': '0.6950', 'groupId': 'OG000'}, {'value': '0.067', 'spread': '0.8951', 'groupId': 'OG001'}]}]}, {'title': 'Urea nitrogen, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.321', 'spread': '0.7415', 'groupId': 'OG000'}, {'value': '0.441', 'spread': '0.7504', 'groupId': 'OG001'}]}]}, {'title': 'Phosphate, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.041', 'spread': '0.0842', 'groupId': 'OG000'}, {'value': '0.044', 'spread': '0.0902', 'groupId': 'OG001'}]}]}, {'title': 'Phosphate, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.014', 'spread': '0.0983', 'groupId': 'OG000'}, {'value': '0.012', 'spread': '0.0349', 'groupId': 'OG001'}]}]}, {'title': 'Phosphate, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.023', 'spread': '0.0854', 'groupId': 'OG000'}, {'value': '0.019', 'spread': '0.0862', 'groupId': 'OG001'}]}]}, {'title': 'Triglycerides, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.111', 'spread': '0.3084', 'groupId': 'OG000'}, {'value': '-0.121', 'spread': '0.2674', 'groupId': 'OG001'}]}]}, {'title': 'Triglycerides, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.215', 'spread': '0.3208', 'groupId': 'OG000'}, {'value': '-0.156', 'spread': '0.2584', 'groupId': 'OG001'}]}]}, {'title': 'Triglycerides, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.089', 'spread': '0.4124', 'groupId': 'OG000'}, {'value': '-0.031', 'spread': '0.2996', 'groupId': 'OG001'}]}]}, {'title': 'Cholesterol, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.121', 'spread': '0.4047', 'groupId': 'OG000'}, {'value': '0.076', 'spread': '0.2377', 'groupId': 'OG001'}]}]}, {'title': 'Cholesterol, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.036', 'spread': '0.3000', 'groupId': 'OG000'}, {'value': '0.113', 'spread': '0.4685', 'groupId': 'OG001'}]}]}, {'title': 'Cholesterol, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.170', 'spread': '0.4438', 'groupId': 'OG000'}, {'value': '-0.119', 'spread': '0.4662', 'groupId': 'OG001'}]}]}, {'title': 'Anion gap, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.5', 'spread': '0.82', 'groupId': 'OG000'}, {'value': '1.3', 'spread': '0.96', 'groupId': 'OG001'}]}]}, {'title': 'Anion gap, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '1.41', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '3.08', 'groupId': 'OG001'}]}]}, {'title': 'Anion gap, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '0.78', 'groupId': 'OG000'}, {'value': '0.6', 'spread': '1.42', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: calcium, CO2, chloride, glucose, potassium, sodium, urea nitrogen, phosphorus, triglycerides, cholesterol, and anion gap. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Millimoles per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Change From Baseline in Clinical Chemistry Parameters: Lipase and Amylase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Lipase, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '5.21', 'groupId': 'OG000'}, {'value': '5.8', 'spread': '13.57', 'groupId': 'OG001'}, {'value': '3.2', 'spread': '10.59', 'groupId': 'OG002'}]}]}, {'title': 'Lipase, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '3.3', 'spread': '3.33', 'groupId': 'OG000'}, {'value': '1.3', 'spread': '3.98', 'groupId': 'OG001'}, {'value': '2.0', 'spread': '9.92', 'groupId': 'OG002'}]}]}, {'title': 'Lipase, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.5', 'spread': '15.61', 'groupId': 'OG000'}, {'value': '-3.6', 'spread': '19.59', 'groupId': 'OG001'}, {'value': '2.1', 'spread': '5.49', 'groupId': 'OG002'}]}]}, {'title': 'Amylase, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.0', 'spread': '5.54', 'groupId': 'OG000'}, {'value': '3.9', 'spread': '5.21', 'groupId': 'OG001'}, {'value': '3.3', 'spread': '8.70', 'groupId': 'OG002'}]}]}, {'title': 'Amylase, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '5.5', 'spread': '4.23', 'groupId': 'OG000'}, {'value': '0.5', 'spread': '4.32', 'groupId': 'OG001'}, {'value': '-1.2', 'spread': '7.94', 'groupId': 'OG002'}]}]}, {'title': 'Amylase, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '5.0', 'spread': '9.08', 'groupId': 'OG000'}, {'value': '-0.7', 'spread': '10.27', 'groupId': 'OG001'}, {'value': '3.5', 'spread': '9.23', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: lipase and amylase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Units per Liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Change From Baseline in Clinical Chemistry Parameters: Lipase and Amylase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Lipase, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.6', 'spread': '5.77', 'groupId': 'OG000'}, {'value': '0.3', 'spread': '3.51', 'groupId': 'OG001'}]}]}, {'title': 'Lipase, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.3', 'spread': '20.10', 'groupId': 'OG000'}, {'value': '5.3', 'spread': '13.17', 'groupId': 'OG001'}]}]}, {'title': 'Lipase, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.2', 'spread': '8.77', 'groupId': 'OG000'}, {'value': '-0.1', 'spread': '4.65', 'groupId': 'OG001'}]}]}, {'title': 'Amylase, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.8', 'spread': '4.11', 'groupId': 'OG000'}, {'value': '2.1', 'spread': '3.83', 'groupId': 'OG001'}]}]}, {'title': 'Amylase, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.8', 'spread': '7.42', 'groupId': 'OG000'}, {'value': '-0.7', 'spread': '6.84', 'groupId': 'OG001'}]}]}, {'title': 'Amylase, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.3', 'spread': '6.28', 'groupId': 'OG000'}, {'value': '1.6', 'spread': '4.39', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: lipase and amylase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Units per Liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Change From Baseline in Clinical Chemistry Parameters: Albumin, Globulin and Protein', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Albumin, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.8', 'spread': '2.65', 'groupId': 'OG000'}, {'value': '0.7', 'spread': '2.08', 'groupId': 'OG001'}, {'value': '0.7', 'spread': '1.49', 'groupId': 'OG002'}]}]}, {'title': 'Albumin, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.8', 'spread': '1.72', 'groupId': 'OG000'}, {'value': '0.2', 'spread': '2.32', 'groupId': 'OG001'}, {'value': '-0.2', 'spread': '2.32', 'groupId': 'OG002'}]}]}, {'title': 'Albumin, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '2.14', 'groupId': 'OG000'}, {'value': '0.0', 'spread': '2.68', 'groupId': 'OG001'}, {'value': '1.3', 'spread': '1.49', 'groupId': 'OG002'}]}]}, {'title': 'Globulin, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.0', 'spread': '2.44', 'groupId': 'OG000'}, {'value': '0.4', 'spread': '1.80', 'groupId': 'OG001'}, {'value': '1.2', 'spread': '2.23', 'groupId': 'OG002'}]}]}, {'title': 'Globulin, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '2.40', 'groupId': 'OG000'}, {'value': '0.2', 'spread': '1.17', 'groupId': 'OG001'}, {'value': '1.0', 'spread': '2.10', 'groupId': 'OG002'}]}]}, {'title': 'Globulin, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '1.67', 'groupId': 'OG000'}, {'value': '-0.5', 'spread': '2.33', 'groupId': 'OG001'}, {'value': '0.6', 'spread': '1.84', 'groupId': 'OG002'}]}]}, {'title': 'Protein, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.8', 'spread': '4.69', 'groupId': 'OG000'}, {'value': '1.1', 'spread': '3.65', 'groupId': 'OG001'}, {'value': '1.9', 'spread': '3.54', 'groupId': 'OG002'}]}]}, {'title': 'Protein, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.7', 'spread': '2.80', 'groupId': 'OG000'}, {'value': '0.3', 'spread': '2.58', 'groupId': 'OG001'}, {'value': '0.8', 'spread': '3.13', 'groupId': 'OG002'}]}]}, {'title': 'Protein, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '3.49', 'groupId': 'OG000'}, {'value': '-0.5', 'spread': '4.56', 'groupId': 'OG001'}, {'value': '1.9', 'spread': '2.81', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Grams per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Change From Baseline in Clinical Chemistry Parameters: Albumin, Globulin and Protein', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Albumin, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.6', 'spread': '2.78', 'groupId': 'OG000'}, {'value': '0.2', 'spread': '2.18', 'groupId': 'OG001'}]}]}, {'title': 'Albumin, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.9', 'spread': '3.00', 'groupId': 'OG000'}, {'value': '1.6', 'spread': '4.36', 'groupId': 'OG001'}]}]}, {'title': 'Albumin, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.9', 'spread': '2.47', 'groupId': 'OG000'}, {'value': '0.4', 'spread': '3.17', 'groupId': 'OG001'}]}]}, {'title': 'Globulin, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '1.98', 'groupId': 'OG000'}, {'value': '0.8', 'spread': '2.28', 'groupId': 'OG001'}]}]}, {'title': 'Globulin, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.8', 'spread': '1.67', 'groupId': 'OG000'}, {'value': '2.0', 'spread': '2.78', 'groupId': 'OG001'}]}]}, {'title': 'Globulin, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.0', 'spread': '3.08', 'groupId': 'OG000'}, {'value': '-0.1', 'spread': '2.42', 'groupId': 'OG001'}]}]}, {'title': 'Protein, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.9', 'spread': '3.95', 'groupId': 'OG000'}, {'value': '1.0', 'spread': '3.33', 'groupId': 'OG001'}]}]}, {'title': 'Protein, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.6', 'spread': '3.85', 'groupId': 'OG000'}, {'value': '3.6', 'spread': '6.27', 'groupId': 'OG001'}]}]}, {'title': 'Protein, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '4.04', 'groupId': 'OG000'}, {'value': '0.3', 'spread': '4.58', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Grams per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Creatinine, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '8.31', 'spread': '4.422', 'groupId': 'OG000'}, {'value': '7.12', 'spread': '5.636', 'groupId': 'OG001'}, {'value': '6.15', 'spread': '4.228', 'groupId': 'OG002'}]}]}, {'title': 'Creatinine, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '3.10', 'spread': '2.440', 'groupId': 'OG000'}, {'value': '3.38', 'spread': '3.026', 'groupId': 'OG001'}, {'value': '1.92', 'spread': '2.671', 'groupId': 'OG002'}]}]}, {'title': 'Creatinine, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2.18', 'spread': '5.799', 'groupId': 'OG000'}, {'value': '0.97', 'spread': '5.027', 'groupId': 'OG001'}, {'value': '1.34', 'spread': '6.215', 'groupId': 'OG002'}]}]}, {'title': 'Direct bilirubin, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.12', 'spread': '0.267', 'groupId': 'OG000'}, {'value': '-0.06', 'spread': '0.329', 'groupId': 'OG001'}, {'value': '-0.01', 'spread': '0.324', 'groupId': 'OG002'}]}]}, {'title': 'Direct bilirubin, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.20', 'spread': '0.261', 'groupId': 'OG000'}, {'value': '0.02', 'spread': '0.354', 'groupId': 'OG001'}, {'value': '0.35', 'spread': '0.138', 'groupId': 'OG002'}]}]}, {'title': 'Direct bilirubin, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.03', 'spread': '0.390', 'groupId': 'OG000'}, {'value': '-0.11', 'spread': '0.330', 'groupId': 'OG001'}, {'value': '-0.11', 'spread': '0.502', 'groupId': 'OG002'}]}]}, {'title': 'Bilirubin, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.68', 'spread': '1.327', 'groupId': 'OG000'}, {'value': '-0.39', 'spread': '1.742', 'groupId': 'OG001'}, {'value': '-0.21', 'spread': '1.236', 'groupId': 'OG002'}]}]}, {'title': 'Bilirubin, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.85', 'spread': '1.958', 'groupId': 'OG000'}, {'value': '-1.12', 'spread': '1.306', 'groupId': 'OG001'}, {'value': '0.55', 'spread': '0.602', 'groupId': 'OG002'}]}]}, {'title': 'Bilirubin, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.10', 'spread': '1.638', 'groupId': 'OG000'}, {'value': '-1.06', 'spread': '1.340', 'groupId': 'OG001'}, {'value': '-1.40', 'spread': '2.078', 'groupId': 'OG002'}]}]}, {'title': 'Urate, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-7.0', 'spread': '17.31', 'groupId': 'OG000'}, {'value': '-7.9', 'spread': '15.31', 'groupId': 'OG001'}, {'value': '-4.2', 'spread': '21.77', 'groupId': 'OG002'}]}]}, {'title': 'Urate, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-11.7', 'spread': '8.36', 'groupId': 'OG000'}, {'value': '-7.0', 'spread': '17.15', 'groupId': 'OG001'}, {'value': '6.7', 'spread': '30.59', 'groupId': 'OG002'}]}]}, {'title': 'Urate, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-6.4', 'spread': '28.61', 'groupId': 'OG000'}, {'value': '-6.8', 'spread': '13.36', 'groupId': 'OG001'}, {'value': '2.3', 'spread': '20.74', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: creatinine, direct bilirubin, bilirubin, and urate. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Micromoles per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Creatinine, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '7.73', 'spread': '4.766', 'groupId': 'OG000'}, {'value': '6.97', 'spread': '5.419', 'groupId': 'OG001'}]}]}, {'title': 'Creatinine, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.54', 'spread': '6.065', 'groupId': 'OG000'}, {'value': '1.28', 'spread': '6.361', 'groupId': 'OG001'}]}]}, {'title': 'Creatinine, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.16', 'spread': '3.830', 'groupId': 'OG000'}, {'value': '-0.98', 'spread': '3.061', 'groupId': 'OG001'}]}]}, {'title': 'Direct bilirubin, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.07', 'spread': '0.328', 'groupId': 'OG000'}, {'value': '0.04', 'spread': '0.405', 'groupId': 'OG001'}]}]}, {'title': 'Direct bilirubin, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.13', 'spread': '0.212', 'groupId': 'OG000'}, {'value': '0.37', 'spread': '0.374', 'groupId': 'OG001'}]}]}, {'title': 'Direct bilirubin, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.04', 'spread': '0.300', 'groupId': 'OG000'}, {'value': '-0.12', 'spread': '0.307', 'groupId': 'OG001'}]}]}, {'title': 'Bilirubin, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.02', 'spread': '1.518', 'groupId': 'OG000'}, {'value': '0.31', 'spread': '1.101', 'groupId': 'OG001'}]}]}, {'title': 'Bilirubin, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.41', 'spread': '1.635', 'groupId': 'OG000'}, {'value': '1.93', 'spread': '2.272', 'groupId': 'OG001'}]}]}, {'title': 'Bilirubin, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.78', 'spread': '2.499', 'groupId': 'OG000'}, {'value': '-0.08', 'spread': '1.358', 'groupId': 'OG001'}]}]}, {'title': 'Urate, Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-12.4', 'spread': '19.25', 'groupId': 'OG000'}, {'value': '2.6', 'spread': '15.74', 'groupId': 'OG001'}]}]}, {'title': 'Urate, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-5.9', 'spread': '12.97', 'groupId': 'OG000'}, {'value': '-2.0', 'spread': '13.42', 'groupId': 'OG001'}]}]}, {'title': 'Urate, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-6.0', 'spread': '19.21', 'groupId': 'OG000'}, {'value': '-18.0', 'spread': '22.32', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: Creatinine, direct bilirubin, bilirubin, and urate. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Micromoles per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Absolute Values for Urinalysis Parameter: Specific Gravity', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.0138', 'spread': '0.00654', 'groupId': 'OG000'}, {'value': '1.0168', 'spread': '0.00685', 'groupId': 'OG001'}, {'value': '1.0153', 'spread': '0.00693', 'groupId': 'OG002'}]}]}, {'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.0137', 'spread': '0.00683', 'groupId': 'OG000'}, {'value': '1.0150', 'spread': '0.00766', 'groupId': 'OG001'}, {'value': '1.0151', 'spread': '0.00763', 'groupId': 'OG002'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.0143', 'spread': '0.00543', 'groupId': 'OG000'}, {'value': '1.0197', 'spread': '0.00638', 'groupId': 'OG001'}, {'value': '1.0197', 'spread': '0.00799', 'groupId': 'OG002'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.0202', 'spread': '0.00569', 'groupId': 'OG000'}, {'value': '1.0159', 'spread': '0.00760', 'groupId': 'OG001'}, {'value': '1.0160', 'spread': '0.00733', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': "Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.", 'unitOfMeasure': 'Ratio', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2 : Absolute Values for Urinalysis Parameter: Specific Gravity', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.0146', 'spread': '0.00742', 'groupId': 'OG000'}, {'value': '1.0164', 'spread': '0.00834', 'groupId': 'OG001'}]}]}, {'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.0157', 'spread': '0.00778', 'groupId': 'OG000'}, {'value': '1.0182', 'spread': '0.00906', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.0123', 'spread': '0.00715', 'groupId': 'OG000'}, {'value': '1.0142', 'spread': '0.01284', 'groupId': 'OG001'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.0161', 'spread': '0.01129', 'groupId': 'OG000'}, {'value': '1.0144', 'spread': '0.00735', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': "Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.", 'unitOfMeasure': 'Ratio', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Absolute Values for Urinalysis Parameters: Potential of Hydrogen (pH)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '6.18', 'spread': '0.733', 'groupId': 'OG000'}, {'value': '5.95', 'spread': '0.631', 'groupId': 'OG001'}, {'value': '5.88', 'spread': '0.582', 'groupId': 'OG002'}]}]}, {'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '6.16', 'spread': '0.585', 'groupId': 'OG000'}, {'value': '6.12', 'spread': '0.723', 'groupId': 'OG001'}, {'value': '6.20', 'spread': '0.785', 'groupId': 'OG002'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '5.83', 'spread': '0.408', 'groupId': 'OG000'}, {'value': '5.83', 'spread': '0.258', 'groupId': 'OG001'}, {'value': '5.75', 'spread': '0.274', 'groupId': 'OG002'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '5.82', 'spread': '0.603', 'groupId': 'OG000'}, {'value': '5.81', 'spread': '0.596', 'groupId': 'OG001'}, {'value': '6.15', 'spread': '0.914', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'pH', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Absolute Values for Urinalysis Parameter: Potential of Hydrogen', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Baseline (Day -1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.12', 'spread': '0.574', 'groupId': 'OG000'}, {'value': '6.08', 'spread': '0.354', 'groupId': 'OG001'}]}]}, {'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.12', 'spread': '0.452', 'groupId': 'OG000'}, {'value': '6.17', 'spread': '0.454', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.13', 'spread': '0.518', 'groupId': 'OG000'}, {'value': '6.28', 'spread': '0.565', 'groupId': 'OG001'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.17', 'spread': '0.433', 'groupId': 'OG000'}, {'value': '5.94', 'spread': '0.464', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'pH', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Number of Participants With Urinalysis Dipstick Results: Glucose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Baseline (Day -1), Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}]}, {'title': 'Day 2, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}]}, {'title': 'Day 5, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}]}, {'title': 'Day 7, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Urine samples were collected at indicated time points to analyze parameters including glucose by dipstick. Urinalysis included dipstick urine test which was used to screen for glucose. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine glucose can be read as negative in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Number of Participants With Urinalysis Dipstick Results: Glucose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Baseline (Day -1), Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}]}, {'title': 'Day 2, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}]}, {'title': 'Day 5, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}]}, {'title': 'Day 7, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Urine samples were collected at indicated time points to analyze parameters including glucose by dipstick. Urinalysis included dipstick urine test which was used to screen for glucose. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine glucose can be read as negative in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Number of Participants With Urinalysis Dipstick Results: Protein', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Baseline (Day -1), Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}]}, {'title': 'Day 2, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}]}, {'title': 'Day 5, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}]}, {'title': 'Day 7, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '10', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}]}, {'title': 'Day 7, Trace', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Urine samples were collected at indicated time points to analyze parameters including protein by dipstick. Urinalysis included dipstick urine test which was used to screen for protein. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine protein can be read as negative, and trace in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Number of Participants With Urinalysis Dipstick Results: Protein', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Baseline (Day -1), Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}]}, {'title': 'Day 2, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}]}, {'title': 'Day 5, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}]}, {'title': 'Day 7, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}]}, {'title': 'Day 7, Trace', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Urine samples were collected at indicated time points to analyze parameters including protein by dipstick. Urinalysis included dipstick urine test which was used to screen for protein. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine protein can be read as negative, and trace in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Number of Participants With Urinalysis Dipstick Results: Occult Blood', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Baseline (Day -1), Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '20', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}, {'value': '18', 'groupId': 'OG002'}]}]}, {'title': 'Baseline (Day -1), Trace', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}]}, {'title': 'Baseline (Day -1), 2+', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Day 2, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '19', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '18', 'groupId': 'OG002'}]}]}, {'title': 'Day 2, Trace', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Day 2, 1+', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Day 2, 2+', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Day 2, 3+', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Day 5, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}]}, {'title': 'Day 5, 1+', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Day 5, 2+', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Day 7, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '10', 'groupId': 'OG000'}, {'value': '11', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}]}, {'title': 'Day 7, Trace', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Urine samples were collected at indicated time points to analyze parameters including occult blood by dipstick. Urinalysis included dipstick urine test which was used to screen for occult blood. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine occult blood can be read as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Number of Participants With Urinalysis Dipstick Results: Occult Blood', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Baseline (Day -1), Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '15', 'groupId': 'OG000'}, {'value': '16', 'groupId': 'OG001'}]}]}, {'title': 'Baseline (Day -1), Trace', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Baseline (Day -1), 1+', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}, {'title': 'Baseline (Day -1), 2+', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}, {'title': 'Day 2, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '17', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}]}]}, {'title': 'Day 2, 1+', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}, {'title': 'Day 5, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}]}, {'title': 'Day 5, Trace', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}, {'title': 'Day 7, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '7', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}]}, {'title': 'Day 7, 1+', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Day 7, 2+', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Urine samples were collected at indicated time points to analyze parameters including occult blood by dipstick. Urinalysis included dipstick urine test which was used to screen for occult blood. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine occult blood can be read as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Number of Participants With Urinalysis Dipstick Results: Ketones', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Baseline (Day -1), Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '22', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}]}, {'title': 'Baseline (Day -1), Trace', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Day 2, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '19', 'groupId': 'OG002'}]}]}, {'title': 'Day 2, Trace', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Day 5, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}]}]}, {'title': 'Day 5, 2+', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Day 7, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '10', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}]}, {'title': 'Day 7, Trace', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Urine samples were collected at indicated time points to analyze parameters including ketones by dipstick. Urinalysis included dipstick urine test which was used to screen for ketones. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine ketones can be read as negative, trace, 2+ indicating proportional concentrations in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Number of Participants With Urinalysis Dipstick Results: Ketones', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Baseline (Day -1), Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '17', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}]}]}, {'title': 'Baseline (Day -1), Trace', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}, {'title': 'Day 2, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '17', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}]}]}, {'title': 'Day 2, 1+', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}, {'title': 'Day 5, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '8', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}]}]}, {'title': 'Day 5, Trace', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}, {'title': 'Day 5, 2+', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}, {'title': 'Day 7, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}]}, {'title': 'Day 7, Trace', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Urine samples were collected at indicated time points to analyze parameters including ketones by dipstick. Urinalysis included dipstick urine test which was used to screen for ketones. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine ketones can be read as negative, trace, 1+, 2+ indicating proportional concentrations in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Number of Participants With Urinalysis Dipstick Results: Bilirubin and Nitrite', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Bilirubin, Baseline (Day -1), Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}]}, {'title': 'Bilirubin, Day 2, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}]}, {'title': 'Bilirubin, Day 5, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}]}, {'title': 'Bilirubin, Day 7, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}]}, {'title': 'Nitrite, Baseline (Day -1), Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}]}, {'title': 'Nitrite, Day 2, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}]}, {'title': 'Nitrite, Day 5, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}]}, {'title': 'Nitrite, Day 7, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Urine samples were collected at indicated time points to analyze parameters including bilirubin and nitrite by dipstick. Urinalysis included dipstick urine test which was used to screen for bilirubin and nitrite. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine bilirubin and nitrite can be read as negative in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Number of Participants With Urinalysis Dipstick Results: Bilirubin and Nitrite', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Bilirubin, Baseline (Day -1), Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}]}, {'title': 'Bilirubin, Day 2, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}]}, {'title': 'Bilirubin, Day 5, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}]}, {'title': 'Bilirubin, Day 7, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}]}, {'title': 'Nitrite, Baseline (Day -1), Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}]}, {'title': 'Nitrite, Day 2, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}]}, {'title': 'Nitrite, Day 5, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}]}, {'title': 'Nitrite, Day 7, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Urine samples were collected at indicated time points to analyze parameters including bilirubin and nitrite by dipstick. Urinalysis included dipstick urine test which was used to screen for bilirubin and nitrite. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine bilirubin and nitrite can be read as negative in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Number of Participants With Urinalysis Dipstick Results: Leukocyte Esterase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Baseline (Day -1), Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '21', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}]}, {'title': 'Baseline (Day -1), Trace', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Day 2, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '22', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}]}, {'title': 'Day 2, 1+', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Day 5, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}]}]}, {'title': 'Day 5, 1+', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Day 7, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '9', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}]}, {'title': 'Day 7, Trace', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Day 7, 1+', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Urine samples were collected at indicated time points to analyze parameters including leukocyte esterase by dipstick. Urinalysis included dipstick urine test which was used to screen for leukocyte esterase. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine leukocyte esterase can be read as negative, trace, 1+ indicating proportional concentrations in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Number of Participants With Urinalysis Dipstick Results: Leukocyte Esterase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Baseline (Day -1), Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '17', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}]}]}, {'title': 'Baseline (Day -1), Trace', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}, {'title': 'Day 2, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '15', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}]}]}, {'title': 'Day 2, Trace', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}, {'title': 'Day 5, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}]}, {'title': 'Day 7, Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Urine samples were collected at indicated time points to analyze parameters including leukocyte esterase by dipstick. Urinalysis included dipstick urine test which was used to screen for leukocyte esterase. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine leukocyte esterase can be read as negative, trace indicating proportional concentrations in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Change From Baseline in Urinalysis Parameter: Specific Gravity', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.0000', 'spread': '0.00662', 'groupId': 'OG000'}, {'value': '-0.0017', 'spread': '0.00770', 'groupId': 'OG001'}, {'value': '-0.0002', 'spread': '0.00738', 'groupId': 'OG002'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.0033', 'spread': '0.00505', 'groupId': 'OG000'}, {'value': '0.0043', 'spread': '0.00524', 'groupId': 'OG001'}, {'value': '0.0030', 'spread': '0.00329', 'groupId': 'OG002'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.0056', 'spread': '0.00877', 'groupId': 'OG000'}, {'value': '-0.0014', 'spread': '0.00957', 'groupId': 'OG001'}, {'value': '0.0010', 'spread': '0.00794', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': "Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.", 'unitOfMeasure': 'Ratio', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Change From Baseline in Urinalysis Parameter: Specific Gravity', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.0011', 'spread': '0.00679', 'groupId': 'OG000'}, {'value': '0.0018', 'spread': '0.00899', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.0005', 'spread': '0.00447', 'groupId': 'OG000'}, {'value': '-0.0019', 'spread': '0.01156', 'groupId': 'OG001'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.0001', 'spread': '0.00551', 'groupId': 'OG000'}, {'value': '-0.0022', 'spread': '0.00748', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': "Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.", 'unitOfMeasure': 'Ratio', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Change From Baseline for Urinalysis Parameter: Potential of Hydrogen', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.02', 'spread': '0.545', 'groupId': 'OG000'}, {'value': '0.17', 'spread': '0.796', 'groupId': 'OG001'}, {'value': '0.33', 'spread': '0.520', 'groupId': 'OG002'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.58', 'spread': '0.665', 'groupId': 'OG000'}, {'value': '-0.08', 'spread': '0.585', 'groupId': 'OG001'}, {'value': '-0.08', 'spread': '0.204', 'groupId': 'OG002'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.45', 'spread': '0.416', 'groupId': 'OG000'}, {'value': '-0.31', 'spread': '0.723', 'groupId': 'OG001'}, {'value': '0.15', 'spread': '0.412', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'pH', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Change From Baseline for Urinalysis Parameter: Potential of Hydrogen', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.586', 'groupId': 'OG000'}, {'value': '0.08', 'spread': '0.393', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.13', 'spread': '0.354', 'groupId': 'OG000'}, {'value': '0.11', 'spread': '0.333', 'groupId': 'OG001'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.06', 'spread': '0.464', 'groupId': 'OG000'}, {'value': '-0.06', 'spread': '0.635', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'pH', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Number of Participants With Worst Case Urine Parameter: Glucose Results by Maximum Grade Increase Post-Baseline Relative to Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Increase to Grade 1', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Increase to Grade 2', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Increase to Grade 3', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Increase to Grade 4', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Day 17', 'description': 'Urine samples were collected to analyze the urine parameter: glucose. Urinalysis parameters were graded according to Division of Acquired Immune Deficiency Syndrome (DAIDS) grading for severity of laboratory toxicities and clinical adverse events, version 2.1. The grades were grade 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening). Baseline was defined as the last assessment before the first dose of the study treatment. Only those urine parameters with maximum post-Baseline grade increase (Grade 1 to Grade 4) have been presented.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population'}, {'type': 'SECONDARY', 'title': 'Part 2: Number of Participants With Worst Case Urine Parameter: Glucose Results by Maximum Grade Increase Post-Baseline Relative to Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Increase to Grade 1', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Increase to Grade 2', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Increase to Grade 3', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Increase to Grade 4', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Day 9', 'description': 'Urine samples were collected to analyze the urine parameter: glucose. Urinalysis parameters were graded according to Division of Acquired Immune Deficiency Syndrome (DAIDS) grading for severity of laboratory toxicities and clinical adverse events, version 2.1. The grades were grade 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening). Baseline was defined as the last assessment before the first dose of the study treatment. Only those urine parameters with maximum post-Baseline grade increase (Grade 1 to Grade 4) have been presented.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Number of Participants With Worst Case Urine Parameter: Protein Results by Maximum Grade Increase Post-Baseline Relative to Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Increase to Grade 1', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Increase to Grade 2', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Increase to Grade 3', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Increase to Grade 4', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Day 17', 'description': 'Urine samples were collected to analyze the urine parameter: protein. Urinalysis parameters were graded according to Division of Acquired Immune Deficiency Syndrome (DAIDS) grading for severity of laboratory toxicities and clinical adverse events, version 2.1. The grades were grade 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening). Baseline was defined as the last assessment before the first dose of the study treatment. Only those urine parameters with maximum post-Baseline grade increase (Grade 1 to Grade 4) have been presented.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population'}, {'type': 'SECONDARY', 'title': 'Part 2: Number of Participants With Worst Case Urine Parameter: Protein Results by Maximum Grade Increase Post-Baseline Relative to Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Increase to Grade 1', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Increase to Grade 2', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Increase to Grade 3', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Increase to Grade 4', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Day 9', 'description': 'Urine samples were collected to analyze the urine parameter: protein. Urinalysis parameters were graded according to Division of Acquired Immune Deficiency Syndrome (DAIDS) grading for severity of laboratory toxicities and clinical adverse events, version 2.1. The grades were grade 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening). Baseline was defined as the last assessment before the first dose of the study treatment. Only those urine parameters with maximum post-Baseline grade increase (Grade 1 to Grade 4) have been presented.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population'}, {'type': 'SECONDARY', 'title': 'Part 1: Number of Participants With Worst Case Urine Parameter: Erythrocytes Results by Maximum Grade Increase Post-Baseline Relative to Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Increase to Grade 1', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Increase to Grade 2', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Increase to Grade 3', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Increase to Grade 4', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Day 17', 'description': 'Urine samples were collected to analyze the urine parameter: erythrocytes. Urinalysis parameters were graded according to Division of Acquired Immune Deficiency Syndrome (DAIDS) grading for severity of laboratory toxicities and clinical adverse events, version 2.1. The grades were grade 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening). Baseline was defined as the last assessment before the first dose of the study treatment. Only those urine parameters with maximum post-Baseline grade increase (Grade 1 to Grade 4) have been presented.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Number of Participants With Worst Case Urine Parameter: Erythrocytes Results by Maximum Grade Increase Post-Baseline Relative to Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Increase to Grade 1', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Increase to Grade 2', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Increase to Grade 3', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Increase to Grade 4', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Day 9', 'description': 'Urine samples were collected to analyze the urine parameter: erythrocytes. Urinalysis parameters were graded according to Division of Acquired Immune Deficiency Syndrome (DAIDS) grading for severity of laboratory toxicities and clinical adverse events, version 2.1. The grades were grade 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening). Baseline was defined as the last assessment before the first dose of the study treatment. Only those urine parameters with maximum post-Baseline grade increase (Grade 1 to Grade 4) have been presented.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population'}, {'type': 'SECONDARY', 'title': "Part 1: Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)", 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'PR Interval, Baseline (Day1 pre-dose)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '162.8', 'spread': '17.39', 'groupId': 'OG000'}, {'value': '162.8', 'spread': '18.05', 'groupId': 'OG001'}, {'value': '163.1', 'spread': '16.90', 'groupId': 'OG002'}]}]}, {'title': 'PR Interval, Day 1, 2 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '159.0', 'spread': '18.13', 'groupId': 'OG000'}, {'value': '158.0', 'spread': '17.16', 'groupId': 'OG001'}, {'value': '157.7', 'spread': '17.78', 'groupId': 'OG002'}]}]}, {'title': 'PR Interval, Day 1, 4 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '159.2', 'spread': '17.50', 'groupId': 'OG000'}, {'value': '160.0', 'spread': '17.51', 'groupId': 'OG001'}, {'value': '159.9', 'spread': '15.79', 'groupId': 'OG002'}]}]}, {'title': 'PR Interval, Day 1, 6 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '160.4', 'spread': '18.70', 'groupId': 'OG000'}, {'value': '158.2', 'spread': '18.10', 'groupId': 'OG001'}, {'value': '160.1', 'spread': '16.87', 'groupId': 'OG002'}]}]}, {'title': 'PR Interval, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '162.2', 'spread': '16.02', 'groupId': 'OG000'}, {'value': '170.8', 'spread': '12.42', 'groupId': 'OG001'}, {'value': '159.8', 'spread': '31.98', 'groupId': 'OG002'}]}]}, {'title': 'QRS Duration, Baseline (Day 1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '92.0', 'spread': '7.09', 'groupId': 'OG000'}, {'value': '93.1', 'spread': '7.83', 'groupId': 'OG001'}, {'value': '93.4', 'spread': '8.61', 'groupId': 'OG002'}]}]}, {'title': 'QRS Duration, Day 1, 2 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '91.3', 'spread': '7.12', 'groupId': 'OG000'}, {'value': '92.8', 'spread': '9.11', 'groupId': 'OG001'}, {'value': '92.8', 'spread': '8.15', 'groupId': 'OG002'}]}]}, {'title': 'QRS Duration, Day 1, 4 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '90.0', 'spread': '8.16', 'groupId': 'OG000'}, {'value': '91.5', 'spread': '8.18', 'groupId': 'OG001'}, {'value': '91.7', 'spread': '9.04', 'groupId': 'OG002'}]}]}, {'title': 'QRS Duration, Day 1, 6 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '91.0', 'spread': '7.67', 'groupId': 'OG000'}, {'value': '91.7', 'spread': '8.87', 'groupId': 'OG001'}, {'value': '93.2', 'spread': '8.63', 'groupId': 'OG002'}]}]}, {'title': 'QRS Duration, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '92.3', 'spread': '4.93', 'groupId': 'OG000'}, {'value': '94.2', 'spread': '6.24', 'groupId': 'OG001'}, {'value': '94.8', 'spread': '9.99', 'groupId': 'OG002'}]}]}, {'title': 'QT Interval, Baseline (Day 1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '397.0', 'spread': '26.26', 'groupId': 'OG000'}, {'value': '393.1', 'spread': '29.10', 'groupId': 'OG001'}, {'value': '394.2', 'spread': '24.66', 'groupId': 'OG002'}]}]}, {'title': 'QT Interval, Day 1, 2 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '381.1', 'spread': '24.29', 'groupId': 'OG000'}, {'value': '375.0', 'spread': '24.49', 'groupId': 'OG001'}, {'value': '375.6', 'spread': '19.77', 'groupId': 'OG002'}]}]}, {'title': 'QT Interval, Day 1, 4 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '391.2', 'spread': '26.27', 'groupId': 'OG000'}, {'value': '385.0', 'spread': '23.31', 'groupId': 'OG001'}, {'value': '386.4', 'spread': '21.34', 'groupId': 'OG002'}]}]}, {'title': 'QT Interval, Day 1, 6 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '387.8', 'spread': '21.90', 'groupId': 'OG000'}, {'value': '379.3', 'spread': '23.66', 'groupId': 'OG001'}, {'value': '382.2', 'spread': '20.88', 'groupId': 'OG002'}]}]}, {'title': 'QT Interval, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '389.5', 'spread': '18.32', 'groupId': 'OG000'}, {'value': '374.8', 'spread': '29.13', 'groupId': 'OG001'}, {'value': '400.5', 'spread': '9.01', 'groupId': 'OG002'}]}]}, {'title': 'QTcF Interval, Baseline (Day 1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '404.3', 'spread': '17.15', 'groupId': 'OG000'}, {'value': '400.7', 'spread': '19.60', 'groupId': 'OG001'}, {'value': '403.7', 'spread': '14.85', 'groupId': 'OG002'}]}]}, {'title': 'QTcF Interval, Day 1, 2 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '397.5', 'spread': '18.03', 'groupId': 'OG000'}, {'value': '393.1', 'spread': '19.20', 'groupId': 'OG001'}, {'value': '397.0', 'spread': '15.11', 'groupId': 'OG002'}]}]}, {'title': 'QTcF Interval, Day 1, 4 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '399.1', 'spread': '19.40', 'groupId': 'OG000'}, {'value': '396.5', 'spread': '399.3', 'groupId': 'OG001'}, {'value': '399.3', 'spread': '17.85', 'groupId': 'OG002'}]}]}, {'title': 'QTcF Interval, Day 1, 6 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '401.8', 'spread': '17.12', 'groupId': 'OG000'}, {'value': '398.4', 'spread': '19.80', 'groupId': 'OG001'}, {'value': '399.0', 'spread': '16.65', 'groupId': 'OG002'}]}]}, {'title': 'QTcF Interval, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '396.5', 'spread': '23.48', 'groupId': 'OG000'}, {'value': '399.0', 'spread': '17.93', 'groupId': 'OG001'}, {'value': '395.7', 'spread': '13.69', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 2, 4, 6 hours, and Day 5', 'description': 'Twelve lead ECGs were obtained to measure PR interval, QRS duration, QT interval, and QTcF interval . Twelve lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments within each treatment', 'unitOfMeasure': 'Milliseconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'PR Interval, Baseline (Day 1 pre-dose)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '168.8', 'spread': '15.94', 'groupId': 'OG000'}, {'value': '170.9', 'spread': '14.96', 'groupId': 'OG001'}]}]}, {'title': 'PR Interval, Day 1, 2 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '160.6', 'spread': '14.92', 'groupId': 'OG000'}, {'value': '167.0', 'spread': '14.71', 'groupId': 'OG001'}]}]}, {'title': 'PR Interval, Day 1, 4 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '162.6', 'spread': '17.19', 'groupId': 'OG000'}, {'value': '167.4', 'spread': '13.84', 'groupId': 'OG001'}]}]}, {'title': 'PR Interval, Day 1, 6 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '162.2', 'spread': '15.23', 'groupId': 'OG000'}, {'value': '160.9', 'spread': '14.18', 'groupId': 'OG001'}]}]}, {'title': 'PR Interval, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '172.1', 'spread': '19.92', 'groupId': 'OG000'}, {'value': '164.1', 'spread': '9.69', 'groupId': 'OG001'}]}]}, {'title': 'PR Interval, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '167.1', 'spread': '9.09', 'groupId': 'OG000'}, {'value': '176.2', 'spread': '18.97', 'groupId': 'OG001'}]}]}, {'title': 'QRS Duration, Baseline (Day 1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '89.8', 'spread': '7.17', 'groupId': 'OG000'}, {'value': '89.1', 'spread': '5.71', 'groupId': 'OG001'}]}]}, {'title': 'QRS Duration, Day 1, 2 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '88.8', 'spread': '6.87', 'groupId': 'OG000'}, {'value': '87.9', 'spread': '5.56', 'groupId': 'OG001'}]}]}, {'title': 'QRS Duration, Day 1, 4 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '87.5', 'spread': '6.74', 'groupId': 'OG000'}, {'value': '89.3', 'spread': '6.49', 'groupId': 'OG001'}]}]}, {'title': 'QRS Duration, Day 1, 6 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '87.5', 'spread': '6.50', 'groupId': 'OG000'}, {'value': '89.7', 'spread': '7.11', 'groupId': 'OG001'}]}]}, {'title': 'QRS Duration, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '87.8', 'spread': '4.03', 'groupId': 'OG000'}, {'value': '89.2', 'spread': '8.51', 'groupId': 'OG001'}]}]}, {'title': 'QRS Duration, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '89.9', 'spread': '6.83', 'groupId': 'OG000'}, {'value': '88.8', 'spread': '3.15', 'groupId': 'OG001'}]}]}, {'title': 'QT Interval, Baseline (Day 1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '382.8', 'spread': '16.73', 'groupId': 'OG000'}, {'value': '383.6', 'spread': '18.49', 'groupId': 'OG001'}]}]}, {'title': 'QT Interval, Day 1, 2 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '367.0', 'spread': '15.73', 'groupId': 'OG000'}, {'value': '385.2', 'spread': '18.67', 'groupId': 'OG001'}]}]}, {'title': 'QT Interval, Day 1, 4 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '373.4', 'spread': '11.37', 'groupId': 'OG000'}, {'value': '391.8', 'spread': '16.57', 'groupId': 'OG001'}]}]}, {'title': 'QT Interval, Day 1, 6 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '372.9', 'spread': '16.48', 'groupId': 'OG000'}, {'value': '367.8', 'spread': '15.07', 'groupId': 'OG001'}]}]}, {'title': 'QT Interval, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '367.8', 'spread': '13.94', 'groupId': 'OG000'}, {'value': '385.2', 'spread': '25.34', 'groupId': 'OG001'}]}]}, {'title': 'QT Interval, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '382.6', 'spread': '17.92', 'groupId': 'OG000'}, {'value': '378.2', 'spread': '14.66', 'groupId': 'OG001'}]}]}, {'title': 'QTcF Interval, Baseline (Day 1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '393.3', 'spread': '11.84', 'groupId': 'OG000'}, {'value': '390.9', 'spread': '13.13', 'groupId': 'OG001'}]}]}, {'title': 'QTcF Interval, Day 1, 2 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '387.2', 'spread': '12.56', 'groupId': 'OG000'}, {'value': '390.3', 'spread': '16.98', 'groupId': 'OG001'}]}]}, {'title': 'QTcF Interval, Day 1, 4 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '388.8', 'spread': '11.52', 'groupId': 'OG000'}, {'value': '392.3', 'spread': '14.99', 'groupId': 'OG001'}]}]}, {'title': 'QTcF Interval, Day 1, 6 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '389.4', 'spread': '11.52', 'groupId': 'OG000'}, {'value': '390.2', 'spread': '13.13', 'groupId': 'OG001'}]}]}, {'title': 'QTcF Interval, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '388.6', 'spread': '7.63', 'groupId': 'OG000'}, {'value': '395.3', 'spread': '14.71', 'groupId': 'OG001'}]}]}, {'title': 'QTcF Interval, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '395.3', 'spread': '12.11', 'groupId': 'OG000'}, {'value': '381.1', 'spread': '9.78', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 2, 4, 6 hours, and Days 5, 7', 'description': 'Twelve lead ECGs were obtained to measure PR interval, QRS duration, QT interval, and QTcF interval. Twelve lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments within each treatment.', 'unitOfMeasure': 'Milliseconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'PR Interval, Day 1, 2 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.8', 'spread': '10.19', 'groupId': 'OG000'}, {'value': '-4.7', 'spread': '7.79', 'groupId': 'OG001'}, {'value': '-5.5', 'spread': '11.16', 'groupId': 'OG002'}]}]}, {'title': 'PR Interval, Day 1, 4 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.6', 'spread': '10.28', 'groupId': 'OG000'}, {'value': '-2.8', 'spread': '6.31', 'groupId': 'OG001'}, {'value': '-3.3', 'spread': '9.04', 'groupId': 'OG002'}]}]}, {'title': 'PR Interval, Day 1, 6 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.5', 'spread': '9.65', 'groupId': 'OG000'}, {'value': '-4.6', 'spread': '11.29', 'groupId': 'OG001'}, {'value': '-3.0', 'spread': '10.31', 'groupId': 'OG002'}]}]}, {'title': 'PR Interval, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2.8', 'spread': '9.13', 'groupId': 'OG000'}, {'value': '-1.8', 'spread': '8.28', 'groupId': 'OG001'}, {'value': '-6.0', 'spread': '9.44', 'groupId': 'OG002'}]}]}, {'title': 'QRS Duration, Day 1, 2 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.7', 'spread': '4.22', 'groupId': 'OG000'}, {'value': '-0.4', 'spread': '4.60', 'groupId': 'OG001'}, {'value': '-0.7', 'spread': '3.12', 'groupId': 'OG002'}]}]}, {'title': 'QRS Duration, Day 1, 4 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.0', 'spread': '4.40', 'groupId': 'OG000'}, {'value': '-1.6', 'spread': '5.00', 'groupId': 'OG001'}, {'value': '-1.7', 'spread': '3.54', 'groupId': 'OG002'}]}]}, {'title': 'QRS Duration, Day 1, 6 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.0', 'spread': '4.55', 'groupId': 'OG000'}, {'value': '-1.4', 'spread': '3.99', 'groupId': 'OG001'}, {'value': '-0.3', 'spread': '2.45', 'groupId': 'OG002'}]}]}, {'title': 'QRS Duration, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2.0', 'spread': '3.46', 'groupId': 'OG000'}, {'value': '-1.3', 'spread': '4.97', 'groupId': 'OG001'}, {'value': '-0.8', 'spread': '2.14', 'groupId': 'OG002'}]}]}, {'title': 'QT Interval, Day 1, 2 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-15.8', 'spread': '11.54', 'groupId': 'OG000'}, {'value': '-18.1', 'spread': '10.24', 'groupId': 'OG001'}, {'value': '-18.6', 'spread': '11.71', 'groupId': 'OG002'}]}]}, {'title': 'QT Interval, Day 1, 4 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-5.8', 'spread': '14.45', 'groupId': 'OG000'}, {'value': '-8.1', 'spread': '13.18', 'groupId': 'OG001'}, {'value': '-7.9', 'spread': '11.78', 'groupId': 'OG002'}]}]}, {'title': 'QT Interval, Day 1, 6 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-9.1', 'spread': '12.89', 'groupId': 'OG000'}, {'value': '-13.8', 'spread': '13.51', 'groupId': 'OG001'}, {'value': '-12.0', 'spread': '13.81', 'groupId': 'OG002'}]}]}, {'title': 'QT Interval, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.8', 'spread': '14.27', 'groupId': 'OG000'}, {'value': '-14.8', 'spread': '19.54', 'groupId': 'OG001'}, {'value': '-14.5', 'spread': '9.85', 'groupId': 'OG002'}]}]}, {'title': 'QTcF Interval, Day 1, 2 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-6.8', 'spread': '7.36', 'groupId': 'OG000'}, {'value': '-7.6', 'spread': '6.58', 'groupId': 'OG001'}, {'value': '-6.8', 'spread': '6.32', 'groupId': 'OG002'}]}]}, {'title': 'QTcF Interval, Day 1, 4 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-5.1', 'spread': '9.07', 'groupId': 'OG000'}, {'value': '-4.2', 'spread': '8.58', 'groupId': 'OG001'}, {'value': '-4.5', 'spread': '6.88', 'groupId': 'OG002'}]}]}, {'title': 'QTcF Interval, Day 1, 6 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.5', 'spread': '8.72', 'groupId': 'OG000'}, {'value': '-2.2', 'spread': '9.87', 'groupId': 'OG001'}, {'value': '-4.7', 'spread': '7.34', 'groupId': 'OG002'}]}]}, {'title': 'QTcF Interval, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-6.0', 'spread': '14.04', 'groupId': 'OG000'}, {'value': '-2.3', 'spread': '14.31', 'groupId': 'OG001'}, {'value': '-5.8', 'spread': '8.16', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, Pre-dose), and Day 1: 2, 4, 6 hours, and Day 5', 'description': 'Twelve lead ECGs were obtained to measure PR interval, QRS duration, QT interval, QTcF interval. Twelve lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Milliseconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'PR Interval, Day 1, 2 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-8.1', 'spread': '10.19', 'groupId': 'OG000'}, {'value': '-3.9', 'spread': '8.27', 'groupId': 'OG001'}]}]}, {'title': 'PR Interval, Day 1, 4 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-6.1', 'spread': '12.06', 'groupId': 'OG000'}, {'value': '-3.4', 'spread': '9.73', 'groupId': 'OG001'}]}]}, {'title': 'PR Interval, Day 1, 6 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-6.5', 'spread': '10.71', 'groupId': 'OG000'}, {'value': '-9.9', 'spread': '12.21', 'groupId': 'OG001'}]}]}, {'title': 'PR Interval, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-4.5', 'spread': '10.94', 'groupId': 'OG000'}, {'value': '-4.8', 'spread': '8.84', 'groupId': 'OG001'}]}]}, {'title': 'PR Interval, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '5.3', 'spread': '7.89', 'groupId': 'OG000'}, {'value': '3.3', 'spread': '11.88', 'groupId': 'OG001'}]}]}, {'title': 'QRS Duration, Day 1, 2 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.0', 'spread': '5.14', 'groupId': 'OG000'}, {'value': '-1.2', 'spread': '2.56', 'groupId': 'OG001'}]}]}, {'title': 'QRS Duration, Day 1, 4 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.3', 'spread': '5.39', 'groupId': 'OG000'}, {'value': '0.2', 'spread': '2.21', 'groupId': 'OG001'}]}]}, {'title': 'QRS Duration Day 1, 6 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.2', 'spread': '4.97', 'groupId': 'OG000'}, {'value': '0.6', 'spread': '2.75', 'groupId': 'OG001'}]}]}, {'title': 'QRS Duration, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-3.8', 'spread': '7.74', 'groupId': 'OG000'}, {'value': '0.0', 'spread': '2.74', 'groupId': 'OG001'}]}]}, {'title': 'QRS Duration, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.7', 'spread': '3.12', 'groupId': 'OG000'}, {'value': '-0.2', 'spread': '3.93', 'groupId': 'OG001'}]}]}, {'title': 'QT Interval, Day 1, 2 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-15.8', 'spread': '13.03', 'groupId': 'OG000'}, {'value': '1.6', 'spread': '11.34', 'groupId': 'OG001'}]}]}, {'title': 'QT Interval, Day 1, 4 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-9.5', 'spread': '13.61', 'groupId': 'OG000'}, {'value': '8.2', 'spread': '10.80', 'groupId': 'OG001'}]}]}, {'title': 'QT Interval, Day 1, 6 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-9.9', 'spread': '14.35', 'groupId': 'OG000'}, {'value': '-15.7', 'spread': '10.87', 'groupId': 'OG001'}]}]}, {'title': 'QT Interval, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-16.0', 'spread': '17.47', 'groupId': 'OG000'}, {'value': '-2.3', 'spread': '19.62', 'groupId': 'OG001'}]}]}, {'title': 'QT Interval, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.6', 'spread': '8.03', 'groupId': 'OG000'}, {'value': '-1.3', 'spread': '16.72', 'groupId': 'OG001'}]}]}, {'title': 'QTcF Interval, Day 1, 2 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-6.1', 'spread': '11.76', 'groupId': 'OG000'}, {'value': '-0.6', 'spread': '8.47', 'groupId': 'OG001'}]}]}, {'title': 'QTcF Interval, Day 1, 4 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-4.5', 'spread': '8.52', 'groupId': 'OG000'}, {'value': '1.4', 'spread': '7.88', 'groupId': 'OG001'}]}]}, {'title': 'QTcF Interval, Day 1, 6 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-3.9', 'spread': '5.96', 'groupId': 'OG000'}, {'value': '-0.8', 'spread': '8.05', 'groupId': 'OG001'}]}]}, {'title': 'QTcF Interval, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.5', 'spread': '6.26', 'groupId': 'OG000'}, {'value': '0.2', 'spread': '9.56', 'groupId': 'OG001'}]}]}, {'title': 'QTcF Interval, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.7', 'spread': '6.48', 'groupId': 'OG000'}, {'value': '-5.7', 'spread': '11.38', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 2, 4, 6 hours, Days 5 and 7', 'description': 'Twelve lead ECGs were obtained to measure PR interval, QRS duration, QT interval, QTcF interval. Twelve lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Milliseconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Absolute Values of Vital Sign Parameters: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'DBP, Baseline (Day 1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '61.5', 'spread': '6.39', 'groupId': 'OG000'}, {'value': '63.2', 'spread': '7.21', 'groupId': 'OG001'}, {'value': '63.2', 'spread': '9.05', 'groupId': 'OG002'}]}]}, {'title': 'DBP, Day 1, 24 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '60.9', 'spread': '7.34', 'groupId': 'OG000'}, {'value': '63.1', 'spread': '8.18', 'groupId': 'OG001'}, {'value': '63.0', 'spread': '6.40', 'groupId': 'OG002'}]}]}, {'title': 'DBP, Day 1, 48 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}, {'value': '16', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '59.8', 'spread': '5.89', 'groupId': 'OG000'}, {'value': '61.2', 'spread': '6.68', 'groupId': 'OG001'}, {'value': '59.6', 'spread': '4.72', 'groupId': 'OG002'}]}]}, {'title': 'DBP, Day 1, 72 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '58.7', 'spread': '6.19', 'groupId': 'OG000'}, {'value': '63.0', 'spread': '8.69', 'groupId': 'OG001'}, {'value': '61.3', 'spread': '4.08', 'groupId': 'OG002'}]}]}, {'title': 'DBP, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '61.7', 'spread': '5.24', 'groupId': 'OG000'}, {'value': '64.2', 'spread': '6.05', 'groupId': 'OG001'}, {'value': '61.5', 'spread': '4.18', 'groupId': 'OG002'}]}]}, {'title': 'DBP Interval, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '62.0', 'spread': '8.46', 'groupId': 'OG000'}, {'value': '61.0', 'spread': '7.18', 'groupId': 'OG001'}, {'value': '59.4', 'spread': '5.48', 'groupId': 'OG002'}]}]}, {'title': 'SBP, Baseline (Day 1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '108.9', 'spread': '11.23', 'groupId': 'OG000'}, {'value': '110.6', 'spread': '13.47', 'groupId': 'OG001'}, {'value': '110.8', 'spread': '16.32', 'groupId': 'OG002'}]}]}, {'title': 'SBP, Day 1, 24 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '106.1', 'spread': '10.41', 'groupId': 'OG000'}, {'value': '112.9', 'spread': '13.30', 'groupId': 'OG001'}, {'value': '108.7', 'spread': '10.54', 'groupId': 'OG002'}]}]}, {'title': 'SBP, Day 1, 48 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}, {'value': '16', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '104.7', 'spread': '8.60', 'groupId': 'OG000'}, {'value': '110.5', 'spread': '14.02', 'groupId': 'OG001'}, {'value': '106.7', 'spread': '10.47', 'groupId': 'OG002'}]}]}, {'title': 'SBP, Day 1, 72 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '100.5', 'spread': '6.53', 'groupId': 'OG000'}, {'value': '114.7', 'spread': '21.57', 'groupId': 'OG001'}, {'value': '112.2', 'spread': '12.19', 'groupId': 'OG002'}]}]}, {'title': 'SBP, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '105.8', 'spread': '8.64', 'groupId': 'OG000'}, {'value': '118.0', 'spread': '19.67', 'groupId': 'OG001'}, {'value': '109.2', 'spread': '10.98', 'groupId': 'OG002'}]}]}, {'title': 'SBP, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '110.5', 'spread': '13.40', 'groupId': 'OG000'}, {'value': '108.2', 'spread': '9.24', 'groupId': 'OG001'}, {'value': '106.8', 'spread': '11.94', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48, 72 hours, Days 5 and 7', 'description': 'SBP and DBP were measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment.', 'unitOfMeasure': 'Millimeters of mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Absolute Values of Vital Signs: DBP and SBP', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'DBP, Baseline (Day 1 pre-dose)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '65.1', 'spread': '8.39', 'groupId': 'OG000'}, {'value': '65.7', 'spread': '9.26', 'groupId': 'OG001'}]}]}, {'title': 'DBP, Day 1, 24 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '64.0', 'spread': '6.44', 'groupId': 'OG000'}, {'value': '62.9', 'spread': '9.09', 'groupId': 'OG001'}]}]}, {'title': 'DBP, Day 1, 48 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '61.8', 'spread': '7.89', 'groupId': 'OG000'}, {'value': '61.1', 'spread': '9.78', 'groupId': 'OG001'}]}]}, {'title': 'DBP, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '68.1', 'spread': '4.49', 'groupId': 'OG000'}, {'value': '60.0', 'spread': '4.30', 'groupId': 'OG001'}]}]}, {'title': 'DBP Interval, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '62.2', 'spread': '7.63', 'groupId': 'OG000'}, {'value': '67.6', 'spread': '7.60', 'groupId': 'OG001'}]}]}, {'title': 'SBP, Baseline (Day 1 pre-dose)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '110.9', 'spread': '9.39', 'groupId': 'OG000'}, {'value': '111.5', 'spread': '11.73', 'groupId': 'OG001'}]}]}, {'title': 'SBP, Day 1, 24 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '110.1', 'spread': '10.84', 'groupId': 'OG000'}, {'value': '110.4', 'spread': '13.49', 'groupId': 'OG001'}]}]}, {'title': 'SBP, Day 1, 48 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '108.4', 'spread': '10.06', 'groupId': 'OG000'}, {'value': '106.9', 'spread': '9.58', 'groupId': 'OG001'}]}]}, {'title': 'SBP, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '113.3', 'spread': '5.97', 'groupId': 'OG000'}, {'value': '108.7', 'spread': '9.31', 'groupId': 'OG001'}]}]}, {'title': 'SBP, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '105.8', 'spread': '6.28', 'groupId': 'OG000'}, {'value': '108.4', 'spread': '9.30', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Days 5 and 7', 'description': 'SBP and DBP were measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment.', 'unitOfMeasure': 'Millimeters of mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Absolute Values of Vital Signs: Pulse Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Baseline (Day 1, Pre-dose)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '64.9', 'spread': '13.41', 'groupId': 'OG000'}, {'value': '66.06', 'spread': '14.53', 'groupId': 'OG001'}, {'value': '67.4', 'spread': '14.19', 'groupId': 'OG002'}]}]}, {'title': 'Day 1, 24 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '61.7', 'spread': '9.05', 'groupId': 'OG000'}, {'value': '68.6', 'spread': '11.69', 'groupId': 'OG001'}, {'value': '64.8', 'spread': '11.47', 'groupId': 'OG002'}]}]}, {'title': 'Day 1, 48 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}, {'value': '16', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '61.7', 'spread': '6.88', 'groupId': 'OG000'}, {'value': '65.5', 'spread': '11.81', 'groupId': 'OG001'}, {'value': '64.9', 'spread': '10.20', 'groupId': 'OG002'}]}]}, {'title': 'Day 1, 72 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '61.2', 'spread': '10.76', 'groupId': 'OG000'}, {'value': '77.7', 'spread': '22.98', 'groupId': 'OG001'}, {'value': '57.7', 'spread': '10.76', 'groupId': 'OG002'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '62.3', 'spread': '6.06', 'groupId': 'OG000'}, {'value': '77.5', 'spread': '20.84', 'groupId': 'OG001'}, {'value': '59.7', 'spread': '11.81', 'groupId': 'OG002'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '58.9', 'spread': '8.29', 'groupId': 'OG000'}, {'value': '60.8', 'spread': '8.49', 'groupId': 'OG001'}, {'value': '69.6', 'spread': '9.83', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48, 72 hours, Days 5 and 7', 'description': 'Pulse rate was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment.', 'unitOfMeasure': 'Beats per minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Absolute Values of Vital Signs: Pulse Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Baseline (Day 1, pre-dose)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '64.4', 'spread': '5.76', 'groupId': 'OG000'}, {'value': '64.2', 'spread': '7.34', 'groupId': 'OG001'}]}]}, {'title': 'Day 1, 24 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '65.7', 'spread': '9.22', 'groupId': 'OG000'}, {'value': '67.3', 'spread': '8.21', 'groupId': 'OG001'}]}]}, {'title': 'Day 1, 48 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '66.9', 'spread': '7.29', 'groupId': 'OG000'}, {'value': '69.1', 'spread': '8.33', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '70.0', 'spread': '7.29', 'groupId': 'OG000'}, {'value': '66.8', 'spread': '7.10', 'groupId': 'OG001'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '65.9', 'spread': '5.64', 'groupId': 'OG000'}, {'value': '62.2', 'spread': '7.12', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Day 5 and 7', 'description': 'Pulse rate was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment.', 'unitOfMeasure': 'Beats per minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Absolute Values of Vital Signs: Oral Temperature', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Baseline (Day 1 pre-dose)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '36.38', 'spread': '0.424', 'groupId': 'OG000'}, {'value': '36.43', 'spread': '0.451', 'groupId': 'OG001'}, {'value': '36.52', 'spread': '0.382', 'groupId': 'OG002'}]}]}, {'title': 'Day 1, 24 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '36.47', 'spread': '0.431', 'groupId': 'OG000'}, {'value': '36.55', 'spread': '0.481', 'groupId': 'OG001'}, {'value': '36.60', 'spread': '0.422', 'groupId': 'OG002'}]}]}, {'title': 'Day 1, 48 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}, {'value': '16', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '36.54', 'spread': '0.343', 'groupId': 'OG000'}, {'value': '36.54', 'spread': '0.385', 'groupId': 'OG001'}, {'value': '36.61', 'spread': '0.264', 'groupId': 'OG002'}]}]}, {'title': 'Day 1, 72 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '36.45', 'spread': '0.423', 'groupId': 'OG000'}, {'value': '36.77', 'spread': '0.314', 'groupId': 'OG001'}, {'value': '36.25', 'spread': '0.505', 'groupId': 'OG002'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}, {'value': '16', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '36.44', 'spread': '0.475', 'groupId': 'OG000'}, {'value': '36.43', 'spread': '0.527', 'groupId': 'OG001'}, {'value': '36.48', 'spread': '0.355', 'groupId': 'OG002'}]}]}, {'title': 'Day 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '36.43', 'spread': '0.317', 'groupId': 'OG000'}, {'value': '36.49', 'spread': '0.468', 'groupId': 'OG001'}, {'value': '36.43', 'spread': '0.267', 'groupId': 'OG002'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '36.51', 'spread': '0.501', 'groupId': 'OG000'}, {'value': '36.46', 'spread': '0.380', 'groupId': 'OG001'}, {'value': '36.72', 'spread': '0.282', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48, 72 hours, Days 5, 6 and 7', 'description': 'Oral temperature were measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment.', 'unitOfMeasure': 'Degrees celsius', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Absolute Values of Vital Signs: Oral Temperature', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Baseline (Day 1, pre-dose)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '36.28', 'spread': '0.366', 'groupId': 'OG000'}, {'value': '36.30', 'spread': '0.230', 'groupId': 'OG001'}]}]}, {'title': 'Day 1, 24 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '36.42', 'spread': '0.325', 'groupId': 'OG000'}, {'value': '36.33', 'spread': '0.307', 'groupId': 'OG001'}]}]}, {'title': 'Day 1, 48 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '36.42', 'spread': '0.321', 'groupId': 'OG000'}, {'value': '36.32', 'spread': '0.349', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '36.41', 'spread': '0.347', 'groupId': 'OG000'}, {'value': '36.31', 'spread': '0.313', 'groupId': 'OG001'}]}]}, {'title': 'Day 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '36.43', 'spread': '0.339', 'groupId': 'OG000'}, {'value': '36.18', 'spread': '0.377', 'groupId': 'OG001'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '36.57', 'spread': '0.269', 'groupId': 'OG000'}, {'value': '36.38', 'spread': '0.402', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Day 5 and 7', 'description': 'Oral temperature were measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment.', 'unitOfMeasure': 'Degree celsius', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Absolute Values of Vital Signs: Respiratory Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Baseline (Day 1, pre-dose)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '14.1', 'spread': '2.65', 'groupId': 'OG000'}, {'value': '13.6', 'spread': '2.58', 'groupId': 'OG001'}, {'value': '13.9', 'spread': '3.28', 'groupId': 'OG002'}]}]}, {'title': 'Day 1, 24 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '13.8', 'spread': '3.26', 'groupId': 'OG000'}, {'value': '13.8', 'spread': '3.03', 'groupId': 'OG001'}, {'value': '14.8', 'spread': '2.93', 'groupId': 'OG002'}]}]}, {'title': 'Day 1, 48 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}, {'value': '16', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '14.9', 'spread': '2.68', 'groupId': 'OG000'}, {'value': '12.7', 'spread': '2.42', 'groupId': 'OG001'}, {'value': '14.1', 'spread': '2.00', 'groupId': 'OG002'}]}]}, {'title': 'Day 1, 72 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '14.0', 'spread': '2.83', 'groupId': 'OG000'}, {'value': '13.0', 'spread': '2.45', 'groupId': 'OG001'}, {'value': '14.0', 'spread': '1.26', 'groupId': 'OG002'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '11.7', 'spread': '3.44', 'groupId': 'OG000'}, {'value': '12.0', 'spread': '2.83', 'groupId': 'OG001'}, {'value': '14.7', 'spread': '3.93', 'groupId': 'OG002'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '14.0', 'spread': '2.97', 'groupId': 'OG000'}, {'value': '14.6', 'spread': '1.89', 'groupId': 'OG001'}, {'value': '12.9', 'spread': '3.78', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48, 72 hours, Days 5 and 7', 'description': 'Respiratory rate was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment.', 'unitOfMeasure': 'Breaths per minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Absolute Values of Vital Signs: Respiratory Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Baseline (Day 1, pre-dose)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '12.7', 'spread': '2.34', 'groupId': 'OG000'}, {'value': '12.9', 'spread': '2.49', 'groupId': 'OG001'}]}]}, {'title': 'Day 1, 24 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '14.5', 'spread': '1.94', 'groupId': 'OG000'}, {'value': '13.9', 'spread': '2.52', 'groupId': 'OG001'}]}]}, {'title': 'Day 1, 48 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '13.1', 'spread': '2.84', 'groupId': 'OG000'}, {'value': '13.8', 'spread': '2.37', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '11.3', 'spread': '2.38', 'groupId': 'OG000'}, {'value': '12.4', 'spread': '3.13', 'groupId': 'OG001'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '13.5', 'spread': '2.07', 'groupId': 'OG000'}, {'value': '13.1', 'spread': '1.45', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Days 5, and 7', 'description': 'Respiratory rate was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment.', 'unitOfMeasure': 'Breaths per minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Change From Baseline in Vital Signs: DBP and SBP', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'DBP, Day 1, 24 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.6', 'spread': '5.27', 'groupId': 'OG000'}, {'value': '-0.1', 'spread': '7.40', 'groupId': 'OG001'}, {'value': '13.9', 'spread': '7.45', 'groupId': 'OG002'}]}]}, {'title': 'DBP, Day 1, 48 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}, {'value': '16', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.4', 'spread': '5.21', 'groupId': 'OG000'}, {'value': '-2.5', 'spread': '5.25', 'groupId': 'OG001'}, {'value': '-2.4', 'spread': '5.66', 'groupId': 'OG002'}]}]}, {'title': 'DBP, Day 1, 72 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-4.2', 'spread': '6.52', 'groupId': 'OG000'}, {'value': '-1.3', 'spread': '6.86', 'groupId': 'OG001'}, {'value': '-1.5', 'spread': '6.66', 'groupId': 'OG002'}]}]}, {'title': 'DBP, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.2', 'spread': '6.18', 'groupId': 'OG000'}, {'value': '-0.2', 'spread': '7.25', 'groupId': 'OG001'}, {'value': '-1.3', 'spread': '5.20', 'groupId': 'OG002'}]}]}, {'title': 'DBP, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '7.49', 'groupId': 'OG000'}, {'value': '-2.3', 'spread': '5.76', 'groupId': 'OG001'}, {'value': '-2.1', 'spread': '8.01', 'groupId': 'OG002'}]}]}, {'title': 'SBP, Day 1, 24 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.8', 'spread': '9.63', 'groupId': 'OG000'}, {'value': '2.3', 'spread': '7.37', 'groupId': 'OG001'}, {'value': '-2.1', 'spread': '9.95', 'groupId': 'OG002'}]}]}, {'title': 'SBP, Day 1, 48 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}, {'value': '16', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-4.0', 'spread': '6.08', 'groupId': 'OG000'}, {'value': '-0.5', 'spread': '6.57', 'groupId': 'OG001'}, {'value': '-3.8', 'spread': '10.80', 'groupId': 'OG002'}]}]}, {'title': 'SBP, Day 1, 72 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-7.8', 'spread': '9.09', 'groupId': 'OG000'}, {'value': '2.8', 'spread': '8.64', 'groupId': 'OG001'}, {'value': '4.2', 'spread': '6.74', 'groupId': 'OG002'}]}]}, {'title': 'SBP, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.5', 'spread': '7.06', 'groupId': 'OG000'}, {'value': '6.2', 'spread': '9.13', 'groupId': 'OG001'}, {'value': '1.2', 'spread': '6.52', 'groupId': 'OG002'}]}]}, {'title': 'SBP, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.4', 'spread': '7.63', 'groupId': 'OG000'}, {'value': '-2.4', 'spread': '10.06', 'groupId': 'OG001'}, {'value': '-5.1', 'spread': '10.71', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48, 72 hours, Days 5, and 7', 'description': 'SBP and DBP were measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Millimeters of mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Change From Baseline in Vital Signs: DBP and SBP', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'DBP, Day 1, 24 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.1', 'spread': '4.34', 'groupId': 'OG000'}, {'value': '-2.8', 'spread': '7.18', 'groupId': 'OG001'}]}]}, {'title': 'DBP, Day 1, 48 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-3.3', 'spread': '6.30', 'groupId': 'OG000'}, {'value': '-4.6', 'spread': '5.28', 'groupId': 'OG001'}]}]}, {'title': 'DBP, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.3', 'spread': '6.96', 'groupId': 'OG000'}, {'value': '-1.8', 'spread': '5.54', 'groupId': 'OG001'}]}]}, {'title': 'DBP Interval, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '4.48', 'groupId': 'OG000'}, {'value': '-2.0', 'spread': '6.61', 'groupId': 'OG001'}]}]}, {'title': 'SBP, Day 1, 24 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.8', 'spread': '9.19', 'groupId': 'OG000'}, {'value': '-1.1', 'spread': '10.57', 'groupId': 'OG001'}]}]}, {'title': 'SBP, Day 1, 48 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.5', 'spread': '5.56', 'groupId': 'OG000'}, {'value': '-4.6', 'spread': '7.81', 'groupId': 'OG001'}]}]}, {'title': 'SBP, Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.3', 'spread': '10.10', 'groupId': 'OG000'}, {'value': '1.9', 'spread': '8.22', 'groupId': 'OG001'}]}]}, {'title': 'SBP, Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-4.1', 'spread': '4.48', 'groupId': 'OG000'}, {'value': '-7.8', 'spread': '8.74', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Days 5, and 7', 'description': 'SBP and DBP were measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Millimeters of mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Change From Baseline in Vital Signs: Pulse Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Day 1, 24 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.2', 'spread': '8.87', 'groupId': 'OG000'}, {'value': '2.6', 'spread': '8.69', 'groupId': 'OG001'}, {'value': '-2.7', 'spread': '10.80', 'groupId': 'OG002'}]}]}, {'title': 'Day 1, 48 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}, {'value': '16', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.7', 'spread': '9.60', 'groupId': 'OG000'}, {'value': '-1.4', 'spread': '8.38', 'groupId': 'OG001'}, {'value': '-2.8', 'spread': '10.94', 'groupId': 'OG002'}]}]}, {'title': 'Day 1, 72 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-5.2', 'spread': '14.32', 'groupId': 'OG000'}, {'value': '7.2', 'spread': '5.98', 'groupId': 'OG001'}, {'value': '0.7', 'spread': '4.41', 'groupId': 'OG002'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-4.0', 'spread': '9.08', 'groupId': 'OG000'}, {'value': '7.0', 'spread': '6.32', 'groupId': 'OG001'}, {'value': '2.7', 'spread': '5.89', 'groupId': 'OG002'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.0', 'spread': '7.33', 'groupId': 'OG000'}, {'value': '-4.4', 'spread': '9.63', 'groupId': 'OG001'}, {'value': '-4.4', 'spread': '9.42', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48, 72 hours, Days 5, and 7', 'description': 'Pulse rate was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Beats per minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Change From Baseline in Vital Signs: Pulse Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Day 1, 24 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.3', 'spread': '9.68', 'groupId': 'OG000'}, {'value': '3.1', 'spread': '8.32', 'groupId': 'OG001'}]}]}, {'title': 'Day 1, 48 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.5', 'spread': '5.37', 'groupId': 'OG000'}, {'value': '4.9', 'spread': '8.36', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '7.0', 'spread': '8.19', 'groupId': 'OG000'}, {'value': '3.4', 'spread': '5.32', 'groupId': 'OG001'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '4.18', 'groupId': 'OG000'}, {'value': '-2.9', 'spread': '6.51', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Days 5, and 7', 'description': 'Pulse rate was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Beats per minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Change From Baseline in Vital Signs: Oral Temperature', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Day 1, 24 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.09', 'spread': '0.507', 'groupId': 'OG000'}, {'value': '0.11', 'spread': '0.479', 'groupId': 'OG001'}, {'value': '0.08', 'spread': '0.443', 'groupId': 'OG002'}]}]}, {'title': 'Day 1, 48 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}, {'value': '16', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.15', 'spread': '0.485', 'groupId': 'OG000'}, {'value': '0.05', 'spread': '0.415', 'groupId': 'OG001'}, {'value': '0.11', 'spread': '0.274', 'groupId': 'OG002'}]}]}, {'title': 'Day 1, 72 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.03', 'spread': '0.497', 'groupId': 'OG000'}, {'value': '0.38', 'spread': '0.313', 'groupId': 'OG001'}, {'value': '-0.03', 'spread': '0.314', 'groupId': 'OG002'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}, {'value': '16', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.05', 'spread': '0.418', 'groupId': 'OG000'}, {'value': '-0.06', 'spread': '0.494', 'groupId': 'OG001'}, {'value': '-0.03', 'spread': '0.401', 'groupId': 'OG002'}]}]}, {'title': 'Day 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.08', 'spread': '0.541', 'groupId': 'OG000'}, {'value': '-0.04', 'spread': '0.435', 'groupId': 'OG001'}, {'value': '-0.20', 'spread': '0.521', 'groupId': 'OG002'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.17', 'spread': '0.443', 'groupId': 'OG000'}, {'value': '-0.07', 'spread': '0.523', 'groupId': 'OG001'}, {'value': '0.09', 'spread': '0.300', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48, 72 hours, Days 5, 6 and 7', 'description': 'Oral temperature was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Degrees Celsius', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Change From Baseline in Vital Signs: Oral Temperature', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Day 1, 24 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.14', 'spread': '0.378', 'groupId': 'OG000'}, {'value': '0.03', 'spread': '0.341', 'groupId': 'OG001'}]}]}, {'title': 'Day 1, 48 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.14', 'spread': '0.326', 'groupId': 'OG000'}, {'value': '0.02', 'spread': '0.350', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.12', 'spread': '0.385', 'groupId': 'OG000'}, {'value': '0.01', 'spread': '0.356', 'groupId': 'OG001'}]}]}, {'title': 'Day 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.11', 'spread': '0.314', 'groupId': 'OG000'}, {'value': '-0.19', 'spread': '0.481', 'groupId': 'OG001'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.24', 'spread': '0.167', 'groupId': 'OG000'}, {'value': '0.01', 'spread': '0.470', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Days 5, 6 and 7', 'description': 'Oral temperature was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Degrees Celsius', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 1: Change From Baseline in Vital Signs: Respiratory Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg', 'description': 'Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG001', 'title': 'Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}, {'id': 'OG002', 'title': 'Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)', 'description': 'Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.'}], 'classes': [{'title': 'Day 1, 24 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.3', 'spread': '2.57', 'groupId': 'OG000'}, {'value': '0.2', 'spread': '3.84', 'groupId': 'OG001'}, {'value': '0.9', 'spread': '2.86', 'groupId': 'OG002'}]}]}, {'title': 'Day 1, 48 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}, {'value': '16', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.9', 'spread': '3.64', 'groupId': 'OG000'}, {'value': '-0.8', 'spread': '3.67', 'groupId': 'OG001'}, {'value': '0.5', 'spread': '2.58', 'groupId': 'OG002'}]}]}, {'title': 'Day 1, 72 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.3', 'spread': '2.07', 'groupId': 'OG000'}, {'value': '-1.3', 'spread': '3.01', 'groupId': 'OG001'}, {'value': '-0.3', 'spread': '2.34', 'groupId': 'OG002'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.7', 'spread': '2.94', 'groupId': 'OG000'}, {'value': '-2.3', 'spread': '4.63', 'groupId': 'OG001'}, {'value': '0.3', 'spread': '3.44', 'groupId': 'OG002'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '4.37', 'groupId': 'OG000'}, {'value': '1.4', 'spread': '2.22', 'groupId': 'OG001'}, {'value': '-0.3', 'spread': '3.40', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Days 5, and 7', 'description': 'Respiratory rate was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Breaths per minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Part 2: Change From Baseline in Vital Signs: Respiratory Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)', 'description': 'Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.'}, {'id': 'OG001', 'title': 'Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)', 'description': 'Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.'}], 'classes': [{'title': 'Day 1, 24 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.8', 'spread': '2.82', 'groupId': 'OG000'}, {'value': '1.0', 'spread': '3.01', 'groupId': 'OG001'}]}]}, {'title': 'Day 1, 48 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '3.48', 'groupId': 'OG000'}, {'value': '0.9', 'spread': '3.01', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.0', 'spread': '3.02', 'groupId': 'OG000'}, {'value': '-1.3', 'spread': '4.24', 'groupId': 'OG001'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '2.83', 'groupId': 'OG000'}, {'value': '1.1', 'spread': '3.33', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Days 5, and 7', 'description': 'Respiratory rate was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Breaths per minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Part 1: Cohort 1: Sequence ABC', 'description': 'Participants received Treatment A as a single oral dose of GSK3640254 25 milligrams (mg) (2 tablets), GSK3640254 100 mg (1 tablet)/dolutegravir (DTG) 50 mg (1 tablet) administered together under moderate fat and calorie conditions on Day 1 in treatment period 1 followed by Treatment B as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 monolayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 2, further followed by Treatment C as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 bilayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 3. There was washout period of 7 days between each treatment period.'}, {'id': 'FG001', 'title': 'Part 1: Cohort 2: Sequence BCA', 'description': 'Participants received Treatment B as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 monolayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 1 followed by Treatment C as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 bilayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 2, further followed by Treatment A as a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) administered together under moderate fat and calorie conditions on Day 1 on treatment period 3. There was washout period of 7 days between each treatment period.'}, {'id': 'FG002', 'title': 'Part 1: Cohort 3: Sequence CAB', 'description': 'Participants received Treatment C as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 bilayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 1 followed by Treatment A as a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet) and DTG 50 mg (1 tablet) administered together under moderate fat and calorie conditions (reference) on Day 1 in treatment period 2, further followed by Treatment B as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 monolayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 3. There was washout period of 7 days between each treatment period.'}, {'id': 'FG003', 'title': 'Part 2: Cohort 1: Sequence DE', 'description': 'Participants received Treatment D as a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under high fat and calorie conditions on Day 1 in treatment Period 1, followed by Treatment E as a single oral dose of selected FDC of GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in treatment Period 2. There was washout period of 7 days between each treatment period.'}, {'id': 'FG004', 'title': 'Part 2: Cohort 2: Sequence ED', 'description': 'Participants received Treatment E as a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in treatment Period 1, followed by Treatment D as a single oral dose of selected FDC of GSK3640254/DTG, 150 mg/50 mg administered under high fat and calorie conditions on Day 1 in treatment Period 2. There was washout period of 7 days between each treatment period.'}], 'periods': [{'title': 'Part 1: Period 1 (Day 1)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '9'}, {'groupId': 'FG001', 'numSubjects': '7'}, {'groupId': 'FG002', 'numSubjects': '7'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '7'}, {'groupId': 'FG002', 'numSubjects': '7'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}]}, {'title': 'Part 1: Washout Period 1 (Up to 7 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '7'}, {'groupId': 'FG002', 'numSubjects': '7'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '7'}, {'groupId': 'FG002', 'numSubjects': '7'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}]}, {'title': 'Part 1: Period 2 (Day 1)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '7'}, {'groupId': 'FG002', 'numSubjects': '7'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '7'}, {'groupId': 'FG002', 'numSubjects': '7'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}]}, {'title': 'Part 1: Washout Period 2 (Up to 7 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '7'}, {'groupId': 'FG002', 'numSubjects': '7'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '6'}, {'groupId': 'FG002', 'numSubjects': '6'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}]}, {'title': 'Part 1: Period 3 (Day 1)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '6'}, {'groupId': 'FG002', 'numSubjects': '6'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '6'}, {'groupId': 'FG002', 'numSubjects': '6'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}]}, {'title': 'Part 2: Period 1 (Day 1)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '9'}, {'groupId': 'FG004', 'numSubjects': '9'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '9'}, {'groupId': 'FG004', 'numSubjects': '9'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}]}, {'title': 'Part 2: Washout Period 1 (Up to 7 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '9'}, {'groupId': 'FG004', 'numSubjects': '9'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '9'}, {'groupId': 'FG004', 'numSubjects': '8'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '1'}]}], 'dropWithdraws': [{'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '1'}]}]}, {'title': 'Part 2: Period 2 (Day 1)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '9'}, {'groupId': 'FG004', 'numSubjects': '8'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '9'}, {'groupId': 'FG004', 'numSubjects': '8'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}]}], 'recruitmentDetails': 'This was a randomized, open-label, single dose, crossover clinical study to assess relative bioavailability and food-effect of the fixed dose combination (FDC) of GSK3640254 and Dolutegravir (DTG) in healthy participants.', 'preAssignmentDetails': 'A total of 41 participants (23 participants in Part 1 and 18 participants in Part 2) were enrolled in the study.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'BG000'}, {'value': '7', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}, {'value': '9', 'groupId': 'BG003'}, {'value': '9', 'groupId': 'BG004'}, {'value': '41', 'groupId': 'BG005'}]}], 'groups': [{'id': 'BG000', 'title': 'Part 1: Cohort 1: Sequence ABC', 'description': 'Participants received Treatment A as a single oral dose of GSK3640254 25 milligrams (mg) (2 tablets), GSK3640254 100 mg (1 tablet)/dolutegravir (DTG) 50 mg (1 tablet) administered together under moderate fat and calorie conditions on Day 1 in treatment period 1 followed by Treatment B as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 monolayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 2, further followed by Treatment C as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 bilayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 3. There was washout period of 7 days between each treatment period.'}, {'id': 'BG001', 'title': 'Part 1: Cohort 2: Sequence BCA', 'description': 'Participants received Treatment B as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 monolayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 1 followed by Treatment C as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 bilayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 2, further followed by Treatment A as a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) administered together under moderate fat and calorie conditions on Day 1 on treatment period 3. There was washout period of 7 days between each treatment period.'}, {'id': 'BG002', 'title': 'Part 1: Cohort 3: Sequence CAB', 'description': 'Participants received Treatment C as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 bilayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 1 followed by Treatment A as a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet) and DTG 50 mg (1 tablet) administered together under moderate fat and calorie conditions (reference) on Day 1 in treatment period 2, further followed by Treatment B as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 monolayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 3. There was washout period of 7 days between each treatment period.'}, {'id': 'BG003', 'title': 'Part 2: Cohort 1: Sequence DE', 'description': 'Participants received Treatment D as a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under high fat and calorie conditions on Day 1 in treatment Period 1, followed by Treatment E as a single oral dose of selected FDC of GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in treatment Period 2. There was washout period of 7 days between each treatment period.'}, {'id': 'BG004', 'title': 'Part 2: Cohort 2: Sequence ED', 'description': 'Participants received Treatment E as a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in treatment Period 1, followed by Treatment D as a single oral dose of selected FDC of GSK3640254/DTG, 150 mg/50 mg administered under high fat and calorie conditions on Day 1 in treatment Period 2. There was washout period of 7 days between each treatment period.'}, {'id': 'BG005', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Customized', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}]}, {'title': '19-64 years', 'measurements': [{'value': '9', 'groupId': 'BG000'}, {'value': '7', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}, {'value': '9', 'groupId': 'BG003'}, {'value': '9', 'groupId': 'BG004'}, {'value': '41', 'groupId': 'BG005'}]}, {'title': '>= 65 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}, {'value': '5', 'groupId': 'BG003'}, {'value': '2', 'groupId': 'BG004'}, {'value': '18', 'groupId': 'BG005'}]}, {'title': 'Male', 'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '4', 'groupId': 'BG003'}, {'value': '7', 'groupId': 'BG004'}, {'value': '23', 'groupId': 'BG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'categories': [{'title': 'Black or African American', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '6', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '18', 'groupId': 'BG005'}]}, {'title': 'White-White/Caucasian/European Heritage', 'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}, {'value': '3', 'groupId': 'BG003'}, {'value': '4', 'groupId': 'BG004'}, {'value': '20', 'groupId': 'BG005'}]}, {'title': 'Multiple', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}]}, {'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}]}, {'title': 'Asian- South East Asian Heritage', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2021-05-05', 'size': 1756919, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2022-08-26T07:27', 'hasProtocol': True}, {'date': '2021-06-22', 'size': 1507294, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2022-08-26T07:31', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE', 'maskingDescription': 'This is an open-label study'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'CROSSOVER', 'interventionModelDescription': 'This is a 2-part crossover study.'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 41}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2021-04-21', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-08', 'completionDateStruct': {'date': '2021-09-10', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-08-18', 'studyFirstSubmitDate': '2021-04-20', 'resultsFirstSubmitDate': '2022-09-05', 'studyFirstSubmitQcDate': '2021-04-20', 'lastUpdatePostDateStruct': {'date': '2024-03-12', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2023-08-18', 'studyFirstPostDateStruct': {'date': '2021-04-23', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2024-03-12', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-09-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Part 1: Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf]) of GSK3640254', 'timeFrame': 'Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK3640254.'}, {'measure': 'Part 1: Area Under the Plasma Concentration-time Curve From Time 0 to Time t (AUC[0-t]) of GSK3640254', 'timeFrame': 'Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period', 'description': 'Blood samples were collected at indicated time points for PK analysis of GSK3640254.'}, {'measure': 'Part 1: Maximum Observed Concentration (Cmax) of GSK3640254', 'timeFrame': 'Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period', 'description': 'Blood samples were collected at indicated time points for PK analysis of GSK3640254.'}, {'measure': 'Part 1: AUC(0-inf) of DTG', 'timeFrame': 'Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period', 'description': 'Blood samples were collected at indicated time points for PK analysis of DTG.'}, {'measure': 'Part 1: AUC(0-t) of DTG', 'timeFrame': 'Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period', 'description': 'Blood samples were collected at indicated time points for PK analysis of DTG.'}, {'measure': 'Part 1: Cmax of DTG', 'timeFrame': 'Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period', 'description': 'Blood samples were collected at indicated time points for PK analysis of DTG.'}, {'measure': 'Part 2: AUC(0-inf) of GSK3640254', 'timeFrame': 'Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period', 'description': 'Blood samples were collected at indicated time points for PK analysis of GSK3640254.'}, {'measure': 'Part 2: AUC(0-t) of GSK3640254', 'timeFrame': 'Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period.', 'description': 'Blood samples were collected at indicated time points for PK analysis of GSK3640254.'}, {'measure': 'Part 2: Cmax of GSK3640254', 'timeFrame': 'Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period', 'description': 'Blood samples were collected at indicated time points for PK analysis of GSK3640254.'}, {'measure': 'Part 2: AUC(0-inf) of DTG', 'timeFrame': 'Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period', 'description': 'Blood samples were collected at indicated time points for PK analysis of DTG.'}, {'measure': 'Part 2: AUC(0-t) of DTG', 'timeFrame': 'Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period', 'description': 'Blood samples were collected at indicated time points for PK analysis of DTG.'}, {'measure': 'Part 2: Cmax of DTG', 'timeFrame': 'Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period', 'description': 'Blood samples were collected at indicated time points for PK analysis of DTG.'}], 'secondaryOutcomes': [{'measure': 'Part 1: Number of Participants With Non-Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)', 'timeFrame': 'Up to 17 days', 'description': 'An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any serious adverse event that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or other situations as per medical or scientific judgment. Adverse events which were not Serious Adverse Events were considered as Non-Serious adverse events.'}, {'measure': 'Part 2: Number of Participants With Non-SAEs and SAEs', 'timeFrame': 'Up to 9 days', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any serious adverse event that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or other situations as per medical or scientific judgment. Adverse events which were not Serious Adverse Events were considered as Non-Serious adverse events.'}, {'measure': 'Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, and platelets. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, leukocytes and platelets. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 1: Absolute Values for Hematology Parameter: Hemoglobin', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 2: Absolute Values for Hematology Parameter: Hemoglobin', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 1: Absolute Values for Hematology Parameter: Erythrocytes', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 2: Absolute Values for Hematology Parameter: Erythrocytes', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 1: Absolute Values for Hematology Parameters: Hematocrit', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 2: Absolute Values for Hematology Parameters: Hematocrit', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 1: Absolute Values for Hematology Parameters: Erythrocytes Mean Corpuscular Hemoglobin', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 2: Absolute Values for Hematology Parameters: Erythrocytes Mean Corpuscular Hemoglobin', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, and platelets. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 2: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, and platelets. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 1: Change From Baseline in Hematology Parameter: Hemoglobin', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 2: Change From Baseline in Hematology Parameter: Hemoglobin', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 1: Change From Baseline in Hematology Parameter: Erythrocytes', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 2: Change From Baseline in Hematology Parameter: Erythrocytes', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 1: Change From Baseline in Hematology Parameter: Hematocrit', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: hemotocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 2: Change From Baseline in Hematology Parameter: Hematocrit', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameters: hemotocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK)', 'timeFrame': 'Baseline (Day -1), and Days 2, 5, and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: ALT, ALP, AST, GGT, LDH, CK. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: ALT, ALP, AST, GGT, LDH, CK. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap', 'timeFrame': 'Baseline (Day -1), and Days 2, 5, and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: calcium, CO2, chloride, glucose, potassium, sodium, urea nitrogen, phosphorus, triglycerides, cholesterol, and anion gap. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: calcium, CO2, chloride, glucose, potassium, sodium, urea nitrogen, phosphorus, triglycerides, cholesterol, and anion gap. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 1: Absolute Values for Chemistry Parameters: Serum Lipase, Serum Amylase', 'timeFrame': 'Baseline (Day -1), and Days 2, 5, and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: serum lipase and serum amylase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 2: Absolute Values for Chemistry Parameters: Serum Lipase, Serum Amylase', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: serum lipase, serum amylase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 1: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein', 'timeFrame': 'Baseline (Day -1), and Days 2, 5, and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 2: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 1: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate', 'timeFrame': 'Baseline (Day -1), and Days 2, 5, and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: creatinine, direct bilirubin, bilirubin, urate. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 2: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: creatinine, direct bilirubin, bilirubin, and urate. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: ALT, ALP, AST, GGT, LDH, CK. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: ALT, ALP, AST, GGT, LDH, CK. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: calcium, CO2, chloride, glucose, potassium, sodium, urea nitrogen, phosphorus, triglycerides, cholesterol, and anion gap. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: calcium, CO2, chloride, glucose, potassium, sodium, urea nitrogen, phosphorus, triglycerides, cholesterol, and anion gap. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 1: Change From Baseline in Clinical Chemistry Parameters: Lipase and Amylase', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: lipase and amylase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 2: Change From Baseline in Clinical Chemistry Parameters: Lipase and Amylase', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: lipase and amylase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 1: Change From Baseline in Clinical Chemistry Parameters: Albumin, Globulin and Protein', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 2: Change From Baseline in Clinical Chemistry Parameters: Albumin, Globulin and Protein', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 1: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: creatinine, direct bilirubin, bilirubin, and urate. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 2: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Blood samples were collected to analyze the chemistry parameters: Creatinine, direct bilirubin, bilirubin, and urate. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 1: Absolute Values for Urinalysis Parameter: Specific Gravity', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': "Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period."}, {'measure': 'Part 2 : Absolute Values for Urinalysis Parameter: Specific Gravity', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': "Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period."}, {'measure': 'Part 1: Absolute Values for Urinalysis Parameters: Potential of Hydrogen (pH)', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 1: Absolute Values for Urinalysis Parameter: Potential of Hydrogen', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 1: Number of Participants With Urinalysis Dipstick Results: Glucose', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Urine samples were collected at indicated time points to analyze parameters including glucose by dipstick. Urinalysis included dipstick urine test which was used to screen for glucose. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine glucose can be read as negative in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 2: Number of Participants With Urinalysis Dipstick Results: Glucose', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Urine samples were collected at indicated time points to analyze parameters including glucose by dipstick. Urinalysis included dipstick urine test which was used to screen for glucose. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine glucose can be read as negative in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 1: Number of Participants With Urinalysis Dipstick Results: Protein', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Urine samples were collected at indicated time points to analyze parameters including protein by dipstick. Urinalysis included dipstick urine test which was used to screen for protein. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine protein can be read as negative, and trace in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 2: Number of Participants With Urinalysis Dipstick Results: Protein', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Urine samples were collected at indicated time points to analyze parameters including protein by dipstick. Urinalysis included dipstick urine test which was used to screen for protein. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine protein can be read as negative, and trace in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 1: Number of Participants With Urinalysis Dipstick Results: Occult Blood', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Urine samples were collected at indicated time points to analyze parameters including occult blood by dipstick. Urinalysis included dipstick urine test which was used to screen for occult blood. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine occult blood can be read as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 2: Number of Participants With Urinalysis Dipstick Results: Occult Blood', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Urine samples were collected at indicated time points to analyze parameters including occult blood by dipstick. Urinalysis included dipstick urine test which was used to screen for occult blood. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine occult blood can be read as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 1: Number of Participants With Urinalysis Dipstick Results: Ketones', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Urine samples were collected at indicated time points to analyze parameters including ketones by dipstick. Urinalysis included dipstick urine test which was used to screen for ketones. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine ketones can be read as negative, trace, 2+ indicating proportional concentrations in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 2: Number of Participants With Urinalysis Dipstick Results: Ketones', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Urine samples were collected at indicated time points to analyze parameters including ketones by dipstick. Urinalysis included dipstick urine test which was used to screen for ketones. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine ketones can be read as negative, trace, 1+, 2+ indicating proportional concentrations in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 1: Number of Participants With Urinalysis Dipstick Results: Bilirubin and Nitrite', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Urine samples were collected at indicated time points to analyze parameters including bilirubin and nitrite by dipstick. Urinalysis included dipstick urine test which was used to screen for bilirubin and nitrite. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine bilirubin and nitrite can be read as negative in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 2: Number of Participants With Urinalysis Dipstick Results: Bilirubin and Nitrite', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Urine samples were collected at indicated time points to analyze parameters including bilirubin and nitrite by dipstick. Urinalysis included dipstick urine test which was used to screen for bilirubin and nitrite. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine bilirubin and nitrite can be read as negative in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 1: Number of Participants With Urinalysis Dipstick Results: Leukocyte Esterase', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Urine samples were collected at indicated time points to analyze parameters including leukocyte esterase by dipstick. Urinalysis included dipstick urine test which was used to screen for leukocyte esterase. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine leukocyte esterase can be read as negative, trace, 1+ indicating proportional concentrations in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 2: Number of Participants With Urinalysis Dipstick Results: Leukocyte Esterase', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Urine samples were collected at indicated time points to analyze parameters including leukocyte esterase by dipstick. Urinalysis included dipstick urine test which was used to screen for leukocyte esterase. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine leukocyte esterase can be read as negative, trace indicating proportional concentrations in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.'}, {'measure': 'Part 1: Change From Baseline in Urinalysis Parameter: Specific Gravity', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': "Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value."}, {'measure': 'Part 2: Change From Baseline in Urinalysis Parameter: Specific Gravity', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': "Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value."}, {'measure': 'Part 1: Change From Baseline for Urinalysis Parameter: Potential of Hydrogen', 'timeFrame': 'Baseline (Day -1) and Days 2, 5, and 7', 'description': 'Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 2: Change From Baseline for Urinalysis Parameter: Potential of Hydrogen', 'timeFrame': 'Baseline (Day -1) and Days 2, 5 and 7', 'description': 'Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 1: Number of Participants With Worst Case Urine Parameter: Glucose Results by Maximum Grade Increase Post-Baseline Relative to Baseline', 'timeFrame': 'Up to Day 17', 'description': 'Urine samples were collected to analyze the urine parameter: glucose. Urinalysis parameters were graded according to Division of Acquired Immune Deficiency Syndrome (DAIDS) grading for severity of laboratory toxicities and clinical adverse events, version 2.1. The grades were grade 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening). Baseline was defined as the last assessment before the first dose of the study treatment. Only those urine parameters with maximum post-Baseline grade increase (Grade 1 to Grade 4) have been presented.'}, {'measure': 'Part 2: Number of Participants With Worst Case Urine Parameter: Glucose Results by Maximum Grade Increase Post-Baseline Relative to Baseline', 'timeFrame': 'Up to Day 9', 'description': 'Urine samples were collected to analyze the urine parameter: glucose. Urinalysis parameters were graded according to Division of Acquired Immune Deficiency Syndrome (DAIDS) grading for severity of laboratory toxicities and clinical adverse events, version 2.1. The grades were grade 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening). Baseline was defined as the last assessment before the first dose of the study treatment. Only those urine parameters with maximum post-Baseline grade increase (Grade 1 to Grade 4) have been presented.'}, {'measure': 'Part 1: Number of Participants With Worst Case Urine Parameter: Protein Results by Maximum Grade Increase Post-Baseline Relative to Baseline', 'timeFrame': 'Up to Day 17', 'description': 'Urine samples were collected to analyze the urine parameter: protein. Urinalysis parameters were graded according to Division of Acquired Immune Deficiency Syndrome (DAIDS) grading for severity of laboratory toxicities and clinical adverse events, version 2.1. The grades were grade 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening). Baseline was defined as the last assessment before the first dose of the study treatment. Only those urine parameters with maximum post-Baseline grade increase (Grade 1 to Grade 4) have been presented.'}, {'measure': 'Part 2: Number of Participants With Worst Case Urine Parameter: Protein Results by Maximum Grade Increase Post-Baseline Relative to Baseline', 'timeFrame': 'Up to Day 9', 'description': 'Urine samples were collected to analyze the urine parameter: protein. Urinalysis parameters were graded according to Division of Acquired Immune Deficiency Syndrome (DAIDS) grading for severity of laboratory toxicities and clinical adverse events, version 2.1. The grades were grade 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening). Baseline was defined as the last assessment before the first dose of the study treatment. Only those urine parameters with maximum post-Baseline grade increase (Grade 1 to Grade 4) have been presented.'}, {'measure': 'Part 1: Number of Participants With Worst Case Urine Parameter: Erythrocytes Results by Maximum Grade Increase Post-Baseline Relative to Baseline', 'timeFrame': 'Up to Day 17', 'description': 'Urine samples were collected to analyze the urine parameter: erythrocytes. Urinalysis parameters were graded according to Division of Acquired Immune Deficiency Syndrome (DAIDS) grading for severity of laboratory toxicities and clinical adverse events, version 2.1. The grades were grade 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening). Baseline was defined as the last assessment before the first dose of the study treatment. Only those urine parameters with maximum post-Baseline grade increase (Grade 1 to Grade 4) have been presented.'}, {'measure': 'Part 2: Number of Participants With Worst Case Urine Parameter: Erythrocytes Results by Maximum Grade Increase Post-Baseline Relative to Baseline', 'timeFrame': 'Up to Day 9', 'description': 'Urine samples were collected to analyze the urine parameter: erythrocytes. Urinalysis parameters were graded according to Division of Acquired Immune Deficiency Syndrome (DAIDS) grading for severity of laboratory toxicities and clinical adverse events, version 2.1. The grades were grade 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening). Baseline was defined as the last assessment before the first dose of the study treatment. Only those urine parameters with maximum post-Baseline grade increase (Grade 1 to Grade 4) have been presented.'}, {'measure': "Part 1: Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)", 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 2, 4, 6 hours, and Day 5', 'description': 'Twelve lead ECGs were obtained to measure PR interval, QRS duration, QT interval, and QTcF interval . Twelve lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments within each treatment'}, {'measure': 'Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 2, 4, 6 hours, and Days 5, 7', 'description': 'Twelve lead ECGs were obtained to measure PR interval, QRS duration, QT interval, and QTcF interval. Twelve lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments within each treatment.'}, {'measure': 'Part 1: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval', 'timeFrame': 'Baseline (Day 1, Pre-dose), and Day 1: 2, 4, 6 hours, and Day 5', 'description': 'Twelve lead ECGs were obtained to measure PR interval, QRS duration, QT interval, QTcF interval. Twelve lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 2, 4, 6 hours, Days 5 and 7', 'description': 'Twelve lead ECGs were obtained to measure PR interval, QRS duration, QT interval, QTcF interval. Twelve lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 1: Absolute Values of Vital Sign Parameters: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48, 72 hours, Days 5 and 7', 'description': 'SBP and DBP were measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment.'}, {'measure': 'Part 2: Absolute Values of Vital Signs: DBP and SBP', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Days 5 and 7', 'description': 'SBP and DBP were measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment.'}, {'measure': 'Part 1: Absolute Values of Vital Signs: Pulse Rate', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48, 72 hours, Days 5 and 7', 'description': 'Pulse rate was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment.'}, {'measure': 'Part 2: Absolute Values of Vital Signs: Pulse Rate', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Day 5 and 7', 'description': 'Pulse rate was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment.'}, {'measure': 'Part 1: Absolute Values of Vital Signs: Oral Temperature', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48, 72 hours, Days 5, 6 and 7', 'description': 'Oral temperature were measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment.'}, {'measure': 'Part 2: Absolute Values of Vital Signs: Oral Temperature', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Day 5 and 7', 'description': 'Oral temperature were measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment.'}, {'measure': 'Part 1: Absolute Values of Vital Signs: Respiratory Rate', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48, 72 hours, Days 5 and 7', 'description': 'Respiratory rate was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment.'}, {'measure': 'Part 2: Absolute Values of Vital Signs: Respiratory Rate', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Days 5, and 7', 'description': 'Respiratory rate was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment.'}, {'measure': 'Part 1: Change From Baseline in Vital Signs: DBP and SBP', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48, 72 hours, Days 5, and 7', 'description': 'SBP and DBP were measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 2: Change From Baseline in Vital Signs: DBP and SBP', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Days 5, and 7', 'description': 'SBP and DBP were measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 1: Change From Baseline in Vital Signs: Pulse Rate', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48, 72 hours, Days 5, and 7', 'description': 'Pulse rate was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 2: Change From Baseline in Vital Signs: Pulse Rate', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Days 5, and 7', 'description': 'Pulse rate was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 1: Change From Baseline in Vital Signs: Oral Temperature', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48, 72 hours, Days 5, 6 and 7', 'description': 'Oral temperature was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 2: Change From Baseline in Vital Signs: Oral Temperature', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Days 5, 6 and 7', 'description': 'Oral temperature was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 1: Change From Baseline in Vital Signs: Respiratory Rate', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Days 5, and 7', 'description': 'Respiratory rate was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Part 2: Change From Baseline in Vital Signs: Respiratory Rate', 'timeFrame': 'Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Days 5, and 7', 'description': 'Respiratory rate was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Dolutegravir', 'GSK3640254', 'Fixed Dose Combinations', 'Bioavailability'], 'conditions': ['HIV Infections']}, 'descriptionModule': {'briefSummary': 'This is a two part study to compare the relative bioavailability (BA) of 2 fixed dose combinations (FDCs) of GSK3640254/DTG with GSK3640254 and DTG administered together as single agents (Part 1) and to assess the effect of food on the pharmacokinetic (PK) of the selected FDC of GSK3640254/DTG (Part 2).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Participant must be 18 to 65 years of age inclusive, at the time of signing the informed consent.\n* Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring (history and ECG).\n* Participants capable of giving signed informed consent.\n\nExclusion Criteria:\n\n* Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).\n* A pre-existing condition interfering with normal gastro intestinal anatomy or motility (for example \\[e.g.\\], gastroesophageal reflux disease, gastric ulcers, gastritis) or hepatic and/or renal function that could interfere with the absorption, metabolism, and/or excretion of the study intervention or render the participant unable to take oral study intervention.\n* Prior cholecystectomy surgery (prior appendectomy is acceptable).\n* Clinically significant illness, including viral syndromes within 3 weeks of dosing.\n* Participant with known or suspected active Coronavirus disease (COVID)-19 infection or contact with an individual with known COVID-19, within 14 days of study enrollment.\n* Current enrollment or past participation within the last 30 days before signing of consent in any other clinical study involving an investigational study intervention (including an investigational COVID vaccine) or any other type of medical research.\n* Prior exposure to GSK3640254 or prior intolerance to DTG in this or another clinical study.\n* Any positive (abnormal) response confirmed by the investigator on a screening clinician- or qualified designee-administered Columbia Suicide Severity Rating Scale (C-SSRS).\n* Any significant arrhythmia or ECG finding (e.g., prior myocardial infarction in the past 3 months, symptomatic bradycardia, non-sustained or sustained atrial arrhythmias, non-sustained or sustained ventricular tachycardia, any degree of atrioventricular block, or conduction abnormality) which, in the opinion of the investigator or ViiV Healthcare (VH)/GlaxoSmithKline (GSK) medical monitor, will interfere with the safety for the individual participant."}, 'identificationModule': {'nctId': 'NCT04857892', 'briefTitle': 'A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants', 'organization': {'class': 'INDUSTRY', 'fullName': 'ViiV Healthcare'}, 'officialTitle': 'A Two-Part, Randomized, Open-Label, Single Dose, Crossover Clinical Study to Assess the Relative Bioavailability of Fixed-Dose Combinations of GSK3640254 and Dolutegravir and to Assess the Effect of Food on the Select Fixed Dose Combination of GSK3640254 and Dolutegravir in Healthy Participants', 'orgStudyIdInfo': {'id': '213055'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Part 1 : Treatment sequence ABC', 'description': 'Participants will receive a single oral dose of GSK3640254 25 milligrams (mg) (2 x tablets), GSK3640254 100 mg (1 x tablet) and DTG 50 mg (1 x tablet) administered together under moderate fat and calorie conditions (reference) (Treatment A) in Period 1, followed by a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 x monolayer tablet) FDC administered under moderate fat and calorie conditions (Treatment B) in Period 2. In Period 3, participants will receive a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 x bilayer tablet) FDC administered under moderate fat and calorie conditions (Treatment C).', 'interventionNames': ['Drug: GSK3640254', 'Drug: DTG', 'Drug: GSK3640254/DTG']}, {'type': 'EXPERIMENTAL', 'label': 'Part 1 : Treatment sequence BCA', 'description': 'Participants will receive a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 x monolayer tablet) FDC administered under moderate fat and calorie conditions (Treatment B) in Period 1, followed by a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 x bilayer tablet) FDC administered under moderate fat and calorie conditions (Treatment C) in Period 2. In Period 3 participants will receive a single oral dose of GSK3640254 25 mg (2 x tablets), GSK3640254 100 mg (1 x tablet) and DTG 50 mg (1 x tablet) administered together under moderate fat and calorie conditions (reference) (Treatment A).', 'interventionNames': ['Drug: GSK3640254', 'Drug: DTG', 'Drug: GSK3640254/DTG']}, {'type': 'EXPERIMENTAL', 'label': 'Part 1 : Treatment sequence CAB', 'description': 'Participants will receive a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 x bilayer tablet) FDC administered under moderate fat and calorie conditions (Treatment C) in period 1, followed by a single oral dose of GSK3640254 25 mg (2 x tablets), GSK3640254 100 mg (1 x tablet) and DTG 50 mg (1 x tablet) administered together under moderate fat and calorie conditions (reference) (Treatment A) in Period 2. In Period 3 participants will receive a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 x monolayer tablet) FDC administered under moderate fat and calorie conditions (Treatment B).', 'interventionNames': ['Drug: GSK3640254', 'Drug: DTG', 'Drug: GSK3640254/DTG']}, {'type': 'EXPERIMENTAL', 'label': 'Part 2 : Treatment sequence DE', 'description': 'Participants will receive a single oral dose of selected FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under high fat and calorie conditions (Treatment D) in Period 1 followed by a single oral dose of selected FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions (Treatment E) in Period 2.', 'interventionNames': ['Drug: GSK3640254/DTG']}, {'type': 'EXPERIMENTAL', 'label': 'Part 2 : Treatment sequence ED', 'description': 'Participants will receive a single oral dose of selected FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions (Treatment E) in Period 1 followed by a single oral dose of selected FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under high fat and calorie conditions (Treatment D) in Period 2.', 'interventionNames': ['Drug: GSK3640254/DTG']}], 'interventions': [{'name': 'GSK3640254', 'type': 'DRUG', 'description': 'GSK3640254 will be administered via oral route.', 'armGroupLabels': ['Part 1 : Treatment sequence ABC', 'Part 1 : Treatment sequence BCA', 'Part 1 : Treatment sequence CAB']}, {'name': 'DTG', 'type': 'DRUG', 'description': 'DTG will be administered via oral route.', 'armGroupLabels': ['Part 1 : Treatment sequence ABC', 'Part 1 : Treatment sequence BCA', 'Part 1 : Treatment sequence CAB']}, {'name': 'GSK3640254/DTG', 'type': 'DRUG', 'description': 'GSK3640254/DTG will be administered via oral route.', 'armGroupLabels': ['Part 1 : Treatment sequence ABC', 'Part 1 : Treatment sequence BCA', 'Part 1 : Treatment sequence CAB', 'Part 2 : Treatment sequence DE', 'Part 2 : Treatment sequence ED']}]}, 'contactsLocationsModule': {'locations': [{'zip': '78744', 'city': 'Austin', 'state': 'Texas', 'country': 'United States', 'facility': 'GSK Investigational Site', 'geoPoint': {'lat': 30.26715, 'lon': -97.74306}}], 'overallOfficials': [{'name': 'GSK Clinical Trials', 'role': 'STUDY_DIRECTOR', 'affiliation': 'ViiV Healthcare'}]}, 'ipdSharingStatementModule': {'url': 'http://clinicalstudydatarequest.com', 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF', 'CSR'], 'timeFrame': 'IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.', 'ipdSharing': 'YES', 'description': 'IPD for this study will be made available via the Clinical Study Data Request site.', 'accessCriteria': 'Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'ViiV Healthcare', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}